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Abstract
Induction of Myosin Cross-Reactive Antibody and Cytolytic T Cell Responses in mice with
Streptococcus pyogenes
Cynthia Cunningham

Impetigo and pharyngitis are two common suppurative infections in man elicited by
Streptococcus pyogenes that lead to autoimmune complications in susceptible individuals.
Although the underlying mechanisms for the onset of post-streptococcal autoimmunity have yet
to be established, experimental information gained thus far suggests that the resultant pathology
is a consequence of immunological cross-reactivity between streptococcal antigens, namely the
anti-phagocytic factor M protein and host proteins, specifically myosin. Experimental animal
model systems developed to date have predominantly relied on the immunization of adult
animals with M protein emulsed in adjuvant. In the laboratory we have undertaken studies with
mice to examine the capacity of S. pyogenes as whole organism without adjuvant to elicit
autoreactive B and T lymphocytes.
We have observed that immunizing mice with heat-killed preparations of S. pyogenes as
neonates, but not adults, induces the production of host cross-reactive serum antibodies akin to
those documented in cases of post-streptococcal autoimmunity. Western blot analysis of
monoclonal antibodies generated from mice immunized with S. pyogenes suggests that
antibodies induced in neonatal mice preferentially recognize the cardiac isoforms of mouse
skeletal myosin, whereas, antibodies derived from adult mice primarily recognize determinants
shared by all isoforms of mouse skeletal myosin. In addition, we have demonstrated the ability of
neonatal, but not adult, mice to mount a myosin-reactive CD8+ cytotoxic T cell response
following immunization with S. pyogenes. Our observations indicate that the response is
additionally dependent on the genetic background of mice, the route of immunization, and
requires M protein.
In summation, our results suggest that in susceptible individuals exposure to S. pyogenes
early in life may serve as a priming event and following a subsequent event later in life, possibly
re-exposure to S. pyogenes, allow the initiation of the pathology associated with poststreptococcal autoimmunity. These results contribute to the understanding of the development of
the mechanisms of post-streptococcal autoimmune complications and may ultimately contribute
to the development of effective diagnostic intervention strategies.
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General Introduction
Introduction. Streptococcus pyogenes is a group A, beta hemolytic gram-positive cocci that is
the causative agent of several infectious manifestations in man. Streptococcal infections are
typically controlled by a protective antibody response with or without the aid of antibiotics,
however, a certain small percentage of children worldwide who do not receive proper timely
antibiotic treatment will develop autoimmune sequelae. Much research has been devoted to
understanding the underlying mechanisms that initiate these autoimmune complications and,
although no clear answers have been found, it is becoming increasingly evident that
characteristics of the host may play just as important of a role as the infectious organism.
Because GAS infections are prevalent and may subsequently result in invasive or autoimmune
complications, the development of an efficacious vaccine is becoming increasingly important.
Despite the significance of information gained thus far, research into all facets of poststreptococcal autoimmune scenarios has been hindered by the lack of a complete autoimmune
animal model system. This chapter will discuss both historic and current research, as well as, the
contributions of the research conducted in our laboratory, towards the advancement of the
understanding of the relationship between host and organism and of the understanding of the
subsequent autoimmune complications.

Group A Streptococcus
Historical Perspective. Streptococci first came into our acquaintance around the late 1870’s,
during the time that Louis Pasteur was beginning to develop the germ theory of disease.
Refusing to accept the currently reigning ideology of diseases being the result of spontaneous
generation, Pasteur began to focus his attention on puerperal fever, which at that time was a very

1

prevalent cause of maternal and neonatal deaths following childbirth. Upon examining samples
acquired from women with puerperal sepsis, he repeatedly encountered chained or paired
microorganisms. Although it was these microorganisms that Pasteur implicated as the causative
agent, it was not until 1879 when he introduced this theory at the Academy of Medicine meeting
streptococci received recognition (reviewed in Stollerman 1975; Horaud et al. 1997). Two years
later Billroth and Ehrlich officially identified the organism and named them Streptococcus (rev.
in Stollerman 1975; Horaud et al. 1997). Since its introduction Streptococcus has made
historically significant contributions to the study of genetics and antibacterial chemotherapy.
Experiments performed in the late 1930’s demonstrated the ability to clear streptococcal
infections with chemical compounds later identified as sulfonamides and providing the first
series of antibacterial chemotherapeutic agents (reviewed in Horaud et al. 1997). About the same
time, McCarty employed Streptococcus as the experimental agent to demonstrate and define
bacterial transformation for the first time (reviewed in Horaud et al. 1997). The focus of more
recent history of Streptococcus has been primarily towards the relationship with human diseases.
Probably one of the most celebrated pioneers in streptococcal research is Dr. Rebecca Lancefield.
Her most notable contributions began in the 1920’s with the definition of streptococcal
subgroups based on cell wall carbohydrate moieties and later changed the course of streptococcal
research with the identification of M protein as the major anti-phagocytic factor (Lancefield
1962). Other notable investigators include Rammelkamp, Edward Kaplan, James Dale, Edwin
Beachey, John Zabriskie, Vincent Fischetti and Mclean McCarty. By expanding on Lancefield’s
initial work these researchers, among others too numerous to mention, have been able to
elucidate aspects of streptococcal virulence and the impact of Streptococcus and streptococcal
related diseases, both primary and sequelae, on the human condition.
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Group A streptococcal infections. S. pyogenes is a human pathogen associated with several
suppurative infections of the skin and throat, as well as, a number of autoimmune diseases
including acute rheumatic fever and acute glomuleronephritis. While the most prevalent
infections are pharyngitis and impetigo, GAS is associated with several, more invasive infections
including scarlet fever, streptococcal toxic shock syndrome, cellulitis, erysipelas, necrotizing
faciitis and gangrene (Stevens 1992; Schlievert et al. 1996). Pharyngitis, or strep throat as it is
commonly known, and impetigo are superficial infections that are easily controlled with
antibiotics, however, these infections may lead to more serious invasive infections such as those
listed above or to autoimmune complications. Streptococcal pharyngitis is characterized by a
sore throat and fever that onsets within 72 hours of initial infection. With the aid of antibiotics,
symptoms generally subside within 7 - 10 days and most organisms are cleared, however, in
untreated cases the organism may be present up to 4 weeks post infection. This merits concern,
considering that up to 40% of all cases are mild to asymptomatic and may not warrant treatment,
thus allowing the spread the organism and creating greater risk of further complications, whether
invasive or autoimmune (Kehoe 1991; Stevens 1992). Impetigo is characterized by pustular skin
lesions most likely found on the extremities and usually is preceded by skin colorization and mild
trauma to the affected area. Typically, pharyngeal infections are cleared by a vigorous host
response that results in lifelong type-specific immunity while impetigo does not. Additionally,
streptococcal pharyngitis may appear in any individual over the age of 5 years, while impetigo
typically reaches peak at two to five years of age.
Phage transformed streptococcal organism produce a set of exotoxins and are known to
induce scarlet fever, a disease characterized by pharyngitis and a rash around the trunk and neck
that spreads to the extremities. Most often this infection occurs in children ranging in age from
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two to ten years. Other streptococcal invasive infections, necrotizing faciitis, myositis, gangrene,
are the result of deep tissue infection and exhibit high mortality rates. These infections usually
occur in immunocompromised individuals or healthy individuals following a trauma or
underlying illness. The most recently identified and potentially most serious invasive GAS
infection is streptococcal toxic shock syndrome. Unlike the other invasive infections these
disease occurs in patients between the ages of 20 and 50 who were otherwise healthy (Scwartz et
al. 1990).
Another potential complication of streptococcal infections is the development of
autoimmune disorders, which include acute rheumatic fever, acute glomerulonephritis,
Syndenham’s chorea, psoriasis, and Kawasaki’s disease. Post-streptococcal autoimmunity
differs from other cross-reactive antibody associated diseases such as SLE in that, antibodies in
post-streptococcal sequelae bind directly to the tissue site while in SLE the antibodies form
immunocomplexes with the autoantigen (DNA) that in turn bind to the tissue site (Chan et al.
1999; Maddison 1999). ARF is an autoimmune complication that primarily affects the heart and
joint tissue and appears in a small percentage of children ranging in age from 5 to 15 years
approximately three to four weeks following untreated GAS nasopharyngeal infection. AGN is
also predominantly a childhood disease, however, it is characterized by renal tissue pathology
and typically follows impetigo. Unlike AGN and ARF, psoriasis is an inflammatory skin disease
that appears to be indiscriminant with age. These diseases have been shown to follow or be
exacerbated by a streptococcal infection and will receive more attention later in the review.
Virulence factors promoting adherence and colonization. Upon entering the host, the
organism typically initiates colonization by adhering to host cell epithelium. S. pyogenes has at
least eleven potential candidates to carry out this action (Hasty and Courtney 1996); however
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only five such factors have been well characterized which include lipoteichoic acid (Beachey and
Simpson 1982; Beachey et al. 1983; Caparon et al. 1991), fibronectin binding protein (Hasty and
Courtney 1996), M protein (Caparon et al. 1991; Kehoe 1991; Okada et al. 1994), protein F
(Hasty and Courtney 1996) and the hyaluronic acid capsule (Schrager et al. 1998). Of course,
other factors that have not yet been characterized cannot be discounted. Protein F and fibronectin
binding protein interact with fibronectin on pharyngeal epithelial cells (Kehoe 1991; Hanski and
Caparon 1992) and purified preparations of these proteins have been shown to inhibit adhesion of
GAS to epithelial cells in vitro (Speziale et al. 1984; Kehoe 1991). Lipoteichoic acid is believed
to mediate adherence to host epithelium and buccal cells (Simpson and Beachey 1983) through
the formation of a complex with M protein and binding via its lipid moiety to fibronectin on the
epithelial cells (Beachey and Simpson 1982).
The standard model of adhesion suggests that during the process of its release from the
cell LTA forms a surface protein-LTA complex where the lipid ends of LTA protrudes outwards
to permit the binding to fibronectin on the surface of epithelial cells (Beachey et al. 1983).
However, Caparon et al. (Caparon et al. 1991) have presented evidence indicating that M protein
does not interact with LTA but instead M protein promotes the formation of aggregates or microcolonies. This suggests that while M protein does not initiate adherence, it directly promotes or
enhance adherence that ultimately aides in counteracting attachment inhibition mediated by
secretory IgA (Williams and Gibbons 1972). While it is generally agreed that M protein itself
does not play a direct role in adhesion to epithelial cells (Caparon et al. 1991; Okada et al. 1994;
Hasty and Courtney 1996), certain serotypes of M protein can mediate binding to human
laryngeal epithelial Hep-2 cells and keratinocytes through CD46 (Okada et al. 1994; Okada et al.
1995). However, the significance of this interaction remains in question since Schrager et al.
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(1998) demonstrated that the hyaluronic acid capsule physically inhibits M protein binding to
keratinocytes while mediating binding through CD44. Despite the ambiguity of the roles of the
various adhesion factors it might be inferred that the availability of such a variety is an indication
of the organism’s ability to adapt to various host conditions. Further, instead of dependence on
one key adhesion factor, each factor may play a minor role, as necessary, in the overall goal of
adhesion.
Host immune response to group A streptococcal infections. Upon bypassing the physical
barriers and entering the host, the organism may initiate an inflammatory response resulting in
the influx of the necessary effector cells of the immune system (phagocytes and lymphocytes)
and serum proteins with effector function, most importantly antibody and complement. The most
effective defense against an extracellular organism such as GAS is phagocytosis and the
activation of the complement system either through the alternative and classical antibody
mediated pathways. Phagocytosis can be directed under two mechanisms; first, phagocytic
macrophages possess receptors for certain bacterial polysaccharides and upon recognition may
directly mediate phagocytosis, and second, phagocytic activity is greatly enhanced with opsonic
help of antibodies and complement.
The complement system is composed of two pathways; antibody mediated classical
pathway and the less specific alternate pathway (Winkelstein 1981). Activation of the alternate
pathway is initiated by the binding of complement factor C3b to the outer surface of the
organism, while the classical pathway is activated by antibody binding to the pathogen or the
formation of antigen-antibody complexes. While the initial events of the two pathways differ
they eventually overlap with factor C3b. Involvement of factor C3b leads to the splicing of
factor C5 into C5a and C5b, where C5a is a major chemotatic agent and C5b will initiate the
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formation of the membrane attack complex. Activation of the complement cascade will
ultimately allow for two potential outcomes, lysis or phagocytosis. First, binding of C3b to the
organism as an event of either pathway can initiate the formation of the membrane attack
complex resulting in membrane permeation and subsequent cellular lysis. Secondly, the bound
antibody and C3b function as a major opsonin thereby enhancing phagocytic uptake of the
organism by monocytes, macrophages, or neutrophils.
The antibody response to GAS plays a pivotal role in controlling GAS infection, not only
as a means to induce phagocytosis as discussed above but also to hinder attachment to mucosal
surfaces or neutralize bacterial toxic factors that may have potentially deleterious effect upon the
host. Antibody titers against a number of extracellular streptococcal antigens, including the
group specific carbohydrate, streptolysin O (SLO), DNase B and C5a peptidase have proven
effective in confirming recent infection. Typically, the geometric mean titers of anti-SLO in sera
from children tend to level at the age of three, while the mean titer of anti-DNase B and anti-C5a
peptidase reach maximum levels around the age of six and nine, respectively (O'Connor et al.
1991). Typically, the antibody response to these antigens is dominated by the IgG subclass;
however, a secretory IgA response to C5a peptidase has been demonstrated (O'Connor et al.
1991). The group specific carbohydrate is considered the immunodominant antibody epitope;
however, the response is primarily mediated by IgM subclass (Emmrich et al. 1985). Because of
the central role in pathogenesis of streptococcal diseases, the response to M protein has received
the most attention. Antibodies to M protein opsonize streptococci for phagocytosis (Maxted
1956) and usually provide serotype specific immunity against infection by strains of the same M
protein serotype (Lancefield 1962; Quinn et al. 1985). Despite the protective value of these typespecific antibodies, detection in patient sera following infection is highly variable, with <20% to
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70% of patients exhibiting detectable levels (Siegel et al. 1961; Quinn et al. 1985). The site of
infection also influences the antibody response. Unlike the throat infection, a very poor serotypespecific response is generated following skin infection (El Kohly et al. 1980). This trend has also
been demonstrated for antibody responses against SLO, while the antibody response against
DNase B is good regardless of infection site (Kaplan et al. 1970).
While the importance of antibodies in GAS infections is well documented, adequate
information regarding the T lymphocyte response has been lacking. Historically, T cell help has
been shown to be a requirement for the antibody response against GAS (Braun et al. 1972), while
anamnestic cellular responses can be demonstrated in vitro with a patient’s peripheral blood
lymphocytes. More recently the CD4+ T cell response against M protein has received the most
attention in attempts to develop a protective serotype non-specific vaccine. Research led by
Good (Pruskakorn et al. 1992; Pruskakorn et al. 1994a; Pruskakorn et al. 1994b) and Kehoe
(Robinson et al. 1993; Rossiter et al. 1994) have shown that antigen-specific T cell responses
against M protein are protective in mice, and the immunodominant epitopes have been mapped.
While the role of the CD4+ T cell population is appreciated in the protective immune response,
information regarding the role, if any, CD8+ T cells play has been lacking. Evidence has been
presented to indicate that GAS may enter host epidermal cells (Hagman et al. 1999), however
GAS is typically an extracellular organism. While the ability of an exogenous antigen like GAS
to enter the class I processing and presentation pathway is not completely understood, several
mechanisms have received extensive attention elsewhere (Yewdell et al. 1999, Heath and
Carbone 1999). Rock et al. (Rock et al. 1993; Kovacsovics-Bankowski and Rock 1995) and
Harding et al. (Pfeifer et al. 1993; Harding 1996) have shown that extracellular particulate
antigens, whether protein coated beads or extracellular bacteria, can be processed and presented
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via class I by activated macrophages in vitro. This activity has also been demonstrated for
dendritic cells (Svensson et al. 1997) and B cells (Ke and Kapp 1996). Cross-priming (Bevan
1976) is an aspect of class I presentation of exogenous antigen that has received extensive
attention and yielded the most recent insight regarding potential mechanisms and requirements
(Bennett et al. 1997, Bennett et al. 1998). Accordingly, APC may uptake high-dosage antigen or
apoptotic cells (Kurts et al. 1998) and present the cell bound antigen via class I MHC under
conditions that require signaling through CD40 by CD4+ T helper cells (Bennett et al. 1997,
Bennett et al. 1998). Therefore, while providing means for class I presentation of tissueassociated antigens for immunological surveillance, this phenomenon may also serve as a means
for extracellular infectious agents to access this presentation pathway.
Virulence factors involved in evasion of host immune responses. Streptococcus pyogenes is
able to evade phagocytosis with an arsenal of somatic and secreted virulence factors. The
hyaluronic acid capsule is considered an important virulence factor, since strains lacking the
capsule are generally more readily phagocytosed and in turn much less infectious (Husmann et al.
1997). The capsule is believed to inhibit phagocytic uptake through steric interactions, physical
repulsion due to a net negative charge, or other potential mechanisms (Whitnack et al. 1981).
Being composed of equimolar concentrations of N-acetyl glucosamine and glucuronic acid,
components ubiquitously found in connective tissue component of the host (Kendall et al. 1937),
the capsule may potentially provide a protective mask over the organism, diminishing
recognition for the phagocytic process. Beyond the physical barrier provided by the capsule,
other virulence factors, notably M protein and C5a peptidase, are able to directly interfere with
the host immune response. M protein is able to prevent non-immune opsonization by binding
factor H (Horstmann et al. 1988; Horstmann et al. 1992) and more preferably factor H-like
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protein 1 (FLH-1), the alternative splice product of the factor H gene (Zipfel et al. 1999). Factor
H and FLH-1 are important regulators of the complement system that enact their functions by
splicing C3b and controlling the stability of C3 convertase (Zipfel et al. 1999). This prevention is
further augmented by C5a peptidase whose primary activity is to selectively cleave a six amino
acid peptide from the carboxy-terminus of the complement component C5 thereby preventing
chemotatic signaling necessary for the immune response (Wexler et al. 1985).
Although their function remains undetermined, another potential virulence aspect of GAS
is the family of immunoglobulin-binding proteins (IGPs) (Cleary and Retnoningrum 1994). This
family of cell associated proteins includes the M-like protein and a set of other proteins that are
classified as type IIa or type IIb, where IIa binds human IgG1, IgG2, and IgG4 and IIb binds only
IgG3 (Cleary and Retnoningrum 1994). Also, a set of these family members demonstrates IgA
binding capabilities (Bessen 1994). While these proteins have been shown to bind
immunoglobulin and could potentially help to mask the organism from phagocytosis, it has been
hypothesized that the immunoglobulin-binding proteins function as sensory protein allowing the
organism to regulate its virulence genes and thus alter the course of infection (Cleary and
Retnoningrum 1994; Boyle 1995).
Other virulence factors involved in promoting infection and pathology. Group A
streptococcus produces a battery of secreted factors that serve to promote the endurance and
spread of infection. While the secreted factors serve to protect the organism, they are also more
apt to elicit cytopathic effects upon host tissue. One set of factors serves to facilitate the spread
of infection by removing physical barriers. Within this set are the enzymes hyaluronidase
(Kehoe 1991) and streptokinase (Kehoe 1991; Husmann et al. 1997) and the surface plasmin
binding protein (Speziale et al. 1984). Hyaluronidase removes hyaluronic acid, an important
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Table 1. Major virulence factors of Streptococcus pyogenes and their potential role in infection
and pathogenesis
Component

Location

Function

Hyaluronic Acid
Capsule

capsule

Anti-phagocytic
factor
Adhesion

N-acetyl glucosamine

Adverse Activity in Host

GlcNAc is a B cell mitogen
Persistent Ab titers to
GlcNAc
Antibody cross-reactivity
between GlcNAc and myosin

cell wall
capsule

Cell Membrane

Induces cross-reactive
antibodies in animals

Lipoteichoic acid
(LTA)

cell wall

Adherence

Protein F
M protein

cell wall
cell wall

Adherence

M-like protein

B and/or T cell mitogen

Anti-phagocytic
factor

Superantigen for human T
cells
Host cross-reactive
antibodies
Induces host-reactive CTL
responses in vitro

cell wall

Sensory proteins?

Bind immunoglobulin and
other plasma proteins

Streptolysin O(SLO)
Streptolysin S (SLS)

secreted

Mediates lysis of
eucaryotic cells

SLO has cardiotoxic effects
SLS suppresses T cells

Pyrogenic exotoxins
SPE A, B, C

secreted

Fever induction
Cytotoxic
Septic shock

PBL mitogen
Suppress antibody response
Scarlet fever rash

Hyaluronidase

cell surface

Tissue invasion

Cleaves hyaluronic acid

C5a peptidase

cell surface

Anti-phagocytic
factor

The above information was obtained from the following: Whitnack et al. 1981; Goldstein et al.
1967; Cunningham and Russell 1983; Hasty and Courtney 1986; Horstmann et al. 1988; Hosein
et al. 1979; Boyle 1995; Thompson et al. 1970; Hryniewicz et al. 1978, Bohach et al. 1989;
Kehoe 1991; Wexler 1985 et al. 1985.
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connective tissue component, thereby permitting tissue penetration (Kehoe 1991). GAS removes
fibrin clots either directly with streptokinase or indirectly with plasmin-binding proteins that bind
plasmin, the key fibrinolytic enzyme (Lottenberg et al. 1987). This binding not only allows
plasmin to remain enzymatically active but also prevents it from regulation by its inhibitor, α-2
plasma inhibitor (Lottenberg et al. 1987).
Other secreted factors include streptolysin O (SLO) (Thompson et al. 1970, Halbert et al.
1961), streptolysin S (SLS) (Hryniewicz et al. 1978), and the pyrogenic exotoxins (SPE A, B, C).
SLO is capable of lysing a wide range of eucaryotic cells, most notably cardiocytes and
hepatocytes, by binding to the cell membrane to form a ring structure that allows high molecular
weight cytoplasmic proteins to leak out (Thompson et al. 1970). SLO is very antigenic and antiSLO antibody titers are a useful diagnostic indicator for recent GAS infection. Because it is
cardiotoxic and highly immunogenic, a potential model for rheumatic fever suggests that SLO is
carried to the cardiac tissue by circulating immune complexes of SLO and antibody however,
supporting in situ data has been lacking (Halbert et al. 1961). SLS is a non-antigenic
extracellular product that has been shown to be lytic for eucaryotic cells, including both red and
white blood cells (Hryniewicz et al. 1978). SLS has been shown to lyse both the cell membranes
and granules of phagocytes that lead to local tissue damage and a local inflammatory response.
Other well-characterized secreted virulence factors are the pyrogenic exotoxins, SPE A, B, and
C. Based on their shared biological activities these proteins belong to a family of pyrogenic
toxin superantigens (Bohach et al. 1989). SPE A and SPE C are encoded by a bacteriophage and
expression of the SPE A gene has been shown to be associated with strains that can cause severe
invasive infections (Schlievert et al. 1996). The primary effect of these exotoxins is to elicit
fever however, they have been shown to cause a wide array of problems: inducing the
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characteristic rash of scarlet fever, myocardial and hepatic necrosis, decrease in antibody
synthesis, and acting as a superantigen for T cells (Marrack and Kappler 1990; Schlievert et al.
1996).
Streptococcal M protein and the M protein family. Of all the virulence factors produced by S.
pyogenes, M protein is considered most important. This is not only by virtue of its antiphagocytic properties but also due to its structural and antigenic diversity (Manjula and Fischetti
1980; Phillips et al. 1981; Manjula et al. 1985), its ability to induce a protective antibody
response (Lancefield 1962; Quinn et al. 1985; Pruskakorn et al. 1992) and its potential to elicit
host cross-reactive immune responses (Kingston and Glynn 1971; Krisher and Cunningham
1985; Dale and Beachey 1987; Huber and Cunningham 1996). Because of these properties M
protein has garnered much attention from the research community as a vaccine candidate for
GAS infections and to understand the role the protein has in post-streptococcal autoimmune
sequelae.
M protein is a dimeric alpha helical coiled-coil protein that extends approximately 60 nm from
the surface of the organism (Phillips et al. 1981). The protein is able to maintain this coiled-coil
conformation due to a seven residue periodicity of non-polar amino acids found throughout the
molecule, with the notable exception of the wall and membrane-spanning region and the short
random sequence at the extreme amino terminus (Manjula and Fischetti 1980; Manjula et al.
1985). Within this periodicity the first and fourth residues are hydrophobic in nature forming the
core residues of the coil, the fifth is typically a basic residue, and an acidic residue can be usually
be found in the last position (Manjula and Fischetti 1980; Manjula et al. 1985). While the
periodicity is conserved, M protein does contain residual interruptions, especially of the
hydrophobic residues at the first and fourth positions of the heptad repeat,
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allowing flexibility (Phillips et al. 1981; Fischetti 1989). Based on these amino acid
irregularities within the heptad repeat, the central portion of the protein can be divided into three
subregions which correlate with the A, B and C sequence repeat regions (Fischetti 1989).
The N-terminal region of M protein contains a significantly higher net negative charge
than the C-terminal region (Fischetti 1989), which may hinder contact between GAS and
phagocytes due to electrostatic repulsion since phagocytes have a net negative surface charge
(Lichtman and Weed 1970; Manjula et al. 1985). The negative charge of the outer surface may
also be a factor in the protective antibody response against M protein since it has been
demonstrated that opsonic antibodies against M protein are more basic that non-opsonic
antibodies thereby eliminating the net negative charge upon binding (Fischetti 1983; Fischetti
1989).
Despite the relatively conserved coiled-coil structural conformation, M protein is able to
maintain antigenic diversity. M protein contains three regions of tandem repeats designated as A,
B and C, where the A and B region are found in the amino terminal portion and the C region is
within the more conserved carboxy region (Hollingshead et al. 1986; Fischetti 1989). Due to
naturally occurring insertional or deletional recombination events the number and size of repeats
within these regions may vary between the various M proteins, even among different strains or
isolates of the same serotype (Fischetti et al. 1985). Sequence analysis of the various M genes
indicates that the exposed amino terminus is the highly variable and the carboxy terminus is more
conserved among the different serotypes (Fischetti et al. 1985). It is the extensive variability of
the amino terminus for which serological typing is conferred, and so far over 100 distinct M
protein serotypes have been identified. Epidemiological studies have indicated that
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the serotype of the M protein is an important factor in the incidence of GAS infections and
sequelae (Berrios et al. 1986; Stollerman 1991; Johnson et al. 1992). GAS serotypes that are
associated with nasopharyngeal infections do not typically cause skin infections and the reverse
typically holds true as well, although there are certain serotypes that can infect both areas.
Furthermore, with a few exceptions, GAS serotypes that are associated with rheumatic fever
typically cause nasopharyngeal infections while serotypes that cause skin infections are
associated with glomerulonephritis (Veasy and Hill 1997). Detailed antibody reactivity studies
indicate that antigenic differences exist within the conserved carboxy region as well, suggesting
that most M protein serotypes may be placed in one of two major classes of M protein (Bessen et
al. 1989; O'Toole et al. 1992). Nearly all serotypes of GAS that have been associated with ARF
have been shown to express class I M protein (Bessen et al. 1989). Therefore, GAS serotypes
associated with rheumatic fever express M proteins that are antigenically distinct from the other
non-rheumatic serotypes.
M protein is a member of the M protein family, which includes structurally related M-like
proteins (Boyle 1995). The family is a large group of fibrous alpha-helical surface proteins that
share similar carboxy terminal halves, including the repeats of the C region and two non-adjacent
domains of the cell wall and membrane spanning portion, while maintaining high variability
within the amino-terminal halves (Bessen and Fischetti 1990; Nilson et al. 1995). Both M
protein and M-like protein bind one or more of several different plasma proteins including
immunoglobulin, fibrinogen, plasminogen, albumin, and complement components and β2microglobulin, however, only M protein exhibits anti-phagocytic activity (Cedervall et al. 1995).
Many GAS may express more than one protein from this family (Cedervall et al. 1995), however,
with the exception of M protein, their overall role in bacterial pathogenesis has not been
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completely understood. It has been observed that GAS isolates exhibiting IgA binding activity
are much more likely to be found in wound and deep tissue infections than in nasopharyngeal
sites (Bessen and Fischetti 1990; Bessen 1994). Also, binding of the various plasma proteins has
been shown to stabilize the dimer structure of the M-like proteins at physiological temperatures
(Nilson et al. 1995).
The most important aspect of M protein is the ability to inhibit non-immune opsonization
either by binding the complement control protein factor H, as already described above, or binding
plasma fibrinogen (Bessen and Fischetti 1990; Dale et al. 1996). It has been suggested that the
interaction with plasma fibrinogen masks C3b binding sites on the streptococcal surface, thereby
preventing activation of the alternative complement pathway and subsequent phagocytosis by
neutrophils (Dale et al. 1996). Also, fibrinogen has been shown to interact with the aminoterminus of M protein (Ryc et al. 1989) and prevent antibody binding to that particular area,
which is especially advantageous considering the immunodominant antibody epitope of M
protein is located within the B repeat region of the amino terminus (Fischetti and Windels 1988).
Despite the effective protective mechanism of binding to either fibrinogen or factor H, M protein
cannot prevent subsequent immune opsonization. Opsonic antibodies are directed against the 10
or so amino acids of the extreme amino terminus, an area not bound by fibrinogen (Fischetti and
Windels 1988). However, GAS may still maintain a slight advantage because the production of
opsonic antibodies is not only delayed but also made in much lower titers as compared to nonopsonic antibodies (Jones and Fischetti 1988). Furthermore, the protective antibody response to
GAS is serotype specific and cannot protect the host against infection from other serotypes.
Immunity to GAS is highly dependent on the production of opsonic antibodies against M
protein; therefore, M protein has become a potential vaccine candidate for GAS. In addition to
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the problem of serotype specificity of the opsonic antibody response as mentioned above, M
protein contains epitopes that have the potential to elicit deleterious autoimmune responses as
will be discussed later in the review. Extensive work contributed by groups led by either Good
(Pruskakorn et al. 1992; Pruskakorn et al. 1994a; Pruskakorn et al. 1994b) or Kehoe (Robinson et
al. 1993; Rossiter et al. 1994; Delvig et al. 1997), have delved into the problem of identifying a
M protein peptide that will elicit a serotype non-specific opsonic antibody response along with a
strong helper T cell response to promote memory. CD4 T cell epitopes have been mapped
throughout the length of select M protein serotypes; however, in order to avoid serotype specific
responses efforts have been focused primarily on the conserved carboxy region (Robinson et al.
1993; Rossiter et al. 1994). Good et al. (Pruskakorn et al. 1994b) have described one particular
epitope derived from the conserved region of M5 that is capable of inducing bactericidial
antibodies as well as a helper T cell response to multiple GAS serotypes, however the antibody
response was less effective in killing than serotype specific antibodies. In addition, human CD4+
T cell lines specific for this peptide also demonstrated proliferative responses to mammalian
myosin (Pruskakorn et al. 1994a).

Acute Rheumatic Fever and Other Post-streptococcal Autoimmune
Sequelae
History and epidemiology. For over three hundred years ARF has been under the scrutiny of the
medical establishment, however, complete appreciation of the disease pathology did not come
until within the last century. During the early period Guillaume de Baillou distinguished ARF
from other causes of rheumatism and Thomas Syndenham described the acute chorea that bears
his name, however neither one connected these symptoms to a disease of the heart (reviewed in
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Stollerman 1975; Read and Zabriskie 1977a). Although the first definitive descriptions of
cardiac lesions of acute rheumatic fever were being published as early as the early eighteenth
century, it took over one hundred years before cardiac involvement in rheumatic fever was
appreciated. It was at this time that William Wells, the man credited for the first description of
the subcutaneous nodules in cases of rheumatic fever, presented a clinical study detailing heart
pathology of a series of true cases of rheumatic fever (Stollerman 1975; Read and Zabriskie
1977a). This was followed by the eloquent studies of Jean-Baptiste Bouillaud, the ‘Father of
rheumatic heart disease’ who in 1836 gave the first detailed auscultation methods for diagnosing
acute rheumatic fever (Stollerman 1975; Read and Zabriskie 1977a). While several
manifestations of rheumatic fever were being described separately during this time, it was Walter
Cheadle who in 1889 comprehensively described, for the first time, all the symptoms of ARF as a
syndrome and his definition has not deviated much even to this day (Read and Zabriskie 1977a).
His classification of the symptoms into phase correlates with major and minor Jones’ criteria still
used today for diagnosis (Dajani 1992).
The symptoms of rheumatic fever, glomerulonephritis and psoriasis have been known to
man for several hundred years. Clinicians knew that outbreaks of rheumatic fever and
glomerulonephritis almost invariably followed epidemics of scarlet fever, however, confirmation
of the diseases being linked to an infectious entity did not come until the early part of this
century. While the relationship of antecedent sore throat and rheumatic fever was first being
described in 1880 by Fowler, it was not appreciated until 1907, when Bela Schick developed the
concept of rheumatic fever being a complication of a bacteria infection (Stollerman 1975; Read
and Zabriskie 1977a). Schick also drafted the concept of the latent period between the initial
infection and the sequelae, which was corroborated about the same time by Poyton and Payne
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and yet again by Coombs in 1924 (Veasy and Hill 1997). These studies were soon followed by
four important studies that provided final evidence supporting the relationship between group A
streptococcus pharyngitis and ARF. During the early 1930’s Rebecca Lancefield defined
subgroups of streptococci based on the cell wall carbohydrate and identified the GAS as the most
important human pathogen (Lancefield 1962). Also in the 1930’s, two independent
epidemiological studies, conducted by Coburn (1935) in the United States, and Collis (1932) in
England, confirmed the relationship between streptococcal pharyngitis and the development of
ARF. The final evidence came from studies conducted by a group led by Rammelkamp, which
demonstrated that rheumatic fever could be prevented by treating streptococcal pharyngitis with
penicillin (rev. in Stollerman 1975). Correlation between streptococcal throat and skin infections
and glomerulonephritis soon followed in 1929 and 1940, respectively. Although psoriasis does
not epidemiological correlate to scarlet fever as does ARF and AGN, the relationship with
antecedent streptococcal sore throat and development of psoriasis was confirmed in 1916.
Probably one of the most interesting aspects of ARF is its changing nature. Once one of
the major causes of death in children in this country, it has now become an occasional outbreak,
while still remaining a serious threat to children in more under-developed countries (Gordis
1985). During the beginning of this century ARF was the leading cause of death for adolescents
and heart disease for individuals under the age of forty in the United States (Homer and Shulman
1991). At this time, ARF had a reported annual incidence of 100 to 200 cases out of 100,000
population and a death rate of 25 to 30 per 100,000 population that seriously outnumbered deaths
related to other infectious diseases including polio, measles, and diphtheria (Homer and Shulman
1991). However, by the 1940’s the incidence had declined to about 50 per 100,000 population
and continued a steady decline to an incidence rate of 0.5 per 100, 000 by the early 1980’s
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(Gordis 1985; Griffiths and Gersony 1990). This steep decline led some in the medical
establishment to predict the eventual disappearance of the disease in the United States; however,
in recent years ARF has had an unexpected resurgence. Isolated outbreaks have been reported in
Utah (Veasy et al. 1987), Ohio (Congeni et al. 1987), Pennsylvania (Wald et al. 1987), New York
(Giardina and Heaton 1988; Griffiths and Gersony 1990), and Tennessee (Westlake et al. 1990).
West Virginia also had an increased incidence rate in recent years (Hoffman et al. 1997).
AGN appears to be following a similar epidemiological path as ARF, in that by the
1950’s the incidence had declined considerably in the United States and Europe, but it continues
to be a major childhood threat in less developed countries (Ayoub and Chun 1990). Like ARF,
AGN is predominantly a childhood disease, where 60% of all cases occur in the 2 to 12 year age
range and less than 5% occurring in children under 2 years of age (Richards 1991). Typically,
AGN occurs in the presence of a nephritogenic strain of GAS with an overall attack rate of 15%
regardless of infection site (Stetson et al. 1955), however, nephritogenic strain of M49 serotype
has been shown to give a 25% and 5% risk of AGN development following skin or throat
infection, respectively (Anthony et al. 1969). Psoriasis, on the other hand, does not demonstrate
such age discrimination and affects about 2% of the Western population.
Predicting the manner of these diseases has proven difficult due to the interplay of several
important epidemiological factors, both environmental and host related. In the past, the major
environmental factor has been socioeconomic status, where ARF has been a disease associated
with crowded, impoverished urban areas and in many under-developed countries this trend still
holds true. The incidence decline witnessed during the past fifty years in the United States has
been widely attributed to better living standards, whether better nutrition, hygiene or housing
(Land and Bisno 1983; Gordis 1985). While socioeconomic conditions are important they alone
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cannot explain the changes in the United States. Recent outbreaks have occurred in mostly
middle-class suburbanian and rural areas instead of the predicted urban areas (Wald et al. 1987;
Westlake et al. 1990; Veasy and Hill 1997). The decline in ARF incidence may also be
attributed to the introduction and widespread use of antibiotics. Penicillin has been shown to be
important in preventing onset and recurrences of ARF as well as decrease the morbidity.
However, the incidence of ARF began decreasing before widespread use of penicillin and about
one-third of ARF cases follow mild or asymptomatic pharyngitis that receive no medical
attention.
Clinical aspects of ARF and other post-streptococcal autoimmune complications. The
clinical presentation of ARF primarily involves three major organs systems; the heart, joints and
nervous system and diagnosis is usually made predominately on the basis of Jones’ criteria
(Dajani 1992). Systemic manifestations may include one or more of the following; polyarthritis,
carditis and chorea, and usually occur simultaneously with skin manifestations that include
erythema marginatum and subcutaneous nodules. The polyarthritis of ARF is the most common
but least specific symptom involving the larger joints and is characteristically asymmetric and
migratory in nature. Syndemham’s chorea is the result of an inflammation of the central nervous
system specifically involving the basal ganglia and caudate nuclei (Ayoub and Chun 1990). It is
a delayed manifestation appearing up to 3 months after the onset of ARF in about 20% of ARF
patients and in some cases may be the only manifestations (Ayoub and Chun 1990).
Rheumatic carditis associated with ARF is a pancarditis affecting the endocardium,
myocardium, and pericardium at varying degrees, however the hallmark of rheumatic carditis is
valvulitis where the inflammation leads to mitral valve insufficiency and potentially valve
stenosis. Another hallmark characteristic of ARF is the granulomatous lesions known as
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Aschoff’s nodules or bodies that were first described in 1904 by Ludwig Aschoff and can be
found in interstitium of myocardium, atrial endocardium and heart valves. While these lesions
are considered one of the major indicators of ARF, doubt still remains about their composition
and, more important, their role in the disease process. Histological analysis reveals that
Aschoff’s bodies are predominately derived from injured heart muscle cells trying to undergo
regeneration, otherwise known as Anitschkow cells (Wagner 1960). It has been inferred that
these Anitschkow cells are responsible for the scarring of heart tissue associated with ARF
(Stehbens and Zuccollo 1999). Established Aschoff’s lesions are not directly stained with typical
lymphocyte and macrophage reagents, however the damage could be the result of inflammatory
cytokines produced during multiple phases of infiltration of macrophages followed by T and B
lymphocyte infiltration (Kemeny et al. 1989; Fraser et al. 1997). In regard to their role in the
disease process, Aschoff himself argued that the cardiac failure associated with this disease is
due to weakness resulting from changes in the myocardium more so than by valvular lesions
(Stollerman 1975). Furthermore, the persistence of Aschoff bodies in the asymptomatic patient
with clinically inactive rheumatic heart disease may actually represent a low-grade chronic
inflammatory process that has little to do with the functional state of the myocardium (Stehbens
and Zuccollo 1999).
Other autoimmune complications of streptococcal infection that have received much
attention from the research community include acute glomerulonephritis and psoriasis. Psoriasis
is an inflammatory skin disease characterized by lesions that are sharply demarcated reddish
plaques of various size and cover with scaling. These symptoms are due to reversible
keratinocyte hyperproliferation giving rise to the increased epidermal turnover or scaling
(England et al. 1997; Prinz 1997). In greater than 10% of patients these symptoms are also
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accompanied by joint involvement which may lead to severe arthritis. AGN is characterized by
renal tissue involvement and glomerular injury is evidenced by the sudden appearance of
hematuria and proteinura that is often accompanied with edema (Richards 1991). Hematuria in
varying degrees is present in all patients with up to 90% exhibiting proteinura (Zarconi and
Smith 1988; Richards 1991). Typically, 60 - 70 percent of these patients display hypertension
and edema. Renal biopsies of patients demonstrate diffuse proliferation of endothelial and
mesangial cells accompanied by polymorphonuclear cell infiltrate (Zarconi and Smith 1988).
Other microscopic finds include diffuse antibody and complement deposits, which are believed
to be the cause of the symptoms and pathology.
Role of humoral immune response in pathology of post-streptococcal acute rheumatic
fever. Although the underlying mechanisms of pathology have yet to be truly understood, ARF
has long been considered an autoimmune event. This suspicion has been based upon several
factors, including the latent period between initial infection and the onset of ARF, the ability to
prevent such an event with effective penicillin treatment, and most importantly, the exaggerated
antibody responses exhibited by ARF patients. One of the earliest and most sustaining theories
suggested that susceptibility to the disease might be due to immune hyperresponsiveness (rev.
Ayoub 1991). This theory eventually became contested when Cavelti described heart-reactive
antibodies for the first time, putting forth the idea that autoimmune mechanisms may be involved
in the pathogenesis of ARF (Cavelti 1945).
Early evidence suggesting that antibodies may play a role in pathology was presented first
by Kaplan, who confirmed the presence of heart reactive serum antibodies in ARF patients and
also found diffuse antibody and complement deposits throughout the myocardium that was
localized primarily at edges of cardiac myofibers (Kaplan 1960; Kaplan et al. 1964b). Kaplan
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then followed up this work by demonstrating for the first time that antibodies raised against GAS
cross-react with cardiac tissue (Kaplan 1963; Kaplan and Suchy 1964a). About the same time,
Goldstein et al. (1967) demonstrated that antibodies to GAS cell wall polysaccharide GlcNAc
cross-react with heart valve glycoproteins and Zabriskie and Freimer (Zabriskie and Freimer
1966) described an antibody cross-reaction between GAS membranes and myocardial
sarcolemma. Seven years later Beachey and Stollerman (Beachey and Stollerman 1973)
demonstrated that M protein was capable of absorbing heart-reactive antibodies from human
sera. Since then, it has been repeatedly shown that ARF patients typically exhibit high titers of
anti-streptococcal antibodies in their sera against M protein and GlcNAc that cross-react with
cardiac myosin (van de Rijn et al. 1977; Cunningham and Russell 1983; Cunningham et al.
1989). Antibody cross-reaction has also been implicated in other aspects of ARF, including
chorea. A study of a group of patients with chorea found that almost half of the patients
exhibited antibodies reactive with the cytoplasm of neurons in the subthalamic and caudate
nuclei (Husby et al. 1976).
Although these antibodies have been extensively described and antibody deposits have
been consistently found in histological sections (Kaplan 1960; Kaplan et al. 1964b; Kemeny et al.
1989), their role on the course of the disease remains largely unknown. The anti-streptococcal
carbohydrate antibodies are typically of the IgM isotype and have been shown to be capable of
mediating complement lysis in vitro (Prehm et al. 1995). Research conducted by the laboratories
of Ayoub (Dudding and Ayoub 1968; Shulman et al. 1974a) and Eichbaum (1995), observed that
ARF patients with heart problems have persistently high titers of anti-streptococcal antibody
compared to controls and ARF patients without cardiac problems suggesting ARF patients have
an exaggerated humoral immune response. Observations have been made in ARF patients that a
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sustained rise in the anti-streptococcal antibody titer that cross-reacts with cardiac tissue has
been shown to precede an attack of ARF (Kaplan and Frengley 1969). Furthermore, sufficient
evidence has been presented to show that streptococcal infections are capable of inducing crossreactive antibody responses in both humans and laboratory animals (Zabriskie and Freimer 1966;
van de Rijn et al. 1977; Cunningham et al. 1988). However, it is difficult to assign a primary role
for the cross-reactive antibodies since evidence that can ascribe pathogenic potential to such
antibodies is lacking (Neu et al. 1993) and because normal healthy individuals exhibit low levels
of self-reactive natural antibodies in their sera without any resultant complications (Klinman et
al. 1988).
Also, it may be postulated that these antibodies are secondary to the disease process,
being the result of antigen release due to organ specific inflammation and damage and not due so
much to direct cross-reactivity (Neu et al. 1993). Patients who have sustained cardiac injury or
surgery exhibit myosin reactive antibodies in their sera, however these antibodies do not crossreact with GAS determinants (Kennedy and Das 1976). Likewise, antibodies raised against
bovine heart valve homogenates were not cross-reactive to GAS polysaccharide (KaspGrochowska et al. 1972a). Upon histological staining of human heart and kidney tissue with this
bovine heart antisera and anti-streptococcal sera they found that the bovine heart sera reacted to
connective tissue and basement membrane while the anti-streptococcal sera reacted to cellular
components of both myocytes and fibroblasts in the heart and the glomerular tufts of the kidney
(Kasp-Grochowska et al. 1972b). Demonstration of this cross-reactivity leads to another
interesting facet of the autoimmune response; a bacterial carbohydrate is capable of eliciting
antibodies that can cross-react with protein determinants. Cunningham et al. (1983; 1984; 1986;
1992) have developed an extensive panel of murine and human monoclonal antibodies that cross-
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react with GAS group specific carbohydrate (GlcNAc) and mammalian proteins including
myosin and keratin. In addition, they have shown that this cross-reaction cannot be inhibited
with the removal of carbohydrate from the proteins with n-acetyl-muraminidase treatment
(Shikhman and Cunningham 1994). Harris et al. (1997) demonstrated that monoclonal
antibodies against GAS polysaccharide were capable of isolating cross-reactive peptides from a
panel of phage display libraries. Since the peptides binding to these antibodies appeared to be
specific they suggested that distinct mechanisms exist for carbohydrate and peptide recognition
and that cross-reactive peptides may be found for most anti-carbohydrate antibodies (Harris et al.
1997).
Involvement of cellular immune response in pathology of post-streptococcal autoimmune
diseases. The group led by Zabriskie (Read et al. 1974) was among the first to note a
relationship between cell-mediated immune responses to streptococcal antigens and attacks of
ARF in humans. Histological sectioning and staining of biopsied cardiac tissue reveals that
pathology is primarily due to lymphocytic infiltrates (Raizada et al. 1983; Kemeny et al. 1994)
however, the question remains as to how and why these cells are recruited. In both active and
chronic cases of ARF, these infiltrates are found to be mostly macrophages and T lymphocytes of
which the CD4+ population outnumbers the CD8+ population 4:1 (Kemeny et al. 1994).
Phenotypic and cytokine profiles of peripheral blood lymphocytes (PBL) of ARF patients
compared to controls indicate that ARF patients exhibit hyperimmune responses where there is a
sustained increase in the number and percentage of CD4+ T cells and B cells but a decrease in the
percentage of CD8+ T cells (Lueker et al. 1975; Williams et al. 1982; Cairns 1988; Bhatia et al.
1989; Alarcon-Riquelme et al. 1990; Morris et al. 1993a; Morris et al. 1993b).
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Several studies have suggested that during the acute phase of disease, the numbers and
percentages of CD4+ T cells were increased, returning to normal during convalescence while the
CD8+ T cells were decreased during the acute phase and increased during recovery (Cairns 1988;
Alarcon-Riquelme et al. 1990; Bhatnagar et al. 1999). This increased percentage in peripheral
CD4+ lymphocytes has been shown to correlate with the increased percentage of peripheral
CD25+ (IL-2R) cells (Morris et al. 1993a; Morris et al. 1993b). Furthermore, the increases in
both CD4+ and CD25+ cells correlate to the increased production of IL-2 in ARF patients (Narin
et al. 1995). In addition to increased IL-2 levels (Morris et al. 1993b; Narin et al. 1995), acute
phase patients exhibit increased levels of inflammatory cytokines, including IL-1 (Morris et al.
1993b; Narin et al. 1995), IL-6, IL-8 (Kutukculer and Narin 1995; Yegin et al. 1997), and TNF-α
(Miller et al. 1989; Yegin et al. 1997). The results of these studies have led to the proposal
suggesting that the pathological outcome of ARF is a CD4+ lymphocyte-driven hyperimmune
response with convalescence mediated by CD8+ lymphocytes down-regulating the deviant
immune responses (Cairns 1988; Alarcon-Riquelme et al. 1990; Bhatnagar et al. 1999).
However, extensive studies with experimental autoimmune myocarditis indicate that CD4+ T
cells are necessary to initiate the response but CD8+ T cells mediate the pathological outcome
and recovery (Rose et al. 1990; Neu et al. 1993; Smith and Allen 1993).
In addition to an overzealous immune response, several reports have indicated that ARF
patients exhibit cross-reactive autoimmune cellular responses. el-Demellawy et al. (1997)
demonstrated that PBL from ARF patients recognize a 50 kDa and 54 kDa protein of myocardial
extracts and that pre-culturing with GAS extracts may intensify the proliferative response.
Cloning of lymphocyte infiltrates has yielded conflicting results. Guilherme et al. (1995) have
been able to isolate clones that cross-reacted with M protein and myosin however; Yoshinaga et
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al. (1995) could not. Cloning of PBL from active and chronic cases of ARF has given no clearer
answer either. The T cell lines produced by Pruksakorn et al. (1994a) that cross-reacted between
M protein and myosin were isolated from healthy individuals. While this study may not confirm
the presence of cross-reactive lymphocytes, it does indicate that precursor myosin reactive T cells
can exist in the periphery. Furthermore, the T cell lines developed from ARF patients in the
Yoshinaga study reacted only with lysates of streptococcal strains associated with ARF but not
strains associated with nephritis or non-pathogenic streptococci (Yoshinaga et al. 1995). While
the T cell data may not provide conclusive support for a cross-reactive immune response, it at
least underscores the notion that these patients exhibit hyperimmune responsiveness.
While ample evidence has been provided indicating a role for the T lymphocyte
compartment in rheumatic fever, the question of tissue-specific recruitment remains. Fibroblasts
of biopsied tissue from ARF patients, but not normal controls or patients of other potentially fatal
cardiac diseases, were shown to have aberrant increases in MHC class II molecule expression,
and therefore have the potential to act as antigen present cells (Amoils et al. 1986). In support of
this data, histological analysis by Raizada et al. (1983) demonstrated that CD4+ T infiltrates were
closely positioned to cardiac fibroblasts and collagen fibrils. Studies conducted with the myosininduced myocarditis murine model indicate the resident APC in the normal myocardium express
MHC class II and can present myosin to primed T cells in vitro (Smith and Allen 1992;
Donermeyer et al. 1995). In addition, myosin immunization activates endothelial ICAM-1
expression which upregulates expression of class II MHC and Class I MHC on cardiac interstitial
cells and myofibers, respectively (Pummerer et al. 1991; Pummerer et al. 1996).
Kotb (1998) has suggested that T cell responses initiated against microbial antigens and
superantigens can generate high levels of inflammatory cytokines that ultimately lead to
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localized tissue destruction and subsequent release of self-antigen that allows for the expansion
of autoreactive T cells. S. pyogenes produces several superantigens, including pyrogenic
exotoxins (SPE), LTA, and M protein. In vitro and in vivo studies have demonstrated that
streptococcal proteins, especially the M protein, can induce the differentiation of human and
rabbit cytotoxic T lymphocytes with the capacity to kill myocardial cells and cell lines (Dale et
al. 1981; Dale and Beachey 1987; Kotb et al. 1989). Certain serotypes of M protein that have
been associated with ARF have been shown to have superantigenic effects on particular subsets
of human lymphocytes (Tomai et al. 1990; Tomai et al. 1991; Tomai et al. 1992; WatanabeOhnishi et al. 1994), however, this has not been correlated to Vβ gene usage in ARF patients
(Abbott et al. 1996).
Role of the immune response in other post-streptococcal autoimmune sequelae. Due to
pathological manifestations and histological findings psoriasis has been suspected to be an
autoimmune disorder, in that, extensive granulocytic and T lymphocytic infiltrates, as well as
antibody deposits, can be found throughout the dermis and epidermis (Bjerke et al. 1978; Baker
et al. 1984a). Lesional eruptions coincide with an influx of activated macrophages and CD4+ T
cells while disease resolution is associated with the influx of CD8+ T cells (Bjerke et al. 1978;
Baker et al. 1984a; Baker and Fry 1992). Infiltrating T cells have been observed in close
proximity to class II MHC-bearing dendritic cells (Baker et al. 1984b). Psoriatic pathology has
been induced in uninvolved psoriatic skin transplants on SCID mice following injection of
activated mononuclear cells (Gottlieb et al. 1996). Further, immunoregulatory agents
cyclosporin A and anti-CD4 antibody clinically alleviate symptoms (Griffiths et al. 1986; Morel
et al. 1992). Studies have demonstrated the capacity of psoriatic T cells to be mitogenic to
keratinocytes in vitro (Prinz et al. 1994; Bata-Csorgo et al. 1995) and T cell stimulating
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cytokines IL-2 and IFN-γ exacerbate skin lesions in vivo (Lee et al. 1988; Fierlbeck and Rassner
1990). T cells isolated from lesions also produce TNF-β, IL-3, and IL-5 (Vollmer et al. 1994),
however it is IFN-γ that is believed to play the central role (Baker et al. 1988; Scheynius et al.
1992; Prinz et al. 1994). IFN-γ along with TNF-α and β, induce ICAM-1 and MHC II
expression on keratinocytes witnessed in vivo (Vollmer et al. 1994).
The relationship between GAS throat infections and psoriasis has long been established;
only recently has direct supporting evidence emerged. Psoriatic patients have been shown to
exhibit circulating autoreactive antibody (Perez-Lorenzo et al. 1998), especially to keratins
(Shikhman and Cunningham 1994; Sigmundsdottir et al. 1997; Valdimarrson et al. 1997) but, as
with ARF, no direct association with pathology can be demonstrated. Circulating T cells from
psoriatic patients demonstrate the ability to respond to streptococcal M protein peptides that
share sequence homology to keratin (McFadden et al. 1991; Sigmundsdottir et al. 1997). T cell
lines derived from psoriatic lesions display specific responses to streptococcal antigens (Baker et
al. 1993). While direct cross-reactivity has been demonstrated, others have postulated a role for
streptococcal superantigens including M protein and SPE (Leung et al. 1995a; Leung et al.
1995b; Valdimarrson et al. 1997).
Unlike ARF and psoriasis, cell mediated immunity is lacking in AGN (Rajajee et al.
1984). Therefore, the resultant pathology of AGN is believed to be due to an elevated antibody
response resulting in antibody and complement deposition and the subsequent inflammatory
response. The mechanisms under investigation include antibody-antigen complexes that build up
in the target tissue (Nordstrand et al. 1996), direct antibody cross-reactivity (Lange 1995), and
streptococcal antigen deposition (Holm 1988; Nordstrand et al. 1998). Dillon et al. (1974) were
among the first to provide supporting evidence when they reported that patients with AGN
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demonstrate elevated antibody titers to DNase B but not SLO as compared to controls and that
following skin infections the anti-DNase B titers rose more often and persisted longer than the
anti-SLO titers. More recently, Mori et al. (1997) found that IgG titers against M12 C region but
not the AB region were higher in AGN patients and persisted after the SLO and streptokinase
titers returned to normal.
In addition to the elevated antibody response witnessed in AGN patients, it is believed
that antibody cross-reactivity may play a role as well. Markowitz and Lange were the first to
observe immunologic cross-reactivity between the streptococcal glycoprotein and the glomerular
basement membrane (Markowitz and Lange 1964). Several groups have since demonstrated in a
variety of in vitro systems the cross-reactivity between anti-streptococcal antibodies and kidney
basement membrane (Fitzsimons et al. 1987; Kraus and Beachey 1988; Kraus et al. 1990).
Antibody cross-reactivity and corresponding pathology have also been demonstrated in vivo with
laboratory animals (Fitzsimons and Lange 1991; Lange 1995). Histological findings indicate that
although IgM and IgG are present, C3 arrives first and is the major immune deposit found in the
kidney (Nordstrand et al. 1996). A possible explanation may be that the localization of
streptokinase to glomeruli causes subsequent deposition of complement as an effect of the ability
of streptokinase to convert plasminogen to plasmin (Holm 1988; Nordstrand et al. 1998).
Immune complexes are believed to have a role in the later stage of disease since C3 deposition is
followed by IgG deposition in humans (Sorger 1986).
Potential role of streptococcal M protein in autoimmunity. Epidemiological studies indicate
the association of particular streptococcal serotypes with systemic infection and sequelae (Berrios
et al. 1986; Johnson et al. 1992). Several groups have demonstrated the ability of M protein to
induce antibodies that cross-react with various host coil-coiled proteins (Hosein et al.
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1979; Dale and Beachy 1985a; Dale and Beachy 1985b; Cunningham et al. 1988; Kraus et al.
1990; Vashishtha and Fischetti 1993). The alpha helical coiled-coil feature of M protein is not a
common conformation for most bacterial surface proteins; however, the conformation is
prevalent among mammalian proteins. Research conducted by laboratory of Fischetti (Manjula
and Fischetti 1980; Manjula et al. 1985) have shown that M protein, especially those serotypes
associated with autoimmune sequelae, shares extensive amino acid sequence and
physicochemical similarities with coiled-coil mammalian proteins, notably myosin heavy chain,
tropomyosin, and type I keratins. Furthermore, the coiled-coil in the B region is characteristically
more similar to mammalian coiled-coil proteins, especially myosin (Manjula and Fischetti 1986)
and the B region contains the immunodominant antibody epitopes (Fischetti and Windels 1988).
These examples of shared homology, especially in regions of immunodominancy, provide an
explanation for the ability of M protein to induce a host-crossreactive antibody response.
Independent studies by Dale and Beachey et al. (1985a; 1985b; Kraus et al. 1990), Cunningham
et al. (1988; 1992), and Fischetti et al. (Vashishtha and Fischetti 1993) have demonstrated in
experimental animals the ability of M protein to elicit antibodies that cross-react with
mammalian coiled-coil proteins; notably myosin, tropomyosin, keratin and actin.
Experimental evidence indicating a role for M protein in inducing a host cross-reactive
cellular response has been conflicting (Robinson et al. 1993; Pruskakorn et al. 1994a; Guilherme
et al. 1995; Yoshinaga et al. 1995; Huber and Cunningham 1996). In vitro and in vivo studies
have shown that M protein has the potential to induce cytotoxic T cell responses that have the
capacity to kill myocardial cells (Friedman et al. 1971; Yang et al. 1977; Dale and Beachey 1987;
Kotb et al. 1989; el-Demellawy et al. 1997). Dale and Beachey et al. (1987; Kotb et al. 1989)
have demonstrated this for human lymphocytes, and Yang et al. (1977) and Friedman et al.
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(1971) were able to actively immunize laboratory animals with GAS and demonstrate lytic
activity to heart cultures. However, several groups that have been able to demonstrate the
antigenicity of M protein have not been able to induce such cross-reactive responses (Robinson et
al. 1993; Pruskakorn et al. 1994a).
Peptic extracts of M protein from rheumatogenic strains of GAS (M5, M6, M18, M19,
and M24) have been shown to have superantigenic potential for human cord blood T cells and
peripheral blood lymphocytes (Dale et al. 1981; Dale and Beachey 1987; Tomai et al. 1991;
Watanabe-Ohnishi et al. 1994). Work initiated by Dale et al. (1981; 1987) and carried on by
Kotb et al. (Tomai et al. 1991; Tomai et al. 1992; Watanabe-Ohnishi et al. 1994) demonstrated
that peptic extracts of M protein (pepM) from rheumatogenic strains of GAS (M5, M6, M18,
M19, and M24) are all superantigens for human T cells with all sharing a specificity for Vβ4,
however, each serotype has its own unique set of Vβ specificity which is also distinct from those
reported for streptococcal pyrogenic exotoxins. Furthermore, phenotypic analysis of psoriatic
lesional T cells indicates an increase in Vβ2 expressing T cells (Lewis et al. 1993), as well as,
Vβ1, 8, 12 (Abe et al. 1991; Lewis et al. 1993). This led to the hypothesis that the
superantigenicity of M protein may play a role in the pathogenesis of post-streptococcal
autoimmune diseases (Tomai et al. 1990; Watanabi-Ohnishi et al. 1995). The superantigenic
ability of M protein has been questioned as other groups have been unable to repeat this response
with recombinant protein (Degnan et al. 1997) or have demonstrated the superantigenicity is due
to exotoxin contamination (Fleischer et al. 1992). Furthermore, while patients with invasive
GAS infections have abnormalities in the Vβ repertoire of peripheral blood T cells consistent
with superantigen stimulation by streptococcal proteins (Watanabi-Ohnishi et al. 1995), namely
the exotoxins, a study of the Vβ repertoire of ARF patients did not show any such abnormalities
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(Abbott et al. 1996). While indicating that superantigen responses are not a primary mechanism
of autoimmune sequelae, it does not rule out the possibility that superantigens may exacerbate
existing autoimmune responses.
Influence of host genetic factors on susceptibility to ARF and other post-streptococcal
autoimmune disorders. It has been long suspected that genetic or heredity factors play a very
important role in the susceptibility to rheumatic fever. Although this theory first came into
existence in the late eighteenth century when Sir Arthur Newsholme conducted the first
epidemiological study of rheumatic fever, tangible scientific evidence has not been forthcoming.
Evidence exists for the genetic control of the immune response to GAS (Greenberg et al. 1980;
Greenberg et al. 1981). Greenberg et al. found that the immune response to streptococcal
antigens is controlled by two HLA-linked genes (Greenberg et al. 1981) and is inherited in an
autosomal dominant manner (Greenberg et al. 1980). In addition, Hafez et al. discovered a
relationship between HLA expression and the immune response to carbohydrates where a
recessive trait exists for hyper-responsiveness to carbohydrates (Hafez et al. 1990). Several
groups have attempted to correlate susceptibility to post-streptococcal autoimmune disorders to
genetic factors, particularly race and HLA antigen expression, for over twenty years and although
correlations have been made they are not without contradictions. In fact, the pioneering
immunogenetic study conducted in 1973 by Falk et al. (1973), which reported a reduced
frequency in HLA-A3 in ARF patients, was contradicted two years later by Caughey et al. (1975)
who saw an increased frequency of HLA-A3, as well as HLA-A8, in RF patients. Another class I
HLA antigen that has received attention is HLA-B5. Greenberg et al. (1975) were the first to
note that lymphocytes from HLA-B5 individuals were more responsive in vitro to streptococcal
antigens than their non-HLA-B5 bearing counterparts. Furthermore, an association has been
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made between the presence of elevated immune complex levels and the presence of HLA-B5 in
RF patients (Yoshinoya and Pope 1980). Yet, the frequency of HLA-B5 was found to be reduced
in RF families (Read et al. 1977b). Similar studies conducted with psoriatic patients indicate that
HLA-Cw6, B13, and Bw57 appear to confer susceptibility (Christophers 1996).
The difficulties in demonstrating susceptibility linkage to HLA class I genes have also
been encountered by several groups who undertook studies beginning in the 1980s that delved
into the linkage to HLA class II genes. Most likely the greatest challenge has been due to
population diversity and ethnicity. Association with HLA-DR4 was reported in Caucasians
populations in the U.S. (Anastasiou-Nana et al. 1986; Ayoub et al. 1986) and Saudia Arabia
(Rajapakse et al. 1987). HLA-DR1 was found associated with black populations in South Africa
(Maharaj et al. 1987) whereas HLA-DR2 was implicated in susceptibility in RF in black
Americans (Ayoub et al. 1986). In Brazilian patients of mixed background (Guilherme et al.
1991) HLA-DR7 and DR53 were found in higher frequencies. Interestingly, psoriasis a
predominantly a Caucasian disease, seems to have an association with HLA-DR7 as well
(Christophers 1996). This data may be interpreted as indicating that the real susceptibility gene
for RF is not represented by any of these markers but instead by another genes present in HLA
complex that could display various linkage patterns with HLA-DR and DQ (Gerbase-DeLima et
al. 1994). Another potential explanation is that the HLA genes do not play a significant role in
dictating susceptibility (Ertug 1993). Either way more substantiated scientific evidence is
necessary.
Another potential indicator for susceptibility to ARF is the expression of a B cell
alloantigen recognized by the D8/17 monoclonal antibody, an antibody produced in mice against
B cells from ARF patients (Patarroyo et al. 1979; Zabriskie et al. 1985; Gibofsky et al. 1991;
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Kemeny et al. 1994). Originally, Patarroyo et al. (1979) developed the alloantisera using B cells
from RF patients and noted the existence of a surface marker on peripheral blood mononuclear
cells stimulated with pokeweed mitogen defined by the alloantisera 883 and that this antisera
reacted to over 75% of RF patients from the United States and Columbia. When the supply of
alloantisera was exhausted, Zabriskie et al. repeated the immunization strategy and developed
D8/17 (Zabriskie et al. 1985). Subsequent analysis found that this D8/17 reacts with an antigen
on a large proportion of B cells from ARF or RHD patients from differing ethnic backgrounds at
various frequencies (Gibofsky et al. 1991; Ganguly et al. 1992) and that it is not an HLA antigen
(Kemeny et al. 1994). Patients with certain neurological disorders, including Syndenhams
chorea, Tourette’s and subgroups of obsessive-compulsive disorder, have been shown to express
higher levels of the alloantigen (Swedom et al. 1997; Hollander et al. 1999). In addition, this
antibody has been shown to recognize helical coiled-coil structures (Gibofsky et al. 1991),
cardiac, skeletal, and smooth muscle, epithelia and hepatocytes, and more specifically, to M6 M
protein, vimentin and myosin (Kemeny et al. 1994).

Overview of our studies
Introduction. Unlike most autoimmune diseases the precipitating event for ARF, streptococcal
pharyngitis, is known. Extensive examination of patients and in vitro experimentation have
given credence to the theory that ARF is an autoimmune sequelae. But despite the
overwhelming evidence indicating that group A streptococcus can induce cross-reactive
autoimmune responses, the underlying mechanisms of rheumatic fever remain elusive. One of
the greatest challenges facing researchers studying this phenomenon is reconciling the data
demonstrating the ability of streptococcal antigens to consistently induce cross-reactive immune
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responses in vitro with the reality that this disease affects only a certain small percentage of the
population and not all of these patients consistently exhibit abnormal cross-reactive immune
responses. Modern medicine has been able to dampen the threat of autoimmune complications
with the advent of prophylatic penicillin treatment, however the ability to predict and ultimately
prevent and treat the acute autoimmune illness still remains an elusive goal. Identification of
susceptible individuals has proven difficult with no clear genetic marker in sight creating a
greater need for prevention. Extensive research has been applied to the development of a GAS
vaccine with the predominance of research targeted towards the major immunodominant antigen
M protein. Despite the promise of inducing protective immunity with such a vaccine, M protein
has been shown to induce host cross-reactive immune responses that may ultimately prove
detrimental to the individual. The ability to confirm the circumstantial evidence obtained thus
far against M protein would be greatly improved with the development of a post-streptococcal
autoimmune animal model.
Based on our observation that neonatal mice immunized with S. pyogenes exhibit lifelong host cross-reactive antibody responses reminiscent of ARF patients, we have decided to take
advantage of this immunization strategy and develop a mouse model for post-streptococcal
autoimmune diseases. Research outlined in the following chapters will include work devoted to
characterizing the antibody and T lymphocytic immune responses following neonatal
immunization with S. pyogenes in an attempt to determine the extent to which GAS may induce
immune responses to mammalian proteins, namely muscle myosin. The data presented within
the subsequent chapters focuses primarily on the antibody and CTL responses elicited following
immunization with heat-killed S. pyogenes. Due to unforeseen problems within our system,
mostly the mitogenicity of streptococcal M protein, we were unable to evaluate autoreactive
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CD4+ T cell responses. In the future methodical approaches will be undertaken to identify
antigen-specific CD4+ cells.
Capacity of the neonatal immune system. Although we have been able to elicit host crossreactive immune responses in our neonatally challenged mice, controversy exists regarding the
extent to which neonates are capable of mounting a productive immune response following
antigenic exposure. Over forty years ago Medawar and colleagues provided the first
experimental evidence suggesting that the neonatal immune system is uniquely susceptible to
tolerance induction (Billingham et al. 1953), an understanding which has provided an excellent
explanation and time-frame for the development of self tolerance. Since this observation, two
major hypotheses have emerged attempting to explain the mechanisms of this phenomenon. The
first hypothesis suggests that experimental neonatal tolerance occurs by negative selection much
in the same manner as natural negative selection occurs (Morrissey et al. 1983), while the second
suggests that neonatal tolerance is due to the generation of a T cell response biased towards a
predominantly suppressive Th2 response (Singh et al. 1996; Adkins and Du 1998). However,
recent evidence has been put forth to contradict these hypotheses by suggesting that under the
proper conditions neonates are capable of eliciting a normal protective Th1-type immune
response comparable to the more immunologically mature adult animal.
Adkins et al. (1994) and Singh et al. (1996) demonstrated that neonatal antigen exposure
of soluble protein or peptide in complete Fruends adjuvant, respectively; can induce a primary T
cell response that is split between a Th1 and Th2 response but becomes biased towards a Th2
response upon secondary challenge, as determined by antibody and cytokine profiles. Forsthuber
et al. (1996) demonstrated that immunizing neonatal mice with protein in incomplete Fruends’
adjuvant can induce a Th1 type response that may be recalled when the animal is an adult,
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provided that the booster contains complete Freunds’ adjuvant. In contrast, Pertmer and
Robinson (1999), while able to induce similar Th1 immune responses with a DNA vaccine of
influenza hemagglutinin, were unable to induce antibody responses to the protein until two
weeks of age. In regard to eliciting protective CTL responses, Sarzotti et al. (1996) and Siegrist
et al. (1998) demonstrated the ability of neonatal mice to mount a protective CTL response using
two distinct viral models. Furthermore, Pilarski et al. (1977) found that mice have detectable
anti-allogenic CTL responses within three days of birth.
While it has been repeatedly demonstrated that neonatal mice have a tendency to elicit a
deviant (Th2) immune response upon antigenic challenge, questions still remain as to the cause.
An obvious explanation would be the immunological immaturity of the neonatal immune system.
In support of this argument, murine T cells have TCR with limited N region addition that
restricts the diversity of the TCR during the neonatal period (Feeney 1991). However, neonatal T
cells have been shown to express receptors for cytokines and costimulatory molecules in similar
amounts as the adult animal (Adkins et al. 1994). Furthermore, neonatally thymectomized mice
produce a Th1 response upon challenge with soluble protein, suggesting that T cells have fully
mature capacity as early as day one of life (Adkins and Du 1998). Other potential explanations
include deficiencies in production of key cytokines (Adkins et al. 1994; Adkins and Du 1998;
Arulanandam et al. 1999) or antigen processing and presentation (Levin and Gershon 1989;
Ridge et al. 1996). Typically neonatal mice produce larger amounts of IL-4, a Th2 cytokine, as
compared to adult mice (Singh et al. 1996; Adkins and Du 1998). Adkins et al. (1994; 1998)
found neonatal mice compared to adult mice, exhibit a more rapid kinetics and produce higher
levels of cytokines, namely IL-2, IL-4 and INF-γ and that in vitro IL-6 enhances the ability of
neonatal T cells to respond to secondary stimuli. Arulanandam et al. (1999)
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demonstrated that upon antigenic challenge neonatal mice have decreased IL-12 production
compared to adult animals, and the addition of IL-12 in the immunization to neonatal mice will
enhance the Th1 response. Deficiencies exist for neonatal antigen processing and presentation as
well. Levin and Gershon (1989) found that neonatal spleen cells exhibit inadequate antigen
processing and presentation of soluble antigen in vitro. Interestingly, the deficiencies of neonatal
spleen cell antigen presentation cannot be ascribed to suppressive cells or factors since neonatal
cells actually produce ample amounts of soluble proliferative factors (Levin and Gershon 1989).
This observation has led Levin and Gershon (1989) to suggest that the problem lies somewhere
in the initial stages of this event. However, Morris et al. (1992) demonstrated that neonatal
splenic B cells are capable of binding, internalizing, and degrading radiolabeled antigen. While
neonatal B cells may express nearly adult levels of MHC class II and necessary costimulatory
molecules, and the neonatal lymph node environment may support T and B cell collaboration,
neonatal B cells are unable to differentiate or induce IL-2 production in T cells (Morris et al.
1992; Astori et al. 1998). Additionally, neonatal dendritic cells demonstrate a limited ability to
induce either adult or cord blood T cells to proliferate in response to T cell mitogens PHA and
Con A. However, this may be overcome with increased doses of mitogen or cell number (Petty
and Hunt 1998). Yet, neonatal dendritic cells may maintain some degree of functionality
compared to spleen APC since Ridge et al. (1996) found that dendritic cells were capable of
eliciting immune responses in neonatal mice; whereas, a mixed spleen population induced
tolerance.
Characterization of myosin cross-reactive monoclonal antibodies. The cross-reactivity
between streptococcal antigens and mammalian myosin has long been established (Cunningham
et al. 1984, Dale and Beachey 1985a, Manjula et al. 1985). The first chapter discusses work
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conducted in the laboratory characterizing the myosin cross-reactive antibody response in
BALB/c mice as a result of neonatal S. pyogenes immunization. Monoclonal antibodies were
produced from mice immunized as adults or neonates with streptococcal strain D471 (serotype
M6), its M- variant UAB152, and J17A4 (non-typable). This immunization scheme allowed for
examination of the cross-reactive antibody response induced in mice as a function of age and M
protein. In ELISA analysis, these monoclonal antibodies demonstrated cross-reactivity to several
mammalian antigens, including keratin, DNA and commercially prepared rabbit myosin. These
results are in agreement with similar work conducted by Cunningham et al (1984; 1986;
Shikhman and Cunningham 1994); and our study takes such analysis a step further.
Extensive Western blotting analysis was undertaken to determine the reactivity against
mouse myosin isolated from both cardiac and skeletal sources. We found that antibodies derived
from mice immunized as neonates with S. pyogenes preferentially recognized the cardiac
isoforms of myosin, whereas, antibodies derived from adult immunized mice display no such
discrimination of the skeletal myosin isoforms. This suggests that exposure to GAS at a young
age may selectively induce a cross-reactive antibody response to the cardiac isoforms of myosin
and could therefore play a potential role in the cardiac pathology associated with acute rheumatic
fever without the destruction of other muscles in the body.
Neonatal immunization with S. pyogenes induces myosin-reactive cytolytic T cell responses
in BALB/c mice. Once we ascertained the extent to which S. pyogenes could induce an autoreactive antibody response, experiments were undertaken to determine if immunization with S.
pyogenes could induce a T cell response against myosin as well. BALB/c were immunized as
adults or neonates with S. pyogenes strain D471, its M- variant UAB152, recombinant M6 M
protein, or the control antigen cytochrome c. BALB/c mice immunized as adults with D471
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mounted a poor CTL response against streptococcal M protein and no CTL response against
mammalian myosin; whereas, mice immunized with the same vaccine within three days of birth
and boosted at 5 - 6 weeks of age mounted a measurable CTL responses against both
streptococcal M protein and mammalian muscle myosin that was inhibitable by the addition of
anti-CD8 antibodies in the assay. The CTL response against myosin, but not M protein, appeared
to be dependent upon the age of initial exposure to the vaccine D471, in that the response against
myosin was detected only in mice primed up to 22 days of birth but not after. Our results suggest
that immunization with a rheumatogenic strain of S. pyogenes can induce age dependent myosinreactive CTL responses providing further evidence to the competence of this immunization
strategy as a suitable mouse model system for studying childhood post-streptococcal autoimmune
complications.
Role of streptococcal M protein and its C-terminal conserved region in inducing myosinreactive CTL responses in neonatal mice. Experiments discussed in chapter three were
designed to determine if the induction of a myosin-reactive CTL response is exclusive to
rheumatogenic serotypes of S. pyogenes (D471). Additionally, we wanted to determine if the
more conserved carboxy terminal region is responsible for eliciting the myosin-reactive CTL
response. These experiments were designed around the findings by Bessen et al. (Bessen et al.
1989; O'Toole et al. 1992) suggesting that most M protein serotypes may be placed in one of two
major classes of M protein and that nearly all serotypes of GAS that have been associated with
ARF have been shown to express class I M protein. Also, this portion of M protein is under
consideration as a vaccine candidate (Robinson et al. 1993; Pruskakorn et al. 1994a; Pruskakorn
et al. 1994b).
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For the first set of experiments neonatal BALB/c mice were immunized with nonrheumatogenic streptococcal strains of GAS that included B737 (M49), H3 (M12) and J17A4.
To address the role of the c-terminal region, mice were immunized with recombinant protein
consisting of the carboxy terminal region of MP (C6), the variable amino-terminal region of M
protein (AB6) or D471 treated with pepsin to cleave away the variable amino terminus of M
protein (D471*).
We found that all strains of GAS tested were capable of eliciting a myosin-reactive CTL
response. Only J17A4 elicited a myosin-reactive CTL response comparable to that elicited by
D471. In addition, only these two strains elicited responses that preferentially recognized mouse
neonatal cardiac myosin. This myosin-reactive cytolytic response was seen in conjunction with a
response against the carboxy-terminal conserved region of M protein and mice primed with C6 or
D471* elicited a response to myosin, whereas, mice treated with AB6 did not. These results
suggest that the carboxy terminal region of M protein contains an epitope that is capable of
inducing a myosin-reactive CTL response in BALB/c mice.
Induction of the myosin-reactive CTL responses in mice with heat-killed S. pyogenes: The
role of age, haplotype, route of immunization and presence of B lymphocytes. To complete
the BALB/c studies we demonstrated the obligate role of M protein in the induction of a CTL
response against myosin following neonatal immunization with heat-killed S. pyogenes.
Specifically, we demonstrate that the M protein must be cell bound because immunization with a
combination of an M protein streptococcal mutant and recombinant protein does not allow for the
development of a myosin-reactive CTL response. Also, in chapter four we undertook a
preliminary study to determine what role, if any, genetic factors play in the develop of myosinreactive CTL response we have measured following neonatal S. pyogenes exposure, mice of the
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same MHC haplotype as BALB/c (DBA/2J) or of differing haplotypes, C57Bl/6 and CBA/J. Our
results suggested that mice of the H-2d background (BALB/c and DBA/2J), as well as, mice of
the H-2b background (C57Bl/6) are capable of eliciting myosin-reactive CTL responses following
neonatal exposure with D471, whereas CBA/2J (H-2k) were incapable. Although not conclusive,
these results suggest that genetic factors can potentially play a role in determining the ability of
the host to develop potentially deleterious auto-reactive CTL responses following exposure to S.
pyogenes. The final set of experiments undertaken and presented in chapter four were performed
to determine what effect the route of immunization and the presence of B lymphocytes has on the
ability of mice to elicit a myosin-reactive response following neonatal S. pyogenes exposure.
Experiments were performed with BALB/c and C57Bl/6 wild type and immunoglobulin heavy
chain knock-out (Igh-/-) mice. The results suggest that intranasal immunization alone does not
elicit an immune response to M protein or myosin, either locally or systemically, regardless of
the age of immunization. However, if the mice are immunized as neonates intranasally with S.
pyogenes vaccine and boosted intraperitoneally with recombinant M protein a CTL response is
generated against both M protein and myosin suggesting that intranasal exposure during the
neonatal period can prime a systemic autoimmune response. Assays conducted with C57Bl/6
Igh-/- mice indicate that the lack of the B cell compartment has no direct effect upon the
development of a CTL response against either M protein or myosin following neonatal
immunization with vaccine.
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Antibodies induced by heat-killed Streptococcus pyogenes in neonatal BALB/c
mice recognize cardiac isoforms of mouse skeletal myosin.

Cynthia Cunningham, Malini Pearce and Meenal Elliott
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ABSTRACT
Antibodies recognizing mammalian cardiac myosin are a hallmark of acute rheumatic
fever, an autoimmune complication of pharyngitis caused by the group A streptococcus.
Previous reports demonstrate that antibodies reactive toward mammalian myosin can be induced
in adult mice following systemic immunization with membrane fractions of GAS or purified
streptococcal M protein, albeit with no pathological consequences. Here, we show that
antibodies capable of binding mammalian myosin are induced and persist for several months in
sera of BALB/c mice immunized within one week of birth with heat killed GAS. We have
constructed representative hybridomas to permit characterization and comparison of myosinreactive antibodies induced following immunization of neonatal versus adult mice. Employing
western blot analyses we demonstrate that most of the myosin-reactive antibodies induced in
neonatal mice cross-react with the group-specific determinant N-acetylglucosamine and
recognize primarily the cardiac isoforms of mouse myosin. In contrast, antibodies derived from
adult mice immunized with GAS and boosted with recombinant M protein or mouse myosin
recognize determinant(s) shared by most isoforms of mouse skeletal myosin. These findings
reveal that different classes of myosin-reactive antibodies can be induced by antigens associated
with the group A streptococcus depending on the age at exposure. We propose that antibodies
recognizing cardiac myosin induced by the group A streptococcus early in ontogeny are likely to
play a key role in the pathogenesis of rheumatic fever.
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INTRODUCTION

Streptococcus pyogenes, a β-hemolytic group A streptococcus, is a causative agent of
several suppurative skin and mucosal infections in humans. In a small percentage of children,
streptococcal pharyngitis may be followed within 3 to 4 weeks by acute rheumatic fever, a
disease characterized by fever, polyarthritis and/or carditis (1, 2). In a significant number of
patients, mitral valve involvement occurs and is characterized by stenosis and/or regurgitation of
valve, which can be fatal (1 - 3). Biopsy and autopsy may reveal thickening and calcification of
the mitral valve leaflets and shortening of the supporting papillary muscles (3, 4). Frequently,
granulomatous lesions called 'Aschcoff nodules' are found within the mitral valve and the
pericardium (2, 4). Additionally, antibody deposits may be found within the valve leaflets and
the myocardium (1, 2). Individuals presenting with ARF display elevated titers of antistreptococcal antibodies; some of these cross-react with cardiac myosin (5). ARF, when not fatal,
resolves itself but can recur with recurring streptococcal pharyngitis. Therefore, the treatment for
ARF is geared towards preventing the recurrence of streptococcal pharyngitis, thereby preventing
the recurrence of ARF. Long-term penicillin prophylaxis is prescribed for ARF patients and is
very effective (2, 6). Timely intervention of streptococcal pharyngitis in children with penicillin
treatment has also effectively reduced the incidence of ARF in developed nations (7). Due to the
reduced incidence of ARF and the lack of suitable animal model systems, the mechanism of ARF
and the mechanism of penicillin intervention remain a mystery.
In both humans and mice the protective antibody response against GAS is directed
primarily against the group specific carbohydrate N-acetyl-β-D-glucosamine and the antiphagocytic virulence factor, M protein (8 - 10). The induction of heart-cross-reactive antibodies
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in ARF is thought to involve antigen mimicry by the pathogen in susceptible individuals (1, 2,
11, 12). Antibodies cross-reactive with mammalian myosin can be induced in laboratory mice
following immunization with preparations of streptococcal membranes as well as purified M
protein (13), arguing in favor of a direct role of the pathogen in the induction of a cross-reactive
humoral immune response.
Mammalian myosins can be divided into three distinct families, the skeletal muscle
myosins, the smooth muscle myosins and the non-muscle myosins. Each family consists of
distinct isoforms of heavy and light chains, encoded by distinct genes (14). Each muscle
expresses one or more isoforms of the appropriate family of myosins (14 - 17); the expression of
distinct isoforms in a given muscle may also change as a function of age (16, 17). The various
isoforms of myosin display high degree of conservation across species at the amino acid as well
as at the nucleotide level (14). Antibodies against streptococcal antigens such as M protein have
been shown to cross-react with the skeletal muscle myosins and not the smooth or non-muscle
myosins. Studies employing synthetic peptides both of M protein and human cardiac myosin
have been instrumental in localizing the cross-reactive epitopes shared by these two proteins (18,
19). The putative myosin epitope mapped in these studies LRRDLD is shared by heavy chains of
all isoforms of the skeletal muscle myosins. It is not clear how antibodies recognizing this
epitope would induce pathological damage of joints and the heart and spare other skeletal
muscles of the body. Furthermore, in the adult inbred mouse model, myosin-reactive antibodies
induced by M protein do not lead to pathology similar to that observed in ARF. Therefore, their
relevance to pathogenesis of ARF remains unclear.
Here we demonstrate that antibodies against mammalian skeletal myosin can be induced
by heat-killed GAS in the absence of any adjuvant in neonatal but not adult mice. We have
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developed panels of monoclonal antibodies reactive toward mouse myosin from BALB/c mice
immunized as neonates with GAS and from adult mice immunized with GAS and boosted with
M protein or myosin. The current study presents a comparison of the monoclonal antibodies
within these panels with respect to their ability to distinguish between distinct isoforms of
autologous myosin. We find that antibodies induced by GAS in neonatal mice bind primarily to
cardiac specific isoforms of mouse skeletal myosin while those induced in adult mice recognize
an epitope shared by most isoforms of skeletal myosin. These results suggest that antibodies
induced by GAS early in life are distinct from the myosin-reactive antibodies described
heretofore. Their potential role in the pathogenesis of ARF is discussed.
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MATERIALS AND METHODS

Mice and immunizations: BALB/c mice were purchased from Jackson Laboratories, Bar
Harbor, ME and bred at the WVU-OLAR. Newborn mice were immunized intraperitoneally with
107 heat-killed GAS of the appropriate strain in 50µl volume. Adult mice were immunized
intraperitoneally with 108 bacteria of appropriate strain or 50 µg of recombinant M6 protein or
myosin extracted from gastrocnemius muscle of BALB/c mice.
Bacteria: GAS strain J17A4 was obtained from ATCC, strain D471 was a gift of Dr. Susan
Hollingshead, UAB, Birmingham AL. Both strains were grown in Todd-Hewitt broth, heatkilled by incubation at 60°C for 1.5 hours, washed extensively with 0.85% saline, resuspended in
0.85% saline. The cell concentration was estimated by measuring absorbance at 600 nm. Heatkilled J17A4 was treated with pepsin at pH 2 for 30 minutes at 37°C as described (20) to cleave
surface proteins and thereby expose the group A carbohydrate. The preparation was neutralized
by the addition of NaOH, washed with and resuspended in 0.85% saline. Bacteria were stored
frozen at -20°C in aliquots of 109/ml.
Antigens: N-acetyl-β-D-glucosamine coupled to BSA (GlcNAc-BSA) was a gift of Dr.
Madeleine Cunningham, University of Oklahoma Health Science Center, Oklahoma City,
Oklahoma. Rabbit muscle myosins (whole myosin, MyHC, MLC, HMM and LMM) were
purchased from Sigma chemical company (St. Louis, MO). Recombinant M6 protein was
prepared as follows: Plasmid TR06 containing codons 1 to 412 of the emm6 mature peptide
cloned in pET20b(+) was a gift from Dr. Susan Hollingshead. This plasmid was expressed in E.
coli strain BL21:DE3 (pLysS). The M6 protein was induced with 1mM IPTG (Sigma Chemical
Company) for 1.5 hrs. Periplasmic extracts were prepared by washing cells with one-half
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volume of TSE (150 mM Tris, 20% Sucrose, 1mM EDTA) followed by a 20 minute osmotic
shock with one-tenth volume 5mM MgSO4 followed by centrifugation at 10,000 g. The M6
protein was purified from the periplasmic extract by affinity chromatography employing NiNTA-Sepharose (Qiagen). The protein was checked by SDS-PAGE for purity and stored frozen
at -20°C. Myosin extracts from muscles of BALB/c mice were prepared essentially as described
(21). Briefly, hind limb muscles, diaphragm and hearts were dissected from BALB/c mice of
appropriate ages. All hind limb muscles were pooled in the case of embryonic, newborn or 7 day
old mice. Adult hearts were separated into atria and ventricles. Muscles were minced on ice in
four volumes/wt of cold extraction buffer (0.3 M NaCl, 0.1 M NaH2PO4, 0.05 M Na2HPO4, 10
mM EDTA and 1.4 mM β-mercaptoethanol). Following a 30-minute incubation on ice, cellular
debris was removed by centrifugation at 13,000 g for 30 min at 4oC. Supernatants were then
diluted with an equal volume of a storage solution (40 mM sodium pyrophosphate, 50% glycerol)
and stored at -20oC. Protein concentrations were determined employing a kit (DC Protein Assay,
Bio-Rad).
Monoclonal antibodies: Splenocytes harvested from experimental mice were fused with
P3.X63.Ag8.653 mouse myeloma by standard procedures (22). Hybridoma supernatants were
screened for binding to BSA, GlcNAc-BSA, M6 protein and rabbit whole myosin by ELISA. All
supernatants reacting strongly with BSA were eliminated from further analysis. Selected
hybridoma wells were subcloned by limiting dilution. Subclones were screened by ELISA.
Positive clones were expanded by bulk culture in RPMI 1640 (Life Technologies) supplemented
with 10% FCS (Hyclone laboratories) and 2x10-5 M β-mercaptoethanol. All selected clones
described here expressed IgM heavy chains and κ light chains. Hybridoma clones A4.840, BFF3, BA-G5, F1.652, N2.261, N3.36, and SC-71 were obtained from ATCC. These were cultured
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as above for collection of supernatants. All supernatants were stored frozen at -20°C until use.
Antibodies NOQ7.4D and hsm-V were purchased from Sigma Chemical Co.
ELISA Analysis: Protein was adsorbed onto 96 well assay plates (Costar) at 1 µg/ml protein in
0.1 M borate saline (overnight at 4oC or 3 hrs at 37oC). Wells were blocked with 1% BSA in
PBS for 1 hour at room temp and following a wash with PBS, undiluted hybridoma supernatants
or serial dilutions of serum samples were added to the wells (overnight at 4oC or 37oC 3 hrs).
Plates were washed and goat anti-mouse IgM or goat anti-mouse IgG antibody conjugated with
alkaline-phosphatase (Southern Biotechnology Associates) was added. Phosphatase substrate was
added after washing plates (Sigma 105, Sigma Chemical Co.) and following the development of
color, absorbance at 405 nm was recorded employing a microplate reader (Bio-Rad, model
3550). The binding of monoclonal antibodies to cardiac MyHC was performed as follows:
Polystyrene plates were coated with antibodies NOQ7.4D or N2.261 (both IgG1 isotype). After
blocking with 1% BSA in PBS, extracts from embryonic of adult hearts was added and incubated
at 4 C overnight. Plates were washed, hybridoma supernatants were added and incubated for 3
hrs at 37 C. After washing, binding was detected by the addition of goat anti-mouse IgM
conjugated to alkaline phosphatase followed by phosphatase substrate.
SDS-PAGE and Western Blot analyses: Muscle extracts (0.2 µg - 2 µg/lane) were resolved by
one of two SDS-PAGE systems. The first consisted of resolving gel containing 5% acrylamide
(C = 5%); 30% glycerol and a stacking gel containing 4% acrylamide; 30% glycerol (23).
Electrophoresis of this assembly was conducted at 4oC at 8 mA for 3.5 hours and 10 mA for an
additional 5 hours using a 25 mM tris, 192 mM glycine, 0.1% SDS running buffer. The other
system consisted of resolving gel containing 8% acrylamide (C = 2%) and 30% glycerol and a
stacking gel of 4% acrylamide and 30% glycerol (24). Preparation and execution these gels were
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carried out as previously described, with the exception that EDTA was omitted from the stacking
gel. In both systems, 2-mercaptoethanol was added to the running buffer of the upper reservoir at
a final concentration of 10 mM. Electrophoresis was conducted in a Mini-PROTEAN II
electrophoresis system (Bio-Rad). Following electrophoresis gels were either silver stained
(Bio-Rad Silver Stain Plus Kit) or transferred to PVDF membranes (Bio-Rad) under semi-dry
transfer conditions (Bio-Rad Trans-Blot SD Transfer Cell) at 50 mA per gel for one hour. The
transfer was facilitated by one of two buffer systems; 10 mM CAPS (Sigma Chemical Company)
with 5% methanol for 5%/30% gels and 10 mM CAPS, 0.05% DTT, 1% methanol for 8%/30%
gels). Membranes were blocked with 5% non-fat milk in PBS at 4oC overnight. Following a
wash in phosphate buffered saline (PBS), membranes were incubated with undiluted hybridoma
tissue culture supernatants for one hour at room temperature followed by a 1 hour incubation
with biotinylated anti-isotype antibody (Southern Biotechnology Associates, Birmingham AL)
and then a 30 min incubation with streptavidin-HRP (Southern Biotechnology Associates).
Membranes were washed extensively with 0.1% tween 20 in PBS after each incubation.
Reactions were visualized by incubating membranes with ECL chemoluminescent reagents
(Amersham) for 1 minute followed by multiple exposures to x-ray film (Fuji) ranging from 1 to
15 minutes.
RESULTS
Induction of anti-myosin antibodies in BALB/c mice
BALB/c mice were immunized with heat killed GAS at different ages. We chose two
strains for our study; D471 expresses M protein of the M6 serotype, which has been associated
with rheumatic fever in humans (i.e. rheumatogenic strain), and J17A4, a non-rheumatogenic
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strain of an unknown M-type. We chose this strain to test whether M protein from rheumatogenic
strains of GAS was necessary for the elicitation of anti-myosin antibodies in mice. The heatkilled preparation of J17A4 was further treated with pepsin at acid pH, as described in materials
and methods, to cleave surface exposed proteins and to maximally expose the group A
carbohydrate. Preparations of GAS treated in this manner have been shown to induce
autoreactive antibodies in mice (25). The treated preparation is known to yield a stronger antiGlcNAc antibody response in neonatal as well as adult BALB/c mice than the untreated one (M.
Elliott, unpublished observations).
We gave 2-day-old mice 2∗107 heat-killed organisms and 6-week-old adult mice 2∗108
organisms by the intraperitoneal route. Neonatally immunized mice were bled at 14 days of age
and then at intervals of 10 weeks. Some mice immunized as neonates were boosted at 8 weeks
of age, bled at 10 weeks and every 10 weeks thereafter. Adult mice were immunized at six
weeks of age, given a booster 14 days following the primary immunization, bled at 10 weeks of
age and at intervals of 10 weeks thereafter. One group of adult mice was immunized with 50 g
of purified recombinant M6 protein at 6 weeks of age and boosted at 8 weeks of age. Data
shown in figure 1 represent a comparison of the levels of antibodies of the IgM subclass against
three distinct antigens in the variously immunized mice as well as unimmunized control mice at
2, 10, 20, 30, 40, 50, 60 and 70 weeks of age. Data are shown for serum dilution of 5,000 for Nacetylglucosamine (fig 1a), 2,500 for myosin (fig 1b) and serum dilution of 500 for M protein
(fig 1c).
In adult mice immunized with D471 or J17A4, high titers of antibodies of the IgM
subclass against N-acetylglucosamine (GlcNAc) were induced within 2 weeks of immunization
(fig1a). The titers dropped as a function of age to slightly above baseline and remained at this
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level through the remainder of the experiment. Levels of anti-myosin antibodies were only
slightly above those in unimmunized mice (fig 1b) and did not rise over the period of the
experiment. Levels of antibodies against M6 protein were increased two weeks after the second
immunization but were much lower in comparison to those induced by purified recombinant M6
protein (fig 1c).
In adult mice immunized and boosted with purified M6 protein, response to M6 protein
was the highest at 10 weeks of age; dropping to background levels within 30 weeks and
remaining low throughout the course of the experiment. Antibodies against GlcNAc as well as
myosin were elevated slightly above background in this group of mice and maintained at that
level throughout the experiment (fig 1a and 1b). The significance of the latter response is not
clear at this point.
In mice immunized within one week of birth with either D471 or J17A4 and boosted at 6
weeks of age with the same preparation, levels of antibodies against all three antigens were
elevated at 10 weeks of age (fig 1 a, b and c). However, in both these groups, antibody levels
dropped to a plateau above the baseline and remained there throughout the course of the
experiment. In mice immunized within one week of birth with D471 or J17A4, levels of
antibodies against GlcNAc increased slowly as a function of age (fig 1a); and continued to rise
throughout the remainder of the experiment. Similarly, levels of antibodies against myosin were
increased steadily in parallel (fig 1b). Levels of anti-GlcNAc as well as anti-myosin antibodies
in these mice between 30 and 60 weeks were significantly higher than in all other groups. This is
reminiscent of antibodies observed in ARF patients (1, 26, 27). The levels of antibodies against
M6 protein were very low in these two groups of mice throughout the course of the experiment
(fig 1c). Thus, a subclass of antibodies against GlcNAc preferentially induced in neonatal mice
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by both strains of GAS was related to anti-myosin antibodies observed in their sera.
Interestingly, high titers against the respective antigens were not observed in mice immunized as
neonates and boosted as adults with heat-killed GAS.
Finally, IgG antibodies against all three antigens were also present in sera of mice
immunized with heat-killed GAS within one week of birth and in mice immunized with M6
protein at 6 weeks of age (results not shown). To explore the basis for the anomalous antimyosin response following immunization with GAS, we established panels of representative
monoclonal antibodies.
Analysis of monoclonal anti-myosin antibodies from BALB/c mice immunized with GAS by
ELISA:
We chose 6 different groups of mice for construction of hybridomas (Table 1). Mice
immunized with either J17A4 or D471 at 2 days of age were sacrificed at the age of 60 weeks for
hybridoma construction (groups 1 and 2). Another group of 2 mice immunized with D471 at 2
days of age was boosted at 8 weeks of age and sacrificed at 10 weeks (group 3). We also
generated hybridomas from adult BALB/c mice immunized with D471 and boosted with either
D471 (group 4), purified recombinant M6 protein (group 5) or mouse myosin (group 6).
Following an ELISA based screen, a total of 22 myosin-reactive monoclonal antibodies were
recovered, all of which were of the IgM isotype. We were able to recover only one IgG antibody
that was specific for M6 protein. Group 4 yielded several anti-GlcNAc antibodies and one antiM6 protein antibody confirming the serological data that GAS fails to induce myosin-reactive
antibodies in adult mice. We excluded this group from further analyses.
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Previous studies have shown that myosin-reactive antibodies induced by streptococcal
antigens recognize the coiled tail region of the skeletal myosin heavy chains (13, 18, 19). We
tested the 22 myosin-reactive antibodies for binding to isolated rabbit myosin heavy chains and
light chains as well as purified heavy meromyosin (the head region of myosin) and the light
meromyosin (the tail region). Table 2 summarizes the findings. Several things are of note:
firstly, all of the antibodies in groups 1,2 and 3 reacted strongly with GlcNAc; as expected,
antibodies from groups 5 and 6 displayed comparatively weaker binding to this antigen, if at all.
Furthermore, while hexoseaminidase treatment of plate-bound antigens eliminated reactivity of
all antibodies with GlcNAc-BSA, it did not alter binding to the myosin components (results not
shown). Secondly, all of the anti-myosin antibodies reacted with MyHC; five antibodies (groups
1, 2 and 3) additionally reacted with MLC. Thirdly, all antibodies reacted with LMM. Antibody
1M12 also reacted with HMM. Five antibodies (group 1 and group 2) displayed weak reactivity
toward M6 protein whereas; antibodies induced in adult mice following boosters with M6 protein
bound M6 very well. Additionally, two antibodies from group 6 also bound M6. Thus, many of
the antibodies described here reacted with GlcNAc, M protein and myosin. Examples of antiGlcNAc antibodies reacting with both M protein and MyHC have been previously described
(28); reactivity with MLC is a novel finding. None of the antibodies bound to laminin, vimentin,
troponin or tropomyosin; all of the antibodies from groups 1 and 2 and two each from groups 3, 5
and 6 bound to keratin (results not shown). These binding assays were unable to identify major
differences between antibodies induced in neonatal versus adult mice. Therefore, we decided to
probe western blots of mouse skeletal myosins resolved to separate distinct isoforms, with our
panels of antibodies.
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Resolution and identification of distinct mouse skeletal myosin isoforms:
Eight distinct isoforms of mammalian skeletal myosin heavy chains (MyHC, Mr =
220Kda) encoded by distinct genes have been described; these are (I) embryonic, (ii) neonatal,
(iii) type IIa, (iv) type IIx/IId, (v) type IIb, (vi) type I (also known as cardiac β, (vii) cardiac α and
(viii) ocular (14). Antibodies against distinct human and rat MyHC have been established and
used extensively in studies addressing the developmental regulation of myosin gene expression
using western blot as well as immunofluorescent techniques (17,29-31). Since no such
information about the mouse MyHC isoform expression was available, we decided to use the
available antibodies and conduct these analyses at the outset.
We prepared crude myosin extracts from a variety of different muscles, from mice of
different ages. The preparations were subjected to electrophoresis on polyacrylamide gels
containing glycerol to permit resolution of myosin isoforms on the basis of net charge. The
myosin isoforms in each sample were identified on the basis of migratory pattern by comparison
with a previous study (32) in combination with western blot analysis using pre-characterized
antibodies raised against human or rat myosins. Ten distinct myosin extracts representing
distinct muscles of fetal to adult BALB/c mice were chosen for this study to identify and
distinguish seven of the eight skeletal MyHC isoforms.
The top panel in figure 2a shows a silver stained SDS-PAGE (8% acrylamide, 30%
glycerol) depicting six of these extracts. The embryonic isoform of skeletal myosin was present
in an extract prepared from hind limbs muscles of fetal (18-day embryonic) mice (lane 1) and
from hind limb muscles of newborn (12-24 hour old) mice (lane 2). Bands corresponding to this
isoform were detected by antibody F1.652 (17, 29).
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The neonatal MyHC isoform was present in extracts from hind limb muscles of fetal mice
(lane 1), newborn mice (lane 2) and 7-day-old mice (lane 3) as well as in the diaphragm of 7-dayold mice (lane 4). Bands corresponding to the NN isoform were detected by antibody N3-36 that
has been shown to bind the NN, IIa, IIb and IIx/IId MyHC isoforms of human and rat origin (29,
30). Antibody SC-71 also recognized bands corresponding to this isoform in extracts of newborn
and 7-day-old hind limbs; although SC-71 was shown to be specific for the type IIa isoform of rat
myosin in previous studies (31). Additionally, SC-71 showed very strong reactivity toward a
band co-migrating with the NN isoform within the embryonic hind limb extract. The type IIa
isoform of mouse myosin was found to be most abundant in an extract of the soleus muscle (lane
5) and was detected by antibody SC-71 (fig 2d). SC-71 also detected this isoform in extract of
hind limb muscles from 7-day-old mice (lane 3).
The type IIb myosin isoform was present only in the extract prepared from the
gastrocnemius muscle of adult (6 week old) mice and was detected by antibody BF-F3 raised
against and shown to be specific for the rat IIb myosin (31).
The type IIx/IId isoform was detected in an extract from the gastrocnemius of adult mice
(lane 6) and was detected by antibody N3.36. Antibody N3.36 also detected a band
corresponding to this isoform in an extract from the diaphragm of 7-day-old mice (lane 4).
The type I isoform was present in extracts of fetal hind limbs, diaphragm and the soleus
muscle (lanes 1, 4 and 5). This isoform was detected by antibody A4.840 that also recognizes the
corresponding isoform of human and rat origin (16, 17, 30).
The EMB, type IIa and type I isoforms were additionally detected by antibody N2.261
which has been shown to recognize the type I/cardiac β as well as the type IIa isoforms of human
and rat origin (16, 17). Of note is the weak reaction with a slow migrating band in the diaphragm
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extract (lane 4), On the basis of non-reactivity of N2.261 with the extract from the gastrocnemius
muscle (lane 6), we adjudged this band to be type IIa MyHC. Overloading of the diaphragm
extract permitted the detection of this isoform by antibody SC-71, thereby confirming its
presence in this extract (results not shown).
Three extracts prepared from hearts of BALB/c mice were resolved by SDS-PAGE (5%
polyacrylamide, 30% glycerol. The abundance and migratory patterns of the two isoforms (α and
β) of cardiac myosin were displayed by silver staining of gel and are shown in the top panel of
figure 2b. The cardiac β isoform, which is expressed in heart ventricles, predominates in the
fetal mouse heart extract (lane 1), the α and the β isoforms are present at about equimolar
concentrations in the hearts of newborn mice (lane 2) and the β isoform is absent in heart
ventricles of adult mice (lane 3). The cardiac β isoform was detected by antibody A4.840
described above. The antibody BA-G5 specific for the rat cardiac α isoform (31) was unable to
detect the corresponding isoform in our extracts (results not shown). However, both the cardiac
α and β isoforms were detected by N2.261. Thus the determinant recognized by the N2.261
antibody appears to be present on the EMB, type IIa, type I/cardiac β as well as cardiac α
isoforms of mouse myosin.
These analyses prepared us for the correct interpretation of binding patterns displayed by
the panel of monoclonal antibodies generated within our laboratory. They also revealed novel
antigenic differences between myosin isoforms of human, rat and mouse origin.
Antibodies recovered from mice primed with GAS as neonates recognize cardiac myosin specific
determinants:
All of the monoclonal antibodies described in Table 2 were screened by western blot
analysis employing the myosin extracts described above. All of the antibodies reacted with
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myosin bands if the extracts were resolved on a 5% acrylamide gel and transferred to the PVDF
membrane in the presence of DTT, but failed to react if the extracts were resolved with 8%
acrylamide and transferred without DTT. The EMB and the NN isoforms of MyHC within the
embryonic extract and the IIx/IId and the IIb isoforms within the gastrocnemius extract migrated
very close together on 5% acrylamide gels and transferred as a single band. Since the embryonic
extract contained large amounts of the EMB isoform, the reactivity with the EMB isoform was
scored negative if the intensity of reaction with the band in lane 1at a position corresponding to
the EMB isoform was weaker than that in lane 2. Detection of reactivity toward the IIb MyHC
isoform was facilitated by the inclusion of an extract from gastrocnemius of 2-week-old mice.
This extract contained primarily the NN and the IIb MyHC isoforms which formed a doublet on
blots prepared from the 5% acrylamide SDS-PAGE (results not shown); the faster migrating
band was identified as the IIb isoform by antibody BF-F3 described above. Panels in figure 3
represent results obtained with SDS-PAGE containing 5% acrylamide, 30% glycerol and
transferred in the presence of DTT.
Antibodies BA1-23, FD3-6-1 (group 1) and 1G19, 1L23, 1M12 and 1N24 (group 2) were
derived from mice that were immunized with heat-killed GAS within the first week of life and
did not receive any additional immunizations. As shown in figure 3, antibodies BA1-23, FD3-61 and 1L23 all detected the type I isoform of mouse myosin in the soleus muscle extract and
showed weak reactivity toward type IIa isoform (lane 5 in corresponding panels). Binding to the
type IIa isoform was not faithfully reproduced in subsequent repeats of the experiment. Antibody
1G19 recognized both type I and type IIa myosins. Antibody 1M12 detected bands in lanes 3, 5
and 6 but not in lane 4. It also recognized the IIb isoform in western blots of 8% acrylamide gels.
It was adjudged that this antibody reacted with type I (weak reaction) as well as types IIa and IIb
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myosin. Antibody 1N24 recognized the NN as well as types I, IIa, IIb and IIx/IId MyHC
isoforms resolved on both 5% and 8% acrylamide gels. Thus, all six myosin-reactive antibodies
from these two groups recognized the type I/cardiac β isoform of mouse myosin, three
recognized only this isoform.
Antibody 11E18 (group 3) recognized the NN, type I, and type IIa isoforms while
antibodies 11L6, 11L24 additionally recognized type IIx/IId isoform. Antibodies 11N24 and
11AA23 detected the NN and type I, IIa, IIb and IIx/IId isoforms.
Antibodies derived from mice immunized at six weeks of age with D471 and boosted
with either M6 protein (group 5) or mouse hind limb myosin (group 6) were tested next.
Antibodies 14A23, 14L7 and 14H15 derived from group 5 reacted with all isoforms of myosin
MyHC except the EMB, but also consistently gave a high background (results not shown).
Antibodies 14I23 and 14J16 failed to detect myosin by western blot. All seven antibodies
derived from group 6 displayed strong reactivity toward all isoforms of mouse myosin except the
embryonic isoform and are represented here by a blot probed with antibody 15E23.
Western blot analysis of heart muscle extracts revealed that all of the antibodies described
above with the exception of 11E18, 11L6 and 11L24 recognized both α and β isoforms of
cardiac MyHC. Antibody 11E18 (group 3) recognized only the β isoform of cardiac MyHC;
Figure 4 shows a sampling of these western blots with at least one example from each of the five
experimental groups that included myosin-reactive monoclonal antibodies. Reactivity toward
cardiac myosins was additionally tested in an indirect ELISA as described in materials and
methods. Antibodies 11L6 and 11L24 were able to recognize MyHC from all three extracts of
BALB/c hearts in this assay (results not shown). It is possible that the epitope(s) recognized by
these antibodies were lost upon dissociation of MLC from MyHC in SDS-PAGE.
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As summarized in Table 3, analyses presented above identified six distinct reactivity
patterns of anti-MyHC antibodies induced in BALB/c mice. Anti-myosin antibodies recovered
from mice exposed to the J17A4 strain of GAS as neonates (group 1) showed the narrowest
pattern of reactivity, primarily binding the cardiac MyHC. One antibody with specificity for the
cardiac MyHC was also recovered from mice immunized as neonates with the D471 strain of
GAS. Two other antibodies from group 2 recognized additional MyHC isoforms and the fourth
one recognized all but the EMB isoforms. The reactivity of one antibody from group 3 was
restricted to the type I / cardiac, IIa and NN MyHC isoforms. The remainder recognized all
MyHC isoforms with the exception of the EMB, by western blot and/or ELISA. Finally,
antibodies from groups 5 and 6 recognized all but the EMB MyHC isoform.
Finally, western blot analyses of MLC resolved on 12% SDS-PAGE with all antibodies
failed (results not shown). Our findings demonstrate that anti-myosin antibodies resulting from
immunization of BALB/c mice with GAS can distinguish between distinct isoforms of skeletal
MyHC depending on the age at primary exposure to GAS.
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DISCUSSION

We have described previously that immunization of neonatal mice with heat-killed S.
pneumoniae induced the production of a class of anti-phosphorylcholine antibodies distinct from
those produced in adult mice and which were non-protective and possibly autoreactive (39). We
decided to explore whether antigens from other pathogenic bacteria could induce autoreactive
and potentially pathogenic antibodies in neonatal mice. We chose GAS for two reasons: the
antibody response in humans and mice against the group-specific determinant GlcNAc has been
characterized (8, 9), and the etiologic relationship between GAS and diseases such as ARF is
established (1, 2). A large number of prior studies demonstrate that myosin-cross-reactive
antibodies are induced by GAS in ARF patients and in laboratory mice (11 - 13, 18, 19).
However, their role in the pathogenesis of ARF remains unclear.
The current study reveals that anti-myosin antibodies are induced and persist in BALB/c
mice that have been exposed to heat-killed GAS as neonates. These antibodies react strongly
with GlcNAc but show weak reactivity toward the M6 protein. While the presence of an emm
gene in J17A4 has been documented (34), whether a functional M protein is expressed by this
strain is unknown. Nevertheless, small amounts of surface proteins may be retained within the
J17A4 preparation treated with pepsin. We have recently observed that a variant of D471 with
an insertional inactivation in the emm6 gene is capable of inducing the production and
persistence of anti-myosin serum antibodies in neonatal BALB/c mice. Thus, the presence of an
M protein is not essential for the induction of myosin-reactive antibodies. Furthermore, we
failed to observe any strain-specific differences in the serum antibody responses in BALB/c mice
(this study) and in DBA/2J and C57Bl/6J mice (M. Elliott, unpublished observations). The
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reasons for failure to boost the autoreactive response induced by GAS in neonates by second
immunization with GAS at 8 weeks of age are unclear. This appears to be a BALB/c strainrelated characteristic since in DBA/2J and C57Bl/6J mice, a booster of D471 in mice neonatally
primed with D471 leads to a prompt increase in GlcNAc- and myosin-reactive antibodies (M.
Elliott, unpublished observations).
We have also demonstrated that heat-killed GAS was unable to induce anti-myosin
antibodies in adult mice without additional boosters with purified M protein or myosin.
Furthermore, monoclonal antibodies recovered following boosters with mouse myosin or the M6
protein, react with all isoforms of skeletal MyHC except the EMB isoform. In contrast,
antibodies induced following immunization with GAS in neonatal mice show restricted
reactivity, binding cardiac MyHC in preference to other isoforms of skeletal myosin heavy
chains. The basis for binding of some of these antibodies to MLC remains unclear.
Since the cardiac myosin extracts employed in our studies were prepared from whole
hearts, we expected contamination by smooth muscle myosins from blood vessels associated
with the heart. Additional protein bands were found in the same molecular weight range as the
cardiac skeletal myosins upon SDS-PAGE. However, we failed to detect any of these bands in
western blots with the antibodies described here and with hsm-V, an antibody specific for human
smooth muscle myosin (35). Therefore, we could not determine whether the antibodies
described in this study could recognize smooth muscle myosins.
Upon histological examination of mice from groups 1 and 2 we failed to observe any
abnormalities of the heart, joints or kidney. All mice within these two groups progressively
developed alopecia of the whole body. Due to lack of evidence in favor of an immunologic
mechanism, the alopecia was adjudged 'idiopathic'. Mice in all other groups maintained perfectly
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normal hair well beyond 70 weeks of age. Histological analyses were also conducted on groups
of mice immunized with GAS within the first week of life and sacrificed at various times
thereafter to detect signs of pathology that might have been overlooked in the absence of overt
symptoms, albeit with negative results.
We have additionally observed that all but one of the antibodies from groups 1 and 2 and
none from groups 3, 5 or 6 bind to hyaluronic acid and/or heparin sulfate by ELISA.
Additionally, BALB/c as well as DBA/2J and C57Bl/6 mice immunized with GAS within one
week of birth, but not as adults, carry persistent antibodies that bind hyaluronic acid and heparin
sulfate (M. Elliott, unpublished observations). Both of these are acidic glycosaminoglycans
found in the mammalian extracellular matrices. Hyaluronic acid commonly occurs at the surface
of certain cells, in the serum and as a backbone in complex proteoglycans (36). Hyaluronic acid
is also found on mitral valve leaflets, within the pericardium of the heart (37) where it probably
functions as a lubricant. We propose that these antibodies may be multireactive like the
monoclonals described here. They may bind hyaluronic acid coating the mitral valve, cardiac
myocytes and resident fibroblasts. They may also gain entry into cardiac myocytes, bind to the
myosins and compromise myocyte function. The lack of these symptoms in our model system
suggests that mere presence of autoantibodies is not sufficient to cause pathology. Hyaluronic
acid may also be responsible for the chronic stimulation of autoreactive antibodies in ARF sera
and in our mouse model system.
In the current study, we immunized mice by the systemic route; attempts to detect
significant amounts of autoantibodies following intranasal immunization have repeatedly failed.
Additionally, in similar studies, we have observed that systemic immunization of neonatal, but
not adult, mice with heat-killed GAS expressing the M protein led to the induction of myosin-
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reactive CD8+ CTL (Cunningham and Elliott, submitted for publication) as well as CD4+ cells
(Elliott and Cunningham, unpublished observations). Despite the identification of functionally
active autoreactive T cells, no pathology was detected in these studies.
Systemic autoimmune diseases such as SLE are thought to be primarily the result of
autoantibodies (38). The pathological insult is primarily through deposition of immune
complexes in basement membranes, cytokine imbalances may also contribute to the disease.
Antibodies capable of binding acidic glycosaminoglycans are also detected in SLE (39); their
role in the disease process is unknown. Recent studies have utilized gene targeting in
combination with genetic animal models of SLE and autoimmune diabetes to establish that B
cells are required for initiation of the disease (40 - 42). In most other autoimmune diseases, the
presence of autoantibodies is thought to reflect the release of sequestered autoantigen following
tissue or organ damage and therefore, secondary to the disease process. In contrast, in ARF,
myosin- and glycosaminoglycan- reactive antibodies appear to be induced by the pathogen and
therefore are likely to be involved in the initial stages of the disease. Since convalescent patients
and individuals on long-term penicillin prophylaxis continue to carry autoantibodies in their sera
(5), their relevance to disease in later stages remains unclear. ARF remains one of the few
diseases where a cause-effect relationship between a pathogen and pathogenesis is firmly
established. Understanding the mechanism of ARF pathogenesis might lead to new insights into
the mechanisms of other autoimmune diseases of man.
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In summary, we have begun to identify various components of the immune system with
potential for pathogenesis and which are stimulated by GAS in neonatal but not adult mice.
Despite the lack of pathology, the similarities with ARF make this model system suitable for
dissecting the mechanisms of post-streptococcal autoimmune diseases. Since autoimmune
diseases are thought to involve multiple events, identification of the pathogenic mechanisms in
ARF will likely involve modifications to this model system in the future.
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Figure 1: Antibody responses in BALB/c mice immunized with heat-killed GAS. Mice were
immunized as described in materials and methods. Data represent geometric means of
absorbance values (Y-axis) corresponding to serum dilutions of 1:5000 (panel a), 1:2500 (panel
b) and 1:500 (panel c) plotted against age of mice (in weeks) for each experimental group, with
eight mice per group. Eight groups (based on the immunizing antigen and age at immunization)
are as follows: unimmunized control (open diamonds), D471 at 6 and 8 weeks (filled circles),
J17A4 at 6 and 8 weeks (filled squares), M6 protein at 6 and 8 weeks (open triangles), D471 at 2
and 8 weeks (filled triangles), J17A4 at 2 and 8 weeks (filled diamonds), D471 at 2 weeks only
(open circles) and J17A4 at 2 weeks only (open squares).
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Table 1: Summary of hybridomas obtained following distinct immunization strategies
Age at
primary
immunization

antigena

1

2d

J17A4

none

2

2d

D471

3

2d

4

Group

a

b

c
d

Booster
antigenb

Age at
fusion

numbers of monoclonal
antibodies reactive towardc
GlcNAc

M6

Myosind

60 wk

> 100

2

2

none

60 wk

> 100

4

4

D471

D471

10 wk

> 100

0

5

6 wk

D471

D471

10 wk

> 100

1

0

5

6 wk

D471

M6

10 wk

21

6

5

6

6 wk

D471

Myosin

10 wk

32

2

6

Heat-killed GAS of appropriate strain (J17A4 or D471) was injected by intraperitoneal route
at 1 - 2∗107 to 2 day old mice and at 1∗108 to 6 wk old mice.
heat-killed GAS was injected at 108 per mouse; recombinant M6 protein mouse myosin
(prepared from the gastrocnemius muscle of adult mice) was injected at 100 µg per mouse.
as determined by ELISA. Scoring based on absorbance at 405nm > 0.5 units above
background.
whole myosin from rabbit hind limbs (Sigma Chemicals)
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Table 2: Binding of myosin components by monoclonal antibodies induced by GAS
Groupa

Binding of antibodies in ELISAb to

mAb

Myosin componentsc

GAS antigens

1

2

3

5

6

a
b
c

GlcNAc

M6

MyHC

MLC

HMM

LMM

BA1-23

+++++

+

+++++

+++

--

++++

FD3-6-1

+++++

+

++++

+++

--

++++

1G19

+++++

+

+++

--

--

+++

1L23

+++++

+

+++

+++

++

+++

1M12

+++++

+

++++

+++

--

+++++

1N24

+++++

--

+++++

--

--

++++

11E18

++++

--

++++

+++

--

++++

11L6

+++

--

++++

--

--

++++

11L24

+++

--

++++

--

--

++++

11N24

+++

--

++++

--

--

++++

11AA23

+++

--

+++++

--

--

+++++

14A23

++

+

+++

--

--

++++

14L7

--

++

+++

--

--

++++

14H15

+

++++

+++

--

--

++++

14I23

++

+++

+++

--

--

++++

14J16

++

+++

+++

--

--

+++

15A11

+++

+++

+++++

--

--

++++

15E23

+++

++

+++++

--

++++

15F19

++

--

+++++

--

--

++++

15K6

+

--

++++

--

--

++++

15K20

+

--

++++

--

--

++++

15L12

++++

--

+++++

--

--

++++

Groups as per Table 1, column 1
absorbance values (at 405 nm) are represented as follows: 0.25-0.5 = +; 0.5-1.0 = ++; 1.0-1.5
= +++; 1.5-2.0 = ++++; >2.0 = +++++.
MyHC = myosin heavy chains, MLC = myosin light chains, HMM = heavy meromyosin,
LMM = light meromyosin.
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a

IIa

EMB

IIx/IId

IIb

NN
F1.652

I/β
β

N3.36
SC-71
BF-F3
A4.840
N2.261
1

2

3

4

5

6

b

α

I/β
β
A4.840
N2.261
1

2

3

Figure 2: Western blot analysis of mouse MyHC with antibodies raised against human and rat
MyHC. Myosin extracts were prepared, electrophoresed and transferred to PVDF membranes as
described in materials and methods. Tissue source of myosin in lanes is as follows: figure 1a 18day-embryonic hindlimb (lane 1), 1 day hindlimb (lane 2), 7-day hindlimb (lane 3), 7-day
diaphragm (lane 4), 3 week soleus (lane 5) and 5 wk gastrocnemius (lane 6). Figure 1b: 18-day
embryonic heart (lane 1), 1 day heart (lane 2), and 5 week heart ventricle (lane 3). Each panel is
probed with the antibody noted.
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1

2

3

4

5

6

BA1-23
FD3-6-1
1G19
1L23
1M12
11E18
1N24
11AA23
11L6
11L24
11N24
15E23

Figure 3: Western Blot analysis of MyHC isoforms from hind limbs and diaphragm with mouse
monoclonal antibodies induced by GAS. Myosin extracts were prepared, electrophoresed and
transferred to PVDF membranes as described in materials and methods. Tissue source of myosin
in lanes is as follows: 18-day-embryonic hindlimb (lane 1), 1 day hindlimb (lane 2), 7-day
hindlimb (lane 3), 7-day diaphragm (lane 4), 3 week soleus (lane 5) and 5 wk gastrocnemius
(lane 6). Each panel is probed with the antibody noted.
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1

2

3

BA1-23
1G19
1M12
11E18
11AA23
14L7
15F19

Figure 4: Western blot analysis of mouse cardiac MyHC with mouse monoclonal antibodies
induced by GAS. Muscle myosin extracts were prepared, electrophoresed and transferred to
PVDF membranes as described in material and methods. Tissue source of myosin in lanes is as
follows: 18-day embryonic heart (lane 1), 1 day heart (lane 2), and 5 week heart ventricle (lane
3). Each panel is probed with the antibody noted.
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TABLE 3: Patterns for cross-recognition of endogenous MyHC by antibodies against GAS
Pattern

a
b
c

# of
repeats

groupa

Mouse myosin heavy chain isoform recognizedb
α

β/I

IIa

IIb

IIx/IId

Neo

1

3

1, 2

+

+

+/-

2

1

2

+

+/-

+

3

1

2

+

+

+

4

1

3

+

+

5

2

3

+c

+c

+

+

+

+

6

11

2,3,5,6

+

+

+

+

+

+

Emb

+
+

Groups as per Table 1, column 1
based on detection by western blots as shown in figs 3 and 4 and indirect ELISA (for cardiac
myosins).
binding as per indirect ELISA only
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Induction of myosin-reactive CTL in mice following immunization with heatkilled Streptococcus pyogenes
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ABSTRACT
Cardiac myosin is one of the hypothetical target autoantigens associated with acute
rheumatic fever; an autoimmune disease induced by the group A streptococcus. We have
investigated the capacity of group A streptococcus to induce a cytotoxic T lymphocyte response
against myosin in laboratory mice. Immunization of adult mice with heat-killed Streptococcus
pyogenes strain D471 (D471) induced a CTL response directed against streptococcal M protein
but not against myosin. In contrast, in newborn mice a CTL response against M protein as well
as myosin was induced following intraperitoneal immunization with D471 or purified
recombinant M protein, but not with a variant of D471 lacking the M protein. The capacity of
D471 to prime myosin-reactive CTL was lost in mice three weeks of age and older. Myosinreactive memory CTL primed in neonatal mice by D471 could be restimulated several weeks
later not only by D471 and myosin but also by purified recombinant M protein. CD8+
splenocytes enriched from neonatal mice immunized with D471 and cultured in the presence of
recombinant M protein lysed target cells pulsed with tryptic digest of M protein or myosin. Our
observations establish the capacity of group A streptococcus to cross-prime and expand CTL
reactive against myosin in BALB/c mice and reveal that age at primary exposure plays a critical
role in determining this capacity.
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INTRODUCTION
Streptococcus pyogenes, a β-hemolytic group A streptococcus, causes infections of the
skin and the nasopharynx in humans (1). In addition, non-suppurative complications occur as
sequelae to streptococcal infections in some individuals (2, 3). Acute rheumatic fever (ARF) and
acute glomerulonephritis (AGN) represent some of the more serious complications as they
involve damage to heart and renal tissues, respectively. The major manifestations of ARF
include arthritis and carditis, the latter being mainly pericarditis, sometimes in combination
Aschcoff bodies and fibrotic stenosis of the mitral valve (4). In biopsy and autopsy specimen
from affected hearts in ARF, infiltrates consisting primarily of T lymphocytes have been noted
(5, 6). The presence of both CD4 and CD8 bearing T cells along with some B cells has been
documented (6). Detailed phenotypic and functional analyses of lymphocytes in these infiltrates
have failed to elucidate their role in disease pathology. Additionally, sera from ARF patients
have been shown to contain antibodies directed against cardiac antigens (7-9).
Studies utilizing lymphocytes isolated from ARF patients as well as attempts to develop
animal model systems for ARF have revealed the capacity of the group A streptococcus to induce
abnormal immune responses in mammalian hosts (10-12). Cross-reactions between
streptococcal antigens, the M protein in particular, and human cardiac antigens such as myosin
have been established at the level of antibody and CD4 T cell epitopes (13-15). Based on these
studies and numerous other reports, it is widely accepted that the autoimmune sequelae to
streptococcal infections result at least in part from elicitation of immune response against host
antigens by S. pyogenes during the course of an infection. Pepsin extracts of M protein from at
least 3 distinct serotypes of Streptococcus pyogenes have been shown to act as superantigens for
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T lymphocytes expressing specific Vβ genes from normal human peripheral blood (16, 17). It
has been proposed that superantigen driven stimulation of T cells may further contribute to
disease pathogenesis associated with ARF and related manifestations.
Additional attempts at understanding the mechanism of ARF have been directed at
identifying cytotoxic lymphocytes capable of destroying cardiac myocytes in ARF patients.
Lymphocytes isolated from valvular tissue from ARF cases have been shown to lyse cultured
cardiac cells (18). Furthermore, peripheral blood lymphocytes from normal humans cultured
with pepsin extracts of M protein have been shown to acquire a capacity for lysis of cultured
myocardial cells in vitro (19).
Studies addressing the possible induction of cytotoxic T lymphocytes against host
antigens following exposure to group A streptococcus have not been documented to date. Since
S. pyogenes is an extracellular pathogen, CTL response against streptococcal antigens most likely
do not constitute a major mechanism of defense against this organism in human hosts.
Nevertheless, the presence of CD8 bearing cells in cardiac biopsy specimen from ARF patients
warrants their evaluation as potential mediators of target organ damage. In the current report we
demonstrate that myosin-reactive CTL are elicited by a rheumatogenic strain of Streptococcus
pyogenes in neonatal but not in adult mice. Furthermore, neonatal exposure to heat-killed S.
pyogenes induces memory for myosin-reactive CTL that can be reactivated by either S. pyogenes
or purified recombinant M protein later in life. We then discuss why despite their presence, we
fail to see pathological damage in the laboratory model.
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MATERIAL AND METHODS
Mice: BALB/c mice were purchased from Jackson Laboratory, Bar Harbor, ME and bred at
WVU animal facility.
Antigens:
Streptococcus pyogenes strains D471 (serotype M6) and UAB152 (a derivative of D471
containing insertional inactivation of the emm6 gene) were grown from single colonies in 2 liters
of Todd-Hewitt broth without aeration in the presence of 7.5% CO2 until growth ceased. The
cultures were pasteurized by incubation in a 5°C water bath for 1.5 hours at which point cells
were centrifuged, washed 5 times with 500ml of 0.85% saline and resuspended in 0.85% saline.
The cells were frozen at –20º C in 5ml aliquots after adjusting the cell density to OD600 of 2.0/ml
(2∗108 bacteria/ml). Both strains were a gift from Dr. Hollingshead (UAB).
Plasmid TR06 was gift of Dr. Hollingshead. This plasmid contains residues 1 to 413 of the
mature M6 protein cloned into the NcoI and XhoI sites of pET20b+ (Novagen). The recombinant
M6 protein with a carboxy-terminal His-6 tag was expressed in BL21:(DE3), pLysS by induction
with Iptg for 1 hr and was purified from periplasmic extracts by adsorption to Ni-NTA-sepharose
(Qiagen).
Gastrocnemius muscles pooled from hindlimbs of 5 week old mice were placed in four volumes
by weight of 0.3 M NaCl, 0.1 M NaH2PO4, 0.05 M Na2HPO4, 10 mM EDTA, 1.4 mM 2mercaptoethanol (20), minced fine and incubated on ice for 30 minutes with periodic mixing.
Samples were centrifuged at 13,000 g for 30 minutes; supernatants were diluted 5 fold in storage
buffer (40 mM Na4P2O7, 50% glycerol) and stored at –20º C. Rabbit myosin and bovine
cytochrome c were purchased from Sigma Chemical Co., St. Louis, MO.
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Immunizations: Mice were immunized with 107 heat-killed S. pyogenes per gram of body weight
or soluble antigens M protein, myosin or bovine cytochrome c at the doses specified in the results
section. The volumes were maintained at 50-100 µl (neonatal) or 200 µl (adult) per mouse by the
intraperitoneal route or in 5 µl (neonatal) or 20 µl (adult) per mouse divided equally between two
nostrils.
Analysis of CTL responses:
Preparation of antigen peptides: M protein, rabbit myosin, mouse muscle extract and bovine
cytochrome c were adjusted to a final concentration of 1 mg/ml in sterile Dulbecco’s phosphate
buffered saline, to which, trypsin (Sigma chemical Co., St. Louis, MO) was added at 10 µg/mg
protein. Proteolysis was carried out for 20 hours at 37º C and digested samples were stored at 20º C.
Cell cultures: Single cell suspension of splenocytes were washed extensively with incomplete
RPMI following red blood cell lysis with 0.15 M NH4Cl lysing buffer. Cell counts and viability
were monitored via trypan blue exclusion. The spleen cells were in a buffer (5mM EDTADPBS) containing pre-determined dilutions of biotinylated anti-CD45R (RA3-6B2) and antiCD4 (a mix of GK1.5 and RM4-4, Pharmingen) monoclonal antibodies. Following a 20 minute
incubation on ice cells were washed and incubated with streptavidin-labeled magnetic beads
(Miltenyi Biotec) for 15 minutes on ice. The stained cells were then passed through a MACS
CS+ depletion column (Miltenyi Biotec) for separation as described by the manufacturers and
non-bound cells were collected for assay and culture. Efficiency of enrichment was monitored
by flow cytometric analysis employing a FACScan (BDIS, San Jose CA). Typically, cells used
for assay and culturing contained <2% CD4+, <5% B220+ cells and >65% CD8+ cells. Nonbound cells were placed in culture with three to five times the number of irradiated adult spleen
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cells and tryptic digests of recombinant M protein or bovine cytochrome c for a period of five
days and washed with serum-free RPMI1640 before subsequent functional assay.
Cytolytic assay: Spleens from experimental mice were processed into single cell suspensions in
serum-free RPMI1640, washed once and resuspended in phenol red-free RPMI with 5% fetal calf
serum. Cultured cells were washed once in RPMI1640 prior to functional assay. P815 cells (H2d expressing mastocytoma cell line) (21) were incubated with tryptic peptides of appropriate
antigen for 30 - 60 minutes in serum-free, phenol red-free RPMI1640 at a concentration of
2∗105/ml. Effector cells (splenocytes) were plated with the P815 cells loaded with peptides at
various ratios in phenol-red free RPMI in 96-well microtiter plates for each antigen tested.
Controls included target cells alone, appropriate serial dilutions of effector cells, target cells
lysed with 1% Triton X-100 and media alone. The assay plates were incubated at 37º C for
approximately 5 hours in the presence of 7.5 % CO2. Subsequently, the plates were centrifuged
for 2 minutes at 500 rpm and 50µl of the supernatants were transferred to a new assay plate. An
equal amount Promega Cytox96 assay substrate (oxidized to a colored product in the presence of
LDH) was added to all wells. The absorbance was read at 490 nm following a 30 minutes
incubation employing a multiscan (Biorad). Absorbance was proportional to the amount of LDH
release by lysed cells and therefore to the amount of target cell lysis. Absorbance values for all
experimental and control sets (run in triplicates) were averaged and the antigen-specific lysis was
calculated as percent of maximum lysis as follows:
Abs [effector + target] - Abs [effectors (spontaneous)] - Abs [target (spontaneous)]
Abs [targets (maximum lysis)] - Abs [targets (spontaneous)]
Inhibition of CTL activity: Monoclonal antibodies against mouse CD4 (RL172) and CD8
(3.155) were harvested from hybridoma (ATCC) tissue culture supernatants by precipitation with
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(NH4)2SO4 and extensive dialysis against phosphate buffered saline, sterilized by filtration.
Antibodies were titrated by staining of BALB/c spleen cells in an indirect immunofluorescence
assay and flow cytometric analysis. Appropriate dilutions of antibodies were added to effector
splenocytes prior to mixing with antigen-pulsed P815 cells. The remainder of assay and analysis
was conducted as described above.
All statistical analyses were performed by calculating the p value by ANOVA and the standard
error using Microsoft Excel Analysis Toolpak. Lytic units were calculated as previously
described (22).
RESULTS
CTL response in adult BALB/c mice immunized with Streptococcus pyogenes:
Our initial experiments were designed to determine whether streptococcal M protein and
mammalian myosin could elicit a CTL response in laboratory mice. To this end we utilized
purified recombinant M protein representing a rheumatogenic strain of S. pyogenes (serotype M6,
strain D471) and a crude extract of myosin obtained from the hind limbs of BALB/c mice as
immmunogens. Tryptic digests prepared from the affinity-purified recombinant M protein and a
commercially available preparation of purified rabbit hind limb myosin were then used as assay
antigens. Bovine cytochrome c has been shown to induce CTL responses in mice when
administered by the intraperitoneal route. Therefore we used this antigen as a control for our
studies. Adult BALB/c mice were administered 100µg of M protein, myosin or bovine
cytochrome c by the intraperitoneal route, and boosted by the same route 12 days later. Five to 7
days following the second immunization, splenocytes were harvested and assayed as described.
As shown in figure 1a immunization of adult BALB/c mice with purified recombinant M protein
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induced specific lysis of P815 (H-2d) cells loaded with tryptic peptides of M protein but not
cytochrome c or myosin. Similarly, immunization with mouse myosin or bovine cytochrome c
induced lysis of P815 cells in an antigen-specific manner (fig 1b and c). Data shown translate
into average lytic units (per 107 effector cells) giving 20% antigen-specific lysis of 10.2, 7.3 and
8.9 for antigens M protein, myosin and cytochrome c, respectively. Lysis of EL4 (H-2b) or
CBA.D1 (H-2k) cells similarly pulsed with the three tryptic digests was negligible (results not
shown). Thus, adult BALB/c mice display the capacity to present as well as recognize
streptococcal M protein and autologous myosin in the context of class I (H-2d) MyHC.
Furthermore, CTL response against mouse myosin in BALB/c mice can be readily measured
employing peptides of rabbit myosin. These results further established that the CTL responses
against the streptococcal M protein and mouse myosin could be easily induced and detected
employing a simple non-radioactive assay.
We next sought to determine whether administration of heat-killed Streptococcus
pyogenes organisms could induce a CTL response against M protein and against myosin which
has been shown to share T-cell epitopes with M protein (14, 15). Adult BALB/c mice (H-2d)
were administered heat-killed whole-cell preparation of S. pyogenes strain D471 (D471) by
intraperitoneal route. Splenocytes harvested 7 days following two intraperitoneal immunizations
with 2∗108 D471 given 12 days apart were harvested and assayed as described in materials and
methods. As shown in fig 1d, the assay detected lysis of a small but significant proportion of
target P815 cells loaded with tryptic peptides of recombinant M protein at the highest effector to
target cell ratio. Lysis of target cells loaded with tryptic peptides of bovine cytochrome c or
rabbit myosin was minimal even at the highest E:T ratio. Antigen-specific lysis of target cells
loaded with M protein was inhibited in the presence of anti-CD8 antibodies but not anti-CD4
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antibodies confirming that lysis was induced primarily by CD8-bearing cells (fig 1e). In adult
BALB/c mice immunized four times with heat-killed D471 over a 4-month period, the CTL
response against M protein was significantly above that against the control antigen cytochrome c
(fig 1f). However, hyperimmunization with D471 failed to elicit a CTL response against myosin,
suggesting that repeated exposure to killed pathogen was not sufficient to induce an immune
response against the autoantigen myosin. Thus, our results clearly demonstrate that the
streptococcal M protein, either soluble or cell-associated, is not capable of inducing a myosinreactive CTL response in adult BALB/c mice.
Myosin-reactive CTL in neonatal BALB/c mice immunized with Streptococcus pyogenes:
The lymphocyte repertoire in mouse and man changes dramatically as a function of age
with respect to antigen specificity (23, 24). It is also known that perturbations of the immune
system in neonatal stages of development can have long-lasting effects (25, 26). While the
mechanism of pathogenesis in most autoimmune diseases remain unclear, it is recognized that
the initiating events may occur long before the disease symptoms are manifest. We therefore
proceeded to test whether S. pyogenes might stimulate myosin-reactive CTL cells in neonatal
mice.
Newborn BALB/c mice were immunized by the intraperitoneal route with heat-killed
Streptococcus pyogenes or purified recombinant M protein within one week of birth and
sacrificed seven days following immunization for analysis of antigen-specific CTL. As shown in
figure 2a, in mice immunized with D471, we detected a CTL response against M protein.
Interestingly, we also detected a CTL response against myosin. These results indicate that
Streptococcus pyogenes can indeed induce the priming of autoreactive and potentially harmful
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CTL in laboratory mice. They further establish that age at exposure to S. pyogenes is critical in
the capacity to mount an autoreactive CTL response.
In mice immunized within one week of birth with 5 µg of recombinant M protein, a
strong CTL response against M protein was noted (fig 2b). The percent M protein-specific lysis
in this group of mice for each of the E:T ratios tested was comparable to or better than that
observed in mice immunized with heat-killed D471 (note difference in x-axis scale, 2a versus
2b). However, while the percent myosin-specific lysis of target cells by splenocytes from this
group of mice was clearly above background, it was not comparable to that observed in mice
immunized with D471. Two explanations for this observation are considered. Firstly, it is
possible that the myosin-reactive CTL are induced by some other streptococcal antigen and that
the M protein alone is not sufficient to induce maximal CTL response against myosin.
Alternately, uptake and processing of the streptococcus by host macrophages may result in the
processing and presentation of unique M protein CTL epitopes that may not be optimally
generated following extracellular degradation of soluble M protein. Such epitopes may be
critical in the elicitation of myosin-reactive CTL.
To investigate whether group A streptococcus might induce myosin-reactive CTL in the
absence of M protein, we utilized strain UAB152, a variant of D471 derived by insertional
inactivation of the emm6 gene. CTL responses against M protein as well as myosin were absent
in mice immunized within one week of birth with a heat-killed preparation of strain UAB152 (fig
2c). While these findings do not exclude the role of other streptococcal antigens in the induction
of a CTL response against myosin, the obligate role of M protein is underscored.
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Kinetics of myosin-reactive CTL in neonatal BALB/c mice
This next set of studies was conducted to compare the kinetics of elicitation of CTL
reactive toward M protein and myosin following immunization with D471 in order to gain
insight into the relationship between the two antigens. We immunized newborn BALB/c mice
within 3 days of birth with D471. They were sacrificed on different days to assay the CTL
responses against M protein and myosin. Four days following immunization with D471, the lytic
response of splenocytes against P815 cells pulsed with tryptic digests of the M protein or myosin
was indistinguishable from non-specific lysis of target cells loaded with cytochrome c (fig 3a and
3f). M protein-specific lysis was significantly above background on days 7, 10 and 13 following
immunization (fig 3b, c, d, respectively), with peak response on day 7 (Fig 3b). By day 18 the
capacity for M protein-specific lysis had dropped to background levels (fig 3e). On day 7 of the
response, anti-CD8 and anti-CD4 antibodies produced about 70-80% and 10-15% inhibition of
antigen-specific lysis of target cells respectively (fig 3b). On days 10 and 13, 90% or greater of
the lytic response was inhibited in the presence of anti-CD8 antibody (fig 3c and 3d). These
findings establish that M protein-specific lysis is induced primarily by CD8-bearing cells
following exposure of newborn BALB/c mice to heat-killed Streptococcus pyogenes by the
systemic route. The kinetics of the response indicates that the antigen (M protein) is rapidly
eliminated.
Interestingly, capacity for lysis of myosin pulsed target cells was also observed in the
same group of mice as above with kinetics identical to that of M protein specific CTL (fig 3f-j).
Lytic indices for myosin-specific lysis for all the E:T ratios on days 7, 10 and 13 of the response
were comparable to those for M protein-specific lysis. (Day 7 - 12.3:10.9, Day 10 - 5.4; 4.6, Day
13 - 5: 4.2) Furthermore, the extent of inhibition of antigen-specific lysis achieved in the
92

presence of anti-CD8 or anti-CD4 antibodies on days 7, 10 and 13 is identical for both antigens.
These observations suggest the existence of shared CTL epitope(s) between the two antigens.

Capacity of D471 to prime a CTL response against myosin is lost at weaning:
Having established that administration of heat-killed Streptococcus pyogenes to neonatal
mice is required for the generation of myosin-reactive CTL in BALB/c mice, we chose to define
the age limits to which this capacity might be restricted. Groups of mice were primed with D471
at 107 heat-killed organisms per gram of body weight on days 10, 20 or 30 after birth and boosted
at 6 to 7 weeks of age with 2∗108 D471. They were sacrificed 7 days later for analysis of the
immune response. As shown in Figure 4, no significant differences were noted in the CTL
response against M protein in mice primed with D471 on days 10, 22 (weaning age) or 30 (fig
4a-c). In contrast, CTL response against myosin was highest in mice primed on day 10 (fig 4a)
and this was equivalent to that seen in mice primed within three days of life (compare with fig
5a). In mice primed on day 22, the myosin-specific CTL response was weaker, (lytic index =
3.4) yet significantly above than that in mice primed with D471 on day 30 (fig 4b). In the latter
group the myosin-specific lytic response at all E:T ratios was indistinguishable from non-specific
lysis (fig 4c). Thus, priming for an optimum CTL response against myosin was best achieved by
immunizing with D471 within the first 10 days of life. The capacity to elicit myosin-reactive
CTL declined with increasing age and was lost in mice 30 days of age or older. These findings
demonstrate the significance of host age in the capacity of the group A streptococcus to
successfully initiate a CTL response against myosin.
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Myosin-reactive memory CTL can be reactivated with soluble M protein and vice versa
In further attempts to explore the relationship between the streptococcal M protein and
mammalian myosin, we examined the secondary CTL response in BALB/c mice primed during
the first week of life with 107 heat-killed D471. As shown in figure 5a, in mice primed with
D471, the CTL response against the M protein as well as against myosin was reactivated
following an intraperitoneal booster with 108 heat-killed D471 given at 4 months of age. An
equivalent dose of the variant strain UAB152 lacking the M protein failed to reactivate CTL
against both the M protein and myosin (fig 5b). These results confirm the requirement for M
protein in the stimulation of myosin-reactive CTL. The absence of a CTL response against
myosin in this group of mice (fig 5b) and in a group boosted with 100µg of the control antigen
bovine cytochrome c (results not shown) suggests the absence of chronic stimulation of specific
CTL by endogenous myosin.
Interestingly, a booster of 100 µg of purified recombinant M protein in mice primed with
D471 reactivated not only the M protein-reactive CTL as expected, but also myosin-reactive CTL
(fig 5c). The lytic indices for myosin-specific lysis in experiments shown in fig 5a and 5b are 5.5
and 1.0 respectively. Additionally, immunization with 100µg of mouse muscle extract induced a
CTL response against myosin as well as M protein (fig 5d). These findings strongly support the
idea that cross-priming between M protein and myosin results from existence of cross-reactive
CTL epitope(s) rather than through indirect mechanisms.
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M protein-reactive CTLs elicited in neonatal mice cross-react with myosin
Our results thus far suggest that the myosin-reactive CTL response elicited in neonatal
mice may be due to antigen cross-reaction to streptococcal M protein. In order to rule out the
possible involvement of endogenous myosin in our experiment, we conducted the following
experiment. CD8+ splenocytes were enriched from adult and neonatal mice immunized with
D471 by magnetic sorting as described in material and methods. The enriched cells were assayed
directly for lysis of antigen labeled target cells or were restimulated in vitro with enzymatic
digests of recombinant M protein or cytochrome c for five days. As shown, CD8+ spleen cells
from mice immunized as adults with D471 were capable of lysing P815 cells labeled with tryptic
digests of M protein but not myosin or cytochrome c (fig 6a). A comparison with figure 1d
shows and 8 – 10 fold enrichment of M protein reactive CTL. The CTL response measured
against both M protein and myosin in cultured cells were inhibited by addition of anti-CD8 but
not anti-CD4 to the assay (data not shown). CD8+ splenocytes obtained from unimmunized age
matched control mice and cultured with either recombinant M protein or cytochrome c failed to
lyse P815 pulsed with tryptic digests of recombinant M protein, myosin or cytochrome c (results
not shown).
Culture of CD8+ splenocytes from adult mice immunized with D471 in the presence of M
protein selectively enriched the specific CD8+ cells and maintained them functionally active (fig
6b) whereas, culture with digest of cytochrome c led to a loss of CTL activity against M protein
(fig 6c). This finding suggests that presence of antigen, in this case M protein, was necessary to
maintain functional activity in vitro.
CD8+ spleen cells from neonatal mice immunized with D471 were capable of lysing P815
cells labeled with either tryptic digests of M protein or myosin but not cytochrome c (fig 6d).
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Following culture with M protein for 5 days, the CTL response against both M protein and
myosin was maintained (fig 6e) whereas, culture in the presence of tryptic digests of cytochrome
c led to a loss of response against M protein as well as myosin (fig 6f). The logical interpretation
of these results is that the myosin-reactive CTL response following neonatal exposure to D471
results from cross-reaction of CTL against M protein.

DISCUSSION
It is becoming increasingly evident that T cells are potential mediators of the pathology
witnessed in rheumatic fever. Due to the shared structural characteristics and epitopes (27, 28), it
has been hypothesized that T cells elicited against streptococcal M protein cross-react with the
host protein myosin. Patients with ARF demonstrate lymphocytic infiltrates in cardiac tissue (5,
6), however, there are conflicting reports of their ability to cross-react with streptococcal
preparations and cardiac proteins. Guilherme et al. (10) reported that T cell clones isolated from
cardiac valve samples of rheumatic fever patients demonstrated cross-reactivity between type 5
M protein and heart tissue protein extracts. Yet, Yoshinaga et al. (12) were unable to
demonstrate such cross-reactivity with their T cell lines isolated from cardiac tissue of RF
patients. el-Demellawy et al. (18) has demonstrated that PBL from ARF patients recognize a 50
kDa and 54 kDa protein of myocardial extracts and that the proliferative response may be
intensified by pre-culturing cells with GAS extracts. Cloning of PBL from active and chronic
cases of ARF has yielded conflicting results as well. The T cell lines of both CD4+ and CD8+
phenotypes produced by Pruskakorn et al. (14) that cross-reacted between M protein and myosin
were isolated from healthy individuals. Further study of human lymphocytes have shown that
peptic preparations of certain serotypes of M protein have a mitogenic effect on a particular
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subset of naive human lymphocytes (16, 29) and this stimulation has the potential to invoke
cytotoxic activity against cultured human heart cells (19, 30). These studies have allowed for
thehypothesis that the superantigenic ability of M protein is able to augment the immune
response against streptococcal antigens and, therefore, the cross-reactive immune response to
host antigens, if one is primed. However, despite these promising studies, having cross-reactive
T cells may not be sufficient to cause disease, in that, M protein-reactive and myosin crossreactive T cells were isolated from normal human subjects with no history of ARF (14).
In depth evaluation of such a hypothesis is hindered by the lack of a good animal model
system. While it has been possible to induce viral mediated autoimmune diseases, such as
experimental allergic encephalomyelitis and Coxsackie B3 myocarditis, in laboratory animals
(31, 32), immunization of adult animals with Streptococcus pyogenes or components thereof
usually does not induce autoreactive T cells (15). Hyperimmunization of guinea pigs or rabbits
with Group A streptococcal preparations has been shown to induce the elicitation of cytotoxic
responses against cardiac cells (30, 33, 34). Cromartie et al. (34) demonstrated the ability to
induce cardiac lesions in mice reminiscent of ARF, however in this case an inflammatory
response to antigen deposited in the tissue was adjudged responsible for the pathology.
Based on our previous observation that immunizing neonatal, but not adult, mice with
whole heat-killed S. pyogenes strain D471 induces the production of antibodies against the group
specific determinant and that cross-react with myosin, we undertook this study to determine the
extent this immunization strategy could elicit a T cell response. Specifically, we wanted to
determine if immunization of neonatal mice with D471 could elicit CTL responses against the
suspect host antigen, myosin, and if so, determine the capacity of M protein in the induction of
such a response. CD8+ T cells have been shown to play an important role in the pathogenesis of
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several tissues targeted autoimmune diseases (35, 36). Our model includes an extracellular
organism and therefore, the induction of a CTL response may not be as evident. Harding et al.
(37, 38) and Rock et al. (39) have demonstrated the ability of extracellular antigens to be
presented via class I MHC. In addition, S. pyogenes has been shown to be capable of binding
and entering and residing in host epithelium in patients with recurrent tonsillitis and in carriers
(40). As such, S. pyogenes may spend some time as a viable intracellular pathogen and elicit a
CTL response. Since we have employed heat-killed vaccine in our studies, our findings suggest
that other mechanisms may also be involved in the generation of a CTL response against this
organism.
Based on studies conducted to date, we know very little about the capacity of neonates to
respond to various antigens. Studies in the area have employed the trial and error approach using
distinct antigens. Of note are recent studies that have attempted to identify conditions conducive
to the generation of optimal immune responses, in neonates. Utilizing the hen egg lysozyme
(HEL) model for neonatal tolerance induction (25, 40), neonates were shown capable of eliciting
an antigen-specific proliferative Th cell response. In addition, Sarzotti et al. (42) and Siegrist et
al. (43) demonstrated the ability of neonatal mice to mount a protective CTL response using two
distinct viral models. Furthermore, Pilarski et al. found that mice have detectable anti-allogenic
CTL responses within three days of birth (44). Our data clearly shows that neonatal mice can
mount CTL responses against bacterial antigens.
Results shown in figure 2 demonstrate the ability of mice neonatally treated with whole
heat-killed S. pyogenes to elicit a CTL response against both M protein and myosin. The
specificity of this response was confirmed by the lack of response against the unrelated control
antigen cytochrome c. Examination of the kinetics of this response (fig 3) reveals that both the
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M protein and myosin CTL responses peak at seven days following exposure to antigen and
diminish after eighteen days. This super-imposable kinetics of the responses against two distinct
antigens suggests the presence of cross-reactive determinants shared by the two proteins. If the
CTL response against myosin was induced by an indirect mechanism, one would expect the
kinetics of this response to be distinct from that of M protein specific CTL. The capacity of M
protein to maintain and enrich for the myosin reactive CTL in vitro further supports the existence
of a shared CTL epitope. We intend to investigate the molecular basis for this cross-reactivity
using synthetic peptides.
Another key finding in this study is the age dependence of the ability to mount a myosinreactive response following exposure to S. pyogenes. First, adult mice are quite capable of
mounting a CTL response against myosin when immunized with purified rabbit myosin, yet
immunization with S. pyogenes or M protein does not lead to the elicitation of myosin-reactive
CTL in adult mice. Second, as shown in figure 4, the level of measurable lytic response against
M protein was maintained despite the age of immunization, however, the level of the lytic
response against myosin decreased steadily with the age of the mouse. A possible explanation
for this is that the population of dual reactive CD8+ T cells prevailing early during ontogeny is
replaced by M protein specific cells as a function of age. The myosin-reactive CD8+ cells may be
deleted, anergized or merely outnumbered by those specific for M protein. This finding is
reminiscent of earlier reports that demonstrate the ontogenic development of dominant idiotypes
associated with bacterial polysaccharide antigens (45 - 47) and the loss of certain TCR Vβ upon
negative selection by endogenous viruses (48, 49). Thus a growing body of evidence suggests
that autoreactive lymphocytes may be most easily activated during early life before the immune
system is fully mature. Together, these findings help shape the theories about how autoimmune
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diseases develop. It is now believed that most autoimmune diseases originate in early life and
are manifest as pathological conditions much later.
We have demonstrated here that in mice immunized with S. pyogenes early in life the
myosin-reactive CTL remain as memory cells fully capable of a response when restimulated by
either M protein or myosin much later in life. Interestingly, the myosin-reactive CTL pose no
harm to the host suggesting that in this model system endogenous myosin is not released and that
the epitopes recognized by these CTL are not presented by the host during their lifetime. Peak
incidence of ARF is known to occur between the ages of five and fifteen, a time when the
immune system is thought to be mature. Perhaps additional events, which may include reexposure to S. pyogenes, are necessary to precipitate the pathology of sequelae such as ARF. Our
model system has thus permitted identification of potentially harmful CTL that can be induced by
S. pyogenes prior to the manifestation of the autoimmune sequelae. Being able to detect such
harmful lymphocytes before autoimmune diseases become debilitating would greatly benefit the
design of intervention strategies.
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Figure 1. Analysis of cytolytic T cell responses induced in adult primed BALB/c mice. Groups
of six to eight mice were immunized at least twice intraperitoneally (i.p.) with either 200 µg of
either recombinant M protein type 6 (a), crude mouse skeletal myosin extract (b) or bovine
cytochrome c (c), or 2∗108 heat-killed D471 either twice (d, e) or four times (f) as outlined in
material and methods. Within 7 - 10 days following the last immunization spleen cells were
harvested and assayed for cytolytic responses against P815 target cells labeled with tryptic
digests of either recombinant M protein type 6 (MP) (!), cytochrome c (Cyt c) (") or
commercially prepared rabbit myosin (MY) (!) starting at a 200:1 effector to target cell ratio.
Assays in figure 1e demonstrate the lose of M protein specific lysis in the presence of anti-CD4
(#) or anti-CD8 (!) monoclonal antibodies. Percent lysis is represented on the y-axis and the
effector to target cell ratio is represented on the x-axis. Error bars represent the standard error.

101

a

40

b

c

% Specific Lysis

30

20

10

0
0

50

100

0

25

50

0

50

100

E:T ratio

Figure 2. Analysis of myosin-specific CTL responses in BALB/c mice challenged as neonates
with heat-killed S. pyogenes. Neonatal mice in groups of four were immunized i.p. within 7 days
post partum with 2∗107 heat-killed D471 or UAB152 (a and c, respectively) or with 5 µg of
recombinant MP (b). Spleen cells were harvested and assayed for antigen specific CTL
responses against MP (!), Cyt c ("), or MY (!). The y-axis represents percent lysis and the
effector to target cell ratio is represented on the x-axis. Each point is the geometric mean for that
group while the error bars represent the standard error.
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Figure 3. Kinetics of the myosin-specific CTL response elicited in BALB/c mice primed as
neonates with heat-killed D471. Groups of four mice were immunized i.p. within 48 hours of
birth with 2∗107 heat-killed D471 and spleen cells were harvested at various timepoints including
day 4 (a, f), day 7 (b, g), day 10 (c, h), day 13 (d, i), and day 18 (e, j) following immunization.
Assays were conducted with E:T ratios starting at 100:1 to measure the MP (!) (a – e) and MY
(!) (f – j) specific CTL responses, as well as, to determine if the responses could be inhibited by
the addition to the assay of anti-CD8 (!) monoclonal antibody.
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Figure 4. The role of age in the induction of a myosin specific CTL response. Groups of 5 mice
were immunized with 2∗107 heat-killed D471 at either day 10, day 22 or day 30 post partum.
CTL assays were performed on spleens cells for antigen specific responses against MP (!), or
MY (!). Lytic responses to target cells loaded with tryptic digest of the irrelevant control
antigen cytochrome c are not shown. Error bars represent standard error.
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Figure 5. Requirement of M protein during neonatal exposure of S. pyogenes for the induction
of a myosin-specific CTL response. Groups of 3 - 5 mice were initially immunized i.p. within 7
days of birth with 2∗107 heat-killed D471 and boosted as adults with either an immunogenic dose
of either D471 (a), UAB152 (b), mouse myosin extract (d) or recombinant M protein (c). Within
7 days of the last immunization spleen cells were harvested and assayed for CTL responses
against MP (!), MY (!) or Cyt c ("). Bars represent standard error.
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Figure 6: CTL activity of CD8+ enriched splenocytes before and after culturing with
recombinant streptococcal M protein. Mice were immunized as adults (a - c) with 100 µg of M6
or within three days of birth with 2∗107 heat-killed D471 (d - f). Splenocytes were harvested and
enriched for CD8+ cells as outlined in material and methods. Enriched cells were either assayed
directly (a, d) against MP (!), MY (!) or Cyt c (") or placed into culture with tryptic digests of
M6 (b, e) or Cyt c (c, f) for five days before being assayed against the same antigens. Percent
specific lysis is represented on the y-axis and the effector to target cell ratio on the x-axis. y-axis
error bars represent standard error and the n value indicates the number of experimental groups
represented in each graph.
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Myosin-reactive CTL are induced in neonatal mice by the C-terminal
conserved region of the streptococcal M protein

Cynthia Cunningham and Meenal Elliott
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ABSTRACT
Previously, we have shown that neonatal, but not adult, BALB/c mice primed with heatkilled Streptococcus pyogenes strain D471 (serotype M6) develop a cytotoxic T cell response to
both streptococcal M protein type 6 (MP) and mammalian myosin. To determine if the
elicitation of a myosin-reactive CTL response is exclusive to rheumatogenic serotypes of S.
pyogenes, neonatal BALB/c mice were immunized with non-rheumatogenic streptococcal strains
B737 (M49), H3 (M12) and J17A4 (M-type unknown). Mice immunized with J17A4 mounted a
myosin-reactive CTL response comparable to that elicited by D471, and mice treated with B737
or H3 mounted a weaker myosin-reactive cytolytic response than that elicited by D471 and
J17A4. Screening for cytolytic responses against myosin purified from hearts and two hindlimb
muscles suggested that myosin-reactive CTL induced by D471 and J17A4, but not B737 and H3,
are primarily mediated against neonatal cardiac myosin. This myosin-reactive cytolytic response
was seen in conjunction with a response against the carboxy-terminal conserved region of M
protein. Furthermore, mice primed with recombinant protein consisting of the carboxy terminal
region of MP or D471 treated with pepsin to cleave away the variable amino terminus of M
protein elicited a response to myosin, whereas, mice treated with the variable amino-terminal
region of M protein did not. Taken together, these results suggest that carboxy terminal region of
M protein, which is under consideration as a vaccine candidate, contains an epitope that is
capable of inducing a myosin-specific CTL response in neonatal BALB/c mice.
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INTRODUCTION
Group A streptococcus is a common human pathogen that primarily causes skin and
nasopharyngeal infections (1). One of the potential consequences of an untreated streptococcal
pharyngeal infection is acute rheumatic fever (ARF), an autoimmune manifestation that primarily
targets the joints and heart (4 - 6). While it is widely accepted that ARF is the result of an
immune response evoked by GAS (4 – 6, 13 -15), the exact mechanism by which the infection
triggers disease in a susceptible host remains unclear. Virulence factors expressed by GAS are
known to share epitopes with mammalian proteins and it has been suggested that this molecular
mimicry has the potential to elicit auto-reactive responses that may initiate tissue destruction (7 13). Such virulence factor is the anti-phagocytic factor M protein, an alpha helical coiled-coil
surface protein of which exists more than 80 different serotypes based upon the antigentically
variable amino terminal region (2, 3). Antigenic determinants within the carboxy terminal C
repeat region allow most M protein serotypes to fall into one of two major classes of M protein.
At the molecular level, specific amino acids marking key residues within the C repeat region
distinguish class I M protein from class II (42). Nearly all serotypes of GAS that have been
associated with ARF have been shown to express class I M protein (42).
In vitro and in vivo studies have shown that M protein has the potential to induce
cytotoxic T cell responses that have the capacity to kill myocardial cells (16 - 18). Furthermore,
extensive in vitro studies suggest that ARF patients can harbor lymphocytes that exhibit crossreactive responses to both M protein and cardiac proteins (19 - 21). M protein serotypes that
have been associated with ARF, especially M5, have been shown to act as superantigens to
human T cells displaying particular Vβ gene elements (24 - 26), however, this has been disputed
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(22, 23) and numbers of T cells expressing these Vβ are not elevated in patients with RHD (27).
Furthermore, peptides from the conserved region of M5 have been shown to induce human T
cells to cross-react with cardiac proteins (2, 29, 30). In attempts to design an effective safe
vaccine for GAS, Good et al. and Robinson et al. have used M5 peptides to map the major CD4
T cell epitopes of M protein, especially the conserved carboxy terminal region (29 - 31). While
they have been able to identify immunogenicity of M5 peptides that fail to induce myosinreactive T cell responses in adult mice, these peptides have not been tested in neonatal mice. Our
previous studies and this one indicate that myosin-specific T cell responses are easily induced in
neonatal mice (28).
Since the peak incidence of ARF and AGN in humans is in children of school age and
preschool age, respectively, the focus of our research has been to identify abnormal immune
responses induced by S. pyogenes in neonatal inbred mice and characterize the basis for these
responses at a molecular level. We have previously observed that neonatal, but not adult mice
immunized with heat-killed D471 (M6 serotype), develop cytotoxic T cell responses against
mammalian myosin and that M protein is required for the induction of this response (28). Also,
these neonatally treated mice develop myosin cross-reactive antibodies that recognize the cardiac
specific isoforms of myosin (37). We have undertaken the current study to determine if the CTL
response elicited by S. pyogenes could distinguish endogenous (mouse) isoforms of cardiac
myosin from skeletal isoforms and to determine which region of M protein was responsible for
the induction of this myosin-reactive CTL response. We report that S. pyogenes can elicit a CTL
response in neonatal mice that preferentially recognizes the cardiac isoforms of mouse myosin.
In addition, our results indicate that it is the conserved carboxy-terminal region of M protein is
capable of inducing a CTL response to myosin, however, in both neonatal and adult mice. These
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results are important in light of the fact that the carboxy-terminal of M protein it is currently
being considered as a candidate for a GAS vaccine (29 - 33).

MATERIAL AND METHODS
Mice:
BALB/c mice were purchased from Jackson Laboratories and bred in our animal facilities.

Immunization with heat-killed S. pyogenes:
S. pyogenes strains D471 (serotype M6), UAB152 (chapter2), H3 (M12), J17A4 (non-typable)
and B737 (M49) (ATCC) were grown overnight in Todd-Hewitt broth and heat-killed with
incubation at 65° C for 1 hour. They were then washed five times in 0.85% saline adjusted to a
density of 109 - 1010/ml and stored at -20° C. To prepare D471*, heat-killed culture was adjusted
to pH 2.0 with HCl and treated pepsin for 1 hour at 37° C, neutralized with NaOH, and washed
and resuspended in 0.85% saline (32). Neonatal mice were immunized by intraperitoneal route
(i.p.) with either 5∗106 heat-killed S. pyogenes strains D471, D471*, UAB152, H3, J17A4 or
B737 diluted in 50 ml Dulbecco’s saline. Controls received saline only. The mice were
subsequently boosted i.p. at 3 weeks of age with 108 organisms of the corresponding heat-killed
vaccine in 0.1 ml of Dulbecco’s saline.

Cloning of M protein and its fragments:
Cloning, expression, and purification of MP6 have been described (28). The amino and
carboxy terminal M protein fragments AB and C were generated by subcloning the Nco1 Bsp1286I (AB region) and Bsp1286I - Xho1 (C region) into pET20b(+) and transformed in
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BL21(DE3):pLysS. Cells were grown to OD600 of 0.5 and induced with IPTG for one hour,
harvested by centrifugation and lysed by resuspension in 8 M urea. The his-tagged recombinant
proteins were purified using Ni-NTA super flow resin (Qiagen). The purified proteins were
dialyzed extensively against Dulbecco’s PBS and stored at -20° C.

Preparation of mouse myosin:
Myosin was prepared from mouse skeletal (gastrocnemius and soleus) and hearts (1 day old
mice) or heart ventricle tissue (adult mice) essentially as described by Margossian et al. (33).
Briefly, crude muscle extracts were prepared by mincing tissue in four volumes/wt extraction
buffer (0.3 KCl, 0.15 M KH2PO4 (pH 6.5), 0.02 M EDTA, and 5 mM MgCl2) and incubated on
ice for 15 min. Samples were precipitated with 10 volumes of cold deionized water and placed at
4˚ C for at least 3 hours or overnight. Precipitate was collected with centrifugation at 9000 rpm
for 25 min at 4˚ C, resuspended in a minimal volume of 1.0 M KCl, 25 mM EDTA, 0.06 M,
KH2PO4 (pH 6.5) buffer, and dialyzed against 30 volumes of 0.6 M KCl, 25 mM KH2PO4 (pH
6.5), 10 mM EDTA, 1 mM DTT buffer. The precipitation and dialysis were repeated once more.
Samples were filter sterilized and protein concentrations were determined by Dc protein
colormetric assay (Bio-Rad). The samples were then aliquoted and stored in aliquots at -20°C.

Electrophoresis of myosin:
Mouse myosin preparations were electrophoresed onto either standard 8% SDS-PAGE gels as
previously described (34) or 8% acrylamide gels with 30% glycerol using a Mini-PROTEAN II
electrophoresis system (Bio-Rad). Preparation and execution of 8% acrylamide gels with 30%
glycerol were carried out as previously described (36), however, with the addition of 2-
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mercaptoethanol in the running buffer of the upper reservoir at a final concentration of 10 mM
(50). Following electrophoresis gels were stained with either Coomassie G-250 (Bio-Rad) or
silver stain (Bio-Rad Silver Stain Plus Kit).
CTL assay:
CTL assays were carried out as described before (28). Briefly, P815 cells were pulsed with
tryptic digests of M protein, AB, CD, the mouse myosins or the control protein cytochrome c at 1
mg/ 2∗105 cells. Single cell suspensions of effector spleen cells were plated with MHC matched
P815 cells at an E/T ratios of 200, 100, 50 25, unless otherwise noted, in phenol red-free RPMI
with 2.5% fetal calf serum and incubated at 37o C for approximately 5 hours. Controls included
spontaneous release of effector and target cells, maximum release of targets and media
background. Supernatants were harvested and assayed using a non-radioactive colorimetric
cytotoxicity assay kit (Cytotox96, Promega). Absorbance was read at 490 nm. Percent lysis was
calculated as follows:
Experimental release- Effector spontaneous release - Target spontaneous release
Target maximum release - Target spontaneous release

RESULTS
Enrichment of myosin heavy chain isoforms from mouse muscle
The relative distribution of distinct isoforms in various muscles in inbred mice has been
described (39 - 41). We isolated myosin from BALB/c mice from two hindlimb muscles of adult
mice and from hearts of newborn and adult mice (figure 1). Myosin was enriched from crude
extracts (fig. 1a), and although the myosin preparations are not completely free of contaminants
(fig. 1b) we were able to achieve preparations with greater than 90% homogeneity. To visually
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determine the myosin isoform composition of each enriched myosin sample they were
electrophoresed under stringent conditions that take advantage of the subtle molecular
differences between the isoforms and allow adequate separation. In figure 1b, the enriched
myosin samples were electrophoresed onto an 8% acrylamide gel containing 30% glycerol for 24
hours as described in material and methods. As seen in figure 1b (lane 1) the neonatal heart
contains both alpha and beta myosin isoforms, while the adult ventricular tissue (lane 2) is
composed of solely of alpha myosin. The gastrocnemius (lane 3) is composed predominantly of
the type IIb and type IIx/IId isoforms with a small amount of IIa and almost type I isoform. On
the other hand, the soleus (lane 4) contains approximately an equal amount type I than type IIa
with a negligible amount of the type IIb and IIx/IId isoforms. Therefore, we could determine
whether the myosin CTL epitopes are shared by most mouse myosin isoforms or are restricted to
isoforms expressed in specific muscle tissues. Therefore, the adult heart ventricle will serve as an
indicator for responses specific for alpha cardiac myosin and can be compared to responses
observed against the neonatal heart and soleus to determine reactivity against the beta cardiac
isoform. Responses that recognize the gastrocnemius and not the soleus can most likely be
attributed to the IIb isoform, while responses against both the gastrocnemius and soleus would
suggest that the response is recognizing an isoform shared between them.
CTL primed by streptococcal M protein recognize the cardiac isoforms of mouse myosin

Mice were immunized within one week of birth with D471 or UAB152 (MP - variant of
D471) and sacrificed seven days following the booster (material and methods). Splenocytes were
harvested and assayed for the presence of CTL as outlined in material and methods. Previous
results have shown us that D471 can induce a CTL response against rabbit myosin (28),
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therefore, this experiment would test whether mouse myosin would be recognized by the M
protein reactive CTL. As shown in figure 2, immunization with D471 is capable of inducing a
CTL response against mouse myosin thus confirming that the endogenous mouse myosin can be
recognized by myosin-reactive CTL primed by S. pyogenes. The CTL response induced by
D471 against myosin from the neonatal heart and soleus is comparable to that measured against
rabbit myosin, and greater in magnitude than that against the gastrocnemius and adult heart
ventricular myosin. These results show that the myosin-reactive CTL response is capable of
recognizing all mouse myosin isoforms to varying degrees, but because the response against the
neonatal heart and soleus is greater, this would suggest that the myosin-reactive CTL response
preferentially recognizes the beta (type I) myosin isoform. Immunizing mice with UAB152 does
not induce a CTL response against myosin, whether of rabbit or mouse origin, thus indicating
that the CTL responses against the mouse myosin induced by D471 are specific and mediated by
M protein.

Myosin-specific CTL may be primed by non-rheumatogenic S. pyogenes serotypes
Strain D471 represents the M6 serotype, which is commonly associated with ARF. The
association of this strain with CTL response against cardiac myosin suggests a possible
contribution to the pathology associated with ARF and rheumatic heart disease (RHD). We
therefore chose to test whether other serotypes of S. pyogenes, particularly those not associated
with ARF, were capable of inducing a myosin reactive CTL response against mouse cardiac
myosin. We selected strains H3 (serotype M12) and B737 (M49), isolated from the nasopharynx
and skin of patients presenting with AGN, respectively. Other strains expressing the M12 or
M49 protein have not been associated with ARF. As previously discussed, S. pyogenes serotypes
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M6 and M12 belong to class I while M49 belongs to class II (42). In addition, we chose strain
J17A4, a non-M typable strain from.
Newborn mice were immunized as described above and in material and methods and CTL
assays were performed seven days following boosters at 3 - 4 weeks of age. As shown in figure
3, in mice immunized with J17A4 mounted a CTL response to MP6 that is comparable to that
mounted by D471 (fig. 2), while H3 and B737 mounted a weaker response. This is not
surprising since the M proteins are antigentically distinct with small regions of shared homology.
Both J17A4 and H3 could induce a CTL response against rabbit, however, B737 did not. Mice
immunized with J17A4 mounted a CTL response to cardiac myosin isolated from neonatal mice
comparable in magnitude to that seen in mice immunized with D471. However, the CTL
response against myosin from soleus was poor. In comparison, mice immunized with H3 or
B737, we failed to detect strong CTL responses against any of the mouse myosins. Thus, at least
one non-rheumatogenic strain of S. pyogenes was capable of inducing a CTL response against
neonatal cardiac myosin.
The conserved region of M protein is responsible for myosin-reactive CTL response in mice
To investigate further the role of M protein in the induction of myosin-reactive CTL, we
generated subclones of the plasmid containing the cloned emm6 gene to express the amino
terminal half of the MP6 containing the A and B repeats separate from the carboxy terminal half
containing the C repeat region and the region associated with the cell wall polysaccharide. The
resulting recombinant proteins designated AB6 and C6 were purified and used to immunize
neonatal mice. In addition, we prepared D471* by treatment with pepsin as described in material
and methods. Since pepsin cleaves M6 protein between the B and C repeat regions this removed
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the A and B repeat regions of the M6 protein from the whole cell preparation. Thus the D471*
represented a whole cell preparation containing the carboxy terminal conserved region of MP.
Newborn BALB/c mice were immunized within a week of birth with D471, D471*, purified AB6
or C6. Within five to seven days following the second immunization splenocytes were removed
and assayed for the presence of CTL against M protein and mouse myosin. None of the
immunizing antigens induced responses to the irrelevant control antigen cytochrome c (fig 4a),
while all groups mounted responses of similar magnitude against recombinant M protein (fig 4b).
As shown in figures 4c and 4d, in mice immunized with D471, equivalent CTL response against
both AB6 and C6 were detected. Thus, CTL epitopes are present in both the variable amino
terminal half and constant carboxy terminal half of MP. Immunization with D471* induced a
CTL response against C6 region that is comparable to the response induced by C6 itself (fig. 4d)
and weak responses against AB6 (fig. 4c). These results indicate that the pepsin treatment of the
vaccine (D471) prior to immunization was sufficient in removing most, if not all, of the AB6
region. Immunization with AB6 induced a CTL response against itself (fig. 4c) and a weak
response against C6 (fig. 4d), whereas, immunization with C6 induced a CTL response to itself
and weak response to AB6.
We next assayed the splenocytes for responses against mouse myosin (fig 4 e - h). Mice
immunized with D471 elicited a response to neonatal heart (fig. 4e) and soleus (fig. 4h) and a
weaker response to adult heart ventricle (fig. 4f) and gastrocnemius (fig. 4g). One the other
hand, mice immunized with D471* exhibited CTL responses of greater magnitude against
gastrocnemius (fig. 4g) and soleus (fig. 4h) and a weaker response to the cardiac samples (fig 4e f). Immunization with C6 induces a response to all mouse myosin samples with the greatest
response against the adult heart ventricle (fig 4f). Immunization with AB6 does not induce a
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CTL response to the mouse myosin. Although we were able to measure responses against
myosin in mice immunized with C6 or D471* they did not discriminate between the mouse
myosin isolated from different muscle as much as the CTL responses induced by D471.
Likewise, the myosin CTL response generated in the mice immunized with C6 or D471* was of
lesser magnitude as those measured in D471 primed mice.

Capacity of M protein C region to induce a myosin-reactive CTL response in adult mice

Previous experiments conducted in our laboratory have shown that immunization of adult
mice with D471 or whole recombinant M protein leads to a CTL response against M protein with
no measurable response against rabbit myosin (28). Since the carboxy terminal half of M protein
can elicit a myosin reactive CTL response in neonatal mice, we then wanted to determine if this
response was also dependent on age as that seen with D471 immunization. Adult mice were
immunized intraperitoneally with 50 µg of recombinant AB6 or C6 and within seven days of the
last immunization the splenocytes were harvested and assayed for CTL responses against mouse
myosin. Both groups of mice developed a CTL response against M protein as measured by target
cells loaded with recombinant MP6 with no background response to the irrelevant control antigen
(fig 5a). Mice immunized with AB6 did not develop CTL responses against the mouse myosin
(fig. 5b). Immunization with the recombinant C fragment induced a CTL response against the
mouse myosin, however, with no significant discrimination between the cardiac and skeletal
isoforms (fig 5b). This CTL response against mouse myosin is comparable to that induced in the
neonatal mice demonstrated in figure 4 (panels e - h), again underscoring the involvement of the
C region. A possible explanation for these results could be that extracellular degradation of
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whole recombinant M protein and the C region does not yield the same epitopes. The results
obtained from mice immunized as neonate or adults with the C region suggest that an epitope
exists within the C region of M protein that is capable of inducing a myosin-specific CTL
response.

DISCUSSION
For several years researchers have attempted to determine the mechanisms of poststreptococcal autoimmune events by both analyzing human tissue and developing animals model
systems. While the argument for a role of cross-reactive antibodies received attention first and is
still being debated (7, 8, 13, 37, 43, 44, 48), it is becoming increasingly clear that the pathology
of ARF is mediated by T cells (4, 16 – 21, 52, 53). In both active and chronic cases of ARF,
these infiltrates are found to be mostly macrophages and T lymphocytes of which the CD4+
population out numbers the CD8+ population 4:1 (14, 15). Analysis into the distribution of
peripheral blood lymphocytes (PBL) of ARF patients compared to controls indicate that T cells
from ARF patients are activated and that there is a sustained increase in the number of CD4+ T
cells and B cells (45). Extensive studies conducted with the mouse model of experimental
autoimmune myocarditis indicate that CD4+ T cells are necessary to initiate the response but the
pathological outcome is mediated by CD8+ T cells (46 - 48).
Various groups have tried to ascertain what the antigenic specificity of these lymphocytes
and if antigen cross-reactivity is involved. In vitro and in vivo studies have shown that
streptococcal proteins, especially the M protein, can induce the differentiation of cytotoxic T
lymphocytes with the capacity to kill myocardial cells and cell lines (16, 17). Demellawy et al.
has demonstrated that PBL from ARF patients recognize a 50 kDa and 54 kDa protein of
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myocardial extracts and that the proliferative response may be intensified by pre-culturing cells
with GAS extracts (21). Cloning of lymphocytic infiltrates, however, have yielded conflicting
results. Guilherme et al. have been able to isolate clones that cross-react with M protein and
myosin, however, Yoshinaga et al. could not, even though they demonstrated that the T cell lines
from ARF patients preferentially react with lysates of streptococcal strains associated with ARF
but not strains associated nephritis or non-pathogenic streptococci (19, 20). Cloning of PBL
from active and chronic cases of ARF has given no clearer answer either. The T cell lines
produced by Pruksakorn et al. that cross-reacted between M protein and myosin were isolated
from healthy individuals (49). While this study may not confirm the presence of cross-reactive
lymphocytes, it does indicate that precursor myosin reactive T cells can exist in the periphery.
Still the question of how these T cells are recruited remains. One possible explanation
that has been put forth by Kotb et al. suggests that T cell responses initiated against microbial
antigens and superantigens can generate high levels of inflammatory cytokines that ultimately
lead to localized tissue destruction and subsequent release of self-antigen that allows for the
expansion of autoreactive T cells (50). Certain serotypes of M protein that have been associated
with ARF have been shown to have superantigenic affects on particular subsets of human
lymphocytes (24 - 26), however, this has not be correlated to Vβ gene usage in ARF patients
(27). In support of Kotb’s hypothesis, local cardiac tissue damage initiated by GAS has been
demonstrated previously in mice by Cromartie et al. (51). However, while the cardiac lesions
they observed were a direct result of an inflammatory response due to antigen localization it
departs from the human condition in several aspects. First, the lesions were detectable within
two days, second, streptococcal antigens are not detectable in biopsied valvular tissue from ARF
patients (14, 15), and lastly, the cellular infiltrates they observed in the mouse cardiac tissue were
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predominantly macrophages but not lymphocytes which have been well documented in the
human disease.
Most animal model systems designed to address the questions regarding this disease have
been unable to yield any information explain the underlying mechanisms. Immunizing mice
with streptococcal heat-killed vaccines or streptococcal cell wall or membrane preparations will
induce anti-streptococcal antibodies that cross-react with mammalian proteins, including myosin
(7, 8, 37, 43), but no pathology has been linked with such an antibody response. Furthermore, it
has been demonstrated in laboratory animals that whole cell GAS preparations can induce cell
mediated cytotoxicity to cultured heart cells (18, 52). Evidence may suggest that this autoreactive immune response is attributed to M protein (9 – 11, 17, 24 – 26, 49, 53), however,
immunizing adult mice with M protein and M protein peptides usually yields a protective T cell
response with no evidence of cross-reaction with myosin (28 - 30). Nonetheless, we have
previously demonstrated the capacity of heat-killed D471, serotype M6, to induce lytic T cell
responses to both M protein and myosin in neonatal but not adult mice, suggesting that the
myosin-reactive CTL response is age dependent (28). However, this ability to induce a response
to myosin is not exclusive to the M6 serotype. The results of the current study have
demonstrated the ability of streptococcal strains representing serotypes M49 and M4 to elicit a
myosin-reactive CTL response in neonatally immunized mice. Furthermore, our results suggest
that M protein plays an important role in the induction of a myosin reactive response, in that,
mice immunized with UAB152 (M- variant of D471) do not mount a lytic response to myosin.
In light of these results we decided to have a closer look at the role M protein plays in the
induction of a myosin-specific lytic response. This is an important issue since studies are
currently being conducted with mice to develop a GAS vaccine using peptides from the C region

125

of M protein (29 - 31), with the intention of developing a vaccine that will induce a protective
immune response to most serotypes of S. pyogenes without the deleterious side effect of inducing
an autoimmune response. Our results indicate that the conserved C region of M protein contains
an epitope that can induce a myosin-reactive response in both adult and neonatal mice. The
location of this punitive epitope has yet to be determined but it draws into question the safety of
using the C region of M protein as a potential vaccine candidate. Furthermore, the results of our
study are in agreement with work conducted by Pruksakorn et al. (49), who showed that human
peripheral blood lymphocytic lines stimulated with peptides from the C region of M protein
cross-reacted to heart proteins.
While we did not see any overt pathology with these mice, these results indicate that
streptococcal M protein, especially the conserved C region, can play a central role in the
induction of an auto-reactive T cell response and requires further study.
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Figure 1. Electrophoretic separation of mouse myosin. Myosin was extracted from mouse
skeletal and cardiac tissue and electrophoresed onto either 8% SDS-PAGE (a) or 8% acrylamide
SDS-PAGE with 30% glycerol (b) as described in material and methods. For comparison of the
protein content, crude muscle extract is shown in 1a (EXT), otherwise, for each gel: Lane 1; one
day heart, lane 2; adult heart ventricle, lane 3; adult gastrocnemius and lane 4; adult soleus.
Electrophoresis of samples onto 8% acrylamide SDS-PAGE with 30% glycerol in figure b was
conducted to determine relative representative amounts of each myosin heavy chain isoform (see
text for isoform definitions).
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Figure 2. Cytolytic activity against myosin primed in neonatal mice requires M protein. Groups
of 5 - 6 BALB/c mice were primed within 5 days of birth and boosted at 4 weeks of age as
described in material and methods with D471 (!) or UAB152 ("). Splenocytes were harvested
and assayed within seven days of last immunization. Data are shown as percent antigen-specific
lysis (y-axis) of P815 cells labeled with tryptic digests of recombinant M6 protein (MP6), rabbit
myosin (RMY), bovine cytochrome c (CTRL), and purified mouse myosin from neonatal heart
(NH), adult heart ventricle (AH), adult gastrocnemius (GAST), and adult soleus (SOL) muscles.
Each symbol represents the calculated antigen specific lysis generated by spleen cells from an
individual mouse at E:T ratios of 100:1. Horizontal bars represent geometric mean. Asterisks
indicate statistical significance based upon a p-value < 0.0001 as calculated by two-way
ANOVA.
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Figure 3. Priming of myosin-specific CTL responses in mice with non-rheumatogenic strains of
S. pyogenes. BALB/c mice in groups of 4 - 6 immunized within 5 days of birth and boosted at 3
- 4 weeks of age with J17A4 (!), B737 (") or H3 (!). Data represent percent antigen-specific
lysis (y-axis) versus E:T ratio (x-axis) of P815 cells labeled of antigen at an effector to target
ratio of 100:1. See legend of figure two for definition of antigen abbreviations. Each symbol
represents the calculated antigen specific lysis generated by spleen cells from an individual
mouse. Horizontal lines of each set represent the geometric means. Asterisks indicate statistical
significance based upon a p-value < 0.0001 as calculated by two-way ANOVA.
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Figure 4. Priming of myosin-specific CTL response in neonatal mice with the conserved region
of M protein. Mice were immunized as neonates with D471 (!), D471* ("), AB6 (!) or C6
(!) and boosted at 4 -5 weeks of age with the corresponding immunogen as described in
material and methods. Data represent percent antigen-specific lysis (y-axis) versus E:T ratio (xaxis) of P815 cells labeled with bovine cytochrome c (panel a), MP6 (panel b), M protein
fragments AB6 (panel c) or C6 (panel d), mouse neonatal heart myosin (panel e), adult heart
ventricle myosin (panel f), adult gastrocnemius myosin (panel g), and adult soleus myosin(panel
h). y-axis error bars represent standard error.
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Figure 5 Priming of a myosin-specific CTL response in adult mice with the conserved region of
M protein. CTL responses in adult mice immunized and boosted with M protein fragments AB6
(!) or C6 (") as described in material and methods. Data represent percent antigen-specific
lysis (y-axis) of P815 cells labeled with antigens listed and defined in legend of figure two at an
E:T ratio of 100:1. Panel a includes responses against streptococcal antigens while panel b
depicts CTL responses against mouse myosin. Each symbol represents the calculated antigen
specific lysis generated by spleen cells from an individual mouse. Horizontal lines represent
geometric mean.
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Addendum

Induction of the myosin-reactive CTL responses in mice with heat-killed
Streptococcus pyogenes: The role of age, haplotype, route of
immunization and presence of B lymphocytes
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INTRODUCTION
In previous studies outlined in chapter one we have observed that BALB/c mice
immunized as neonates with heat-killed Streptococcus pyogenes are capable of eliciting a myosin
cross-reactive antibody response that is reminiscent of that in acute rheumatic fever patients
(ARF). We have also observed a myosin-reactive CTL response following neonatal systemic
challenge of heat-killed S. pyogenes (chapter 2). In addition, we observed that the potential M
protein epitope responsible for eliciting a myosin-reactive CTL response is found within the
carboxy conserved region (chapter 3), a region under intense investigation as a potential vaccine
candidate (1-3). Additionally, we wanted to examine various aspects of the host that may affect
the development of the myosin-reactive CTL response including the MHC haplotype, the route of
infection and the necessity of the B lymphocyte compartment.
All studies thus far have been conducted with BALB/c mice, hence experiments were
performed with mice representing other MHC haplotypes to test their ability to develop a
myosin-reactive CTL responses following exposure to S. pyogenes. Next, we addressed the
potential role route of immunization has since all previous studies were conducted with systemic
immunizations and most post-streptococcal autoimmune complications follow nasopharyngeal
infection. Therefore, these studies would include experiments involving priming through the
intranasal route, an immunization route most comparable to human nasopharnygeal infection.
In our neonatal systemically immunized mice we have a concurrent myosin cross-reactive
antibody and CTL response. While it is believed that CD8+ lymphocytes can mediate tissue
specific cytolytic damage in ARF and other autoimmune processes (4-10), with the exception of
SLE no role has been found for the cross-reactive antibody response (7, 11, 12). B lymphocytes
can function as antigen presenting cells (APC) and present exogenous antigen, such as
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bacterium, by the classical MHC class II pathway, and non-classically via MHC class I pathway
(13-15). In addition, Lin et al. (16) has shown that autoreactive B cells can function as APC and
initiate autoreactive T cell responses. We conducted a series of experiments to determine what
effect the presence of the B lymphocyte compartment has on the capacity to elicit the myosinreactive CTL response. A portion of the following experiments were performed with BALB/c
mice, however, since the immunoglobulin heavy chain knock-out mutation (Igh-/-) is on the
C57Bl/6 background we also performed repetitive experiments with C57Bl/6 mice to acquire
control data for Igh -/- experiments.
MATERIAL and METHODS
Mice. BALB/c, C57Bl/6, DBA/2J, and CBA/J mice were purchased from Jackson Laboratory,
Bar Harbor, ME and bred at WVU animal facility. Mice were immunized with 107 heat-killed S.
pyogenes per gram of body weight or 200 µg or 5 µg of recombinant M protein and it
subfragments for adult and neonatal mice, respectively. The volumes were maintained at 50-100
µl (neonatal) or 200 µl (adult) per mouse by the intraperitoneal route or in 5 µl (neonatal) or 20
µl (adult) per mouse divided equally between two nostrils.
Preparation of antigens. Streptococcus pyogenes strains D471 (serotype M6) and UAB152 (a
derivative of D471 containing insertional inactivation of the emm6 gene) were grown from
single colonies in 2 liters of Todd-Hewitt broth without aeration in the presence of 7.5% CO2
until growth ceased. The cultures were pasteurized by incubation in a 56°C waterbath for 1.5
hours at which point cells were centrifuged, washed 5 times with 500ml of 0.85% saline and
resuspended in 0.85% saline. The cells were frozen at -20oC in 5 ml aliquots after adjusting the
cell density to OD600 of 2.0/ml (2∗108 bacteria / ml). Both strains were a gift from Dr.
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Hollingshead (UAB). D471* was prepared as previously described (chapter 3). Plasmid TR06
containing the M6 gene was gift of Dr. Hollingshead. This plasmid contains residues 1 to 413 of
the mature M6 protein cloned into the NcoI and XhoI sites of pET20b+ (Novagen). The
recombinant M6 protein with a carboxy-terminal His-6 tag was expressed in BL21:(DE3), pLysS
by induction with Iptg for 1 hr and was purified from periplasmic extracts by adsorption to NiNTA-sepharose (Qiagen). Cloning, expression, and purification of AB6 and C6 have been
described (chapter 3).
Non-radioactive assay for antigen specific CTL activity. Assay antigens M protein, rabbit
myosin and bovine cytochrome c were adjusted to a final concentration of 1 mg/ml in sterile
Dulbecco’s phosphate buffered saline, to which, trypsin (Sigma chemical Co., St. Louis, MO)
was added at 10 mg/mg protein. Proteolysis was carried out overnight at 37o C and digested
samples were stored at -20 o C. CTL assays were conducted as previously described (chapter 2).
Briefly, single cell suspensions were processed from spleens in serum-free RPMI1640, washed
once and resuspended in phenol red-free RPMI with 5% fetal calf serum. Target cells of the
corresponding haplotype (P815 (H-2d), EL4 (H-2b), CBA.D1 (H-2k)) were incubated with tryptic
peptides of antigen for a minimum of 20 minutes in serum-free, phenol red-free RPMI1640 at a
concentration of 2∗105/ml. Effector cells (splenocytes) were plated with the peptide labeled
target cells at various ratios in phenol-red free RPMI in 96-well microtiter plates for each antigen
tested. The assay plates were incubated at 37º C for approximately 5 hours in the presence of 7.5
% CO2. Cytotoxicity was measured using Promega Cytox96 assay substrate as outlined in
manufacturers instructions. Absorbance values and percent lysis were determine as before
(chapter 2).
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RESULTS and DISCUSSION
Myosin-reactive CTL response in C57Bl/6 mice following immunization with heat-killed S.
pyogenes as a factor of age and M protein. In BALB/c both the age of the animal at the time
of immunization and the presence of M protein were key factors in the induction of the CTL
response against myosin. In order to carry out the next set of experiments designed to study the
effects of immunization route and the role of B lymphocytes in the induction of a myosin reactive
CTL response, we needed to ascertain whether C57Bl/6 mice are capable of responding to
systemic challenge of heat-killed D471 in a similar manner as BALB/c mice. To this end, groups
of 4 - 6 C57Bl/6 mice were immunized within 3 days post partum or at 6 weeks of age with heatkilled D471 (fig 1a and 1d) as described in material and methods. As shown in figure 1a,
C57Bl/6 mice immunized as either adult or neonates with D471 elicit comparable CTL responses
against M protein. In comparison to the response elicited in BALB/c mice (chapter 2), adult
C57Bl/6 mice primed with D471 elicits a CTL response against M protein of greater magnitude,
whereas the M protein specific CTL response in neonatal mice remained relatively comparable.
In agreement with the BALB/c data previously acquired (chapter 2), C57Bl/6 mice are capable of
generating a myosin specific CTL response if immunized systemically with D471 as neonates but
not adults (fig 1d). No CTL responses were observed against the irrelevant control protein
cytochrome c in either group of adult or neonatal mice immunized with D471 (data not shown).
Next, we wanted to determine whether the myosin-reactive CTL response in C57Bl/6
mice exhibits a similar requirement for M protein as previously observed in BALB/c mice. Mice
were immunized as neonates or adults with UAB152 (fig 1b and 1e). As previously observed in
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BALB/c mice, C57Bl/6 mice immunized with UAB152 were incapable of responding against
either M protein (fig 1b) or myosin (fig 1e) whether immunized as neonates or adults. To begin
further analysis into the involvement of M protein with the myosin-reactive CTL response, mice
were immunized as adults or neonates with D471*, a preparation of D471 treated with pepsin to
remove the antigenically variable amino terminus leaving the more conserved carboxy terminus
remaining. As shown in figure 1, C57Bl/6 mice immunized as neonates with D471* elicit a
response against both M protein (fig 1c) and myosin (fig 1f), whereas adult mice elicit a response
only against M protein (fig 1c and 1f). These results demonstrate that C57Bl/6 mice immunized
as neonates with heat-killed S. pyogenes are capable of eliciting a myosin-reactive CTL response.
Further, this response is dependent upon M protein and the potential epitope for such a crossreactive response appears to lie within the carboxy terminal region. Again, all of the results are
in agreement with results obtained previously with BALB/c mice.
M protein is required but not exclusively responsible for the myosin-reactive CTL
response. As previously established with BALB/c mice and demonstrated in figure 1 with
C57Bl/6 mice, M protein is required to induce the myosin-reactive CTL response. We have also
demonstrated that the potential M protein epitope necessary to induce the myosin-reactive CTL
response lies within the carboxy terminal region (fig 1f). To investigate further the role of M
protein in the induction of myosin-reactive CTL responses used recombinant M protein
subfragments AB6 and C6 for immunization.
Experiments conducted with BALB/c mice suggested that the C region but not the A and
B of M protein is sufficient for the elicitation of the myosin-reactive response in both neonatal
and adult mice (chapter 3). However, as shown in figure 2, immunization of adult C57Bl/6 mice
with either AB6 (fig 2a) or C6 (fig 2b) results in lytic responses against M protein, as well as
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respective immunizing subfragments (data not shown) without the induction of a lytic response
against myosin. Further, immunizing neonatal mice with the recombinant fragments of M
protein (fig 2c) or C6 (fig 2d) does not elicit a CTL response against myosin above background
levels despite the measurable levels of M protein specific lytic response. A potential reason for
the disparity of the results between these two strains of mice is their differing haplotype
backgrounds. Thus it is conceivable that the epitopes processed and presented from the
recombinant M protein and C6 within the BALB/c mice that allow cross-priming are not being
presented in C57Bl/6.
The myosin-reactive CTL response cannot be elicited by the intranasal route. All
experiments conducted thus far in both BALB/c and C57Bl/6 mice have followed systemic
challenge, however, with the exception of AGN, most post-streptococcal autoimmune diseases
are known to follow nasopharyngeal infection. In an effort to determine what role the route of
infection may play in the development of a CTL response against myosin, groups of mice were
immunized as either as adults (fig 3a and 3b) or neonates (fig 3c and 3d) with D471 by the
intraperitoneal route (i.p.) (fig 3a and 3c) or the intranasal route (i.n.) (fig 3b and 3d) as outlined
in material and methods. Both spleens and cervical lymph nodes were harvested for assay 7 or
10 days following the last i.p. or i.n. immunization, respectively. As previously observed,
immunization of adult mice with D471 by the i.p. route invokes a M protein response but no
response to either the irrelevant control protein or myosin (fig 3a). However, immunization of
adult mice by the intranasal route is unable to elicit the response against M protein (fig 3b). As
expected, immunization of neonatal mice with D471 by the i.p. route elicits a CTL response
against both M protein and myosin (fig 3c). In contrast, neonatal mice primed with D471 by the
intranasal route do not mount a CTL response against either M protein or myosin (fig 3d).
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Similar results were obtained with BALB/c mice immunized intranasally with D471 as either
adults or neonates (data not shown).
The lack of measurable CTL responses in intranasally challenged mice could be attributed
to several factors. First, the immunization may not allow for either a local or systemic response
to be primed, perhaps as a result of inadequate antigen processing and presentation. Preliminary
observations suggest that no response to either M protein or myosin were detectable with CLN
lymphocytes either (data not shown). Second, immunization by the intranasal route may instead
initiate tolerance, either as a result of the nature of the antigen or the antigenic dose.
Intranasal immunization with S. pyogenes during the neonatal period primes for a systemic
myosin-reactive response. We next wanted to test the hypothesis that perhaps as a means for
priming an autoimmune event, an individual is first exposed to the organism by the
nasopharyngeal route and an initial, potentially autoreactive immune response is primed which
may be subsequently boosted by systemic challenge of the organism. Although in our mice
immunization by the intranasal route alone did not prime an immune response, it does not negate
the possibility that an initial intranasal priming event may alter the systemic response following
subsequent systemic challenge. To conduct the experiment, mice were immunized within the
first three days of life by the intranasal route with heat-killed D471, UAB152, or D471* as
described in material and methods. After reaching 4 - 6 weeks of age the mice were challenged
intraperitoneally with the respective streptococcal vaccine or recombinant M protein. Seven days
following the last immunization splenocytes were harvested and assayed for lytic activity against
M protein, myosin and an irrelevant control antigen.
As shown in figure 4, mice immunized with D471 (fig 4a) or D471* (fig 4b) intranasally
as neonates and boosted as adults with D471 i.p. mount a measurable CTL response against M

144

protein but the response against myosin is barely above background. Mice intranasally
challenged with D471 or D471* and boosted i.p. with M protein (fig 4c and 4d, respectively)
mount an antigen specific CTL response against M protein, however, in addition to the antigen
specific response, these mice mounted a CTL response against myosin. This indicates that i.n.
challenge with heat-killed streptococcal vaccine does not induce systemic tolerance against M
protein. Further, since systemic challenge with M protein in adult animals primes only for an
antigen specific CTL response (chapter 2 and data not shown) the elicitation of a myosin-reactive
CTL response following the M protein systemic challenge in this set of experiments must be a
consequence of the neonatal intranasal challenge with S. pyogenes. Unlike D471 and D471*,
intranasal immunization with UAB152 does not allow for a myosin-reactive CTL response
following systemic challenge with M protein (data not shown). These results suggest that not
only is M protein required during the initial intranasal exposure but also that epitopes within the
C-region of M protein are most likely responsible. Additionally, the need for subsequent
systemic challenge with M protein to initiate the myosin-reactive response is further established
by the fact that mice primed intranasally with D471 as neonates and boosted i.n. with M protein
elicit a weak response to M protein and no response to myosin (fig 4e).
Role of B lymphocytes in the elicitation of the myosin-reactive CTL response. B cells are
known to function as antigen presenting cells and it has been demonstrated that autoreactive B
cells can function as an APC and initiate autoreactive T cell responses (16). Also, B cells have
been shown to be capable of processing and presenting exogenous antigen via class I MHC (13,
15). Such autoantigen presentation by B cells is believe to occur by receptor mediated uptake of
the antigen via the surface immunoglobulin (13, 15, 16). In the laboratory, we have observed
that mice immunized as neonates with D471 i.p. exhibit life-long myosin cross-reactive antibody
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responses, therefore, the next set of experiments were designed as a preliminary study to
determine if these autoreactive B cell serve a role in the elicitation of the myosin-reactive CTL
response. To perform these experiments we obtained C57Bl/6 immunoglobulin heavy chain
knockout mice (Igh-/-) that are unable to produce antibody or express a functional
immunoglobulin receptor on their surface. Experiments were carried out by immunizing groups
of Igh-/- mice as adults (fig 5a and 5c) or neonates (fig 5b and 5d) with D471 by either the i.p.
route (fig 5a and 5b) or the i.n. route (fig 5c and 5d). Igh-/- mice immunized as adults with D471
by either by the i.p. route (fig 5a) or i.n. route (fig 5c) mounted a response against M protein that
is comparable in magnitude to that measured in wild-type C57Bl/6 mice (fig 3a, 3b). Likewise
for the myosin-reactive CTL response in Igh-/- mice immunized as neonates with D471 i.p. (fig
5b) or i.n. (fig 5d) when comparing the magnitude of the response in wild-type C57Bl/6 mice (fig
3c, 3d). Despite the lack of functional B cells, no obvious deficiencies with the lytic responses
were observed. Thus, this preliminary study suggests that the B lymphocyte compartment does
not play any obvious role in the capacity of mice to elicit a myosin-reactive CTL response
following neonatal systemic challenge with S. pyogenes.
Influence of MHC haplotype on the development of myosin-reactive CTL response. Host
genetics has long been suspected a factor in the susceptibility to post-streptococcal autoimmune
complications (17-20). Preliminary studies were then conducted to determine what affect if any,
the MHC haplotype may have on the development of a myosin-reactive CTL response following
neonatal immunization with D471 and UAB152. To conduct the experiment, mouse strains
C57Bl/6 and CBA/J were chosen to represent the H-2b and H-2k haplotypes, respectively.
Experiments with BALB/c mice indicate the ability of mice with the H-2d haplotype to respond
against myosin, however, mouse strain DBA/2 (H-2d) was also selected to serve as a control for

146

the data generated from the BALB/c mice. Mouse strains, AKR/J, 129/J, representing haplotypes
H-2b and H-2k respectively, were also chosen for this study as a means to serve as duplicate
controls for data generated in C57Bl/6 and CBA/J mice. However, we were unable to acquire
adequate numbers of neonates with these strains to perform our experiments.
First, we immunized groups of at least six C57Bl/6, DBA/2J and CBA/J mice, as adults
i.p. at least twice with heat-killed D471 or UAB152. As we have previously documented with
BALB/c mice, none of these strains demonstrated CTL responses to myosin (data not shown)
following adult administration with either heat-killed vaccine and therefore served as a controls
for the experiment. Next, groups of neonatal mice representing each strain were immunized i.p.
with either D471 or UAB152 and boosted as adults with the same vaccine. Within sevens days
following the adult boosting splenocytes were harvested and assayed for cytolytic activity against
P815 cells labeled with tryptic digests of recombinant M protein, rabbit skeletal myosin or the
irrelevant control protein cytochrome c. Results of the cytolytic assays are summarized in table
1. The resultant data, albeit preliminary, suggests that the haplotype may play a role. CBA/J
mice (H-2k) are unable to elicit a myosin-reactive CTL response following neonatal
immunization with D471, while C57Bl/6 (H-2b) respond to both vaccines in the same manner as
BALB/c mice. As anticipated, DBA/2J mice elicit a myosin-reactive CTL response following
neonatal priming with D471. However, unlike BALB/c, this strain also developed a detectable
myosin-reactive CTL response following neonatal immunization with UAB152, suggesting that
streptococcal antigens other than M protein may initiate a myosin-reactive CTL response. Again,
these results are preliminary and require further examination.
Conclusion. The data presented within the addendum were compiled as a means to better
understand the induction of a myosin-reactive CTL response in neonatal mice following
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immunization with heat-killed S. pyogenes vaccine. They represent the efforts undertaken to
determine what aspects of the host and organism were key in the induction of an autoreactive
CTL response. Together these data suggest that on the part of the host, genetic background may
play a role in the susceptibility of developing autoreactive CTL responses. We have shown that
mice of the H-2d (BALB/c and DBA/2J) and H-2b (C57Bl/6) background are capable of eliciting
a myosin-reactive CTL response following neonatal but not adult immunization with wild-type S.
pyogenes, while CBA/J mice (H-2k) were unable regardless of age of immunization. However,
because we were unable to obtain enough neonates from AKR/J and 129/J mice, we were unable
to duplicate the results obtained with C57Bl/6 and CBA/J mice.
We have shown that intranasal immunization, a route of immunization most closely
related to natural infection, in itself cannot induce autoreactive CTL responses but can alter the
subsequent systemic response following i.p. challenge with M protein from one that is antigen
specific to a myosin cross-reactive CTL response. These results suggest that local (intranasal)
exposure to S. pyogenes may be able to have a lasting effect upon subsequent systemic responses.
In the last set of experiments we attempted to discern a role for the autoreactive B cells within
our immunized mice. We wanted to determine if the B cells could potentially act as antigen
presenting cells, present host antigen and have a down-stream effect upon the autoreactive T cell
responses. However, upon repeating experiments in Igh-/- mice, we were unable to detect any
differences in the subsequent myosin-reactive CTL responses, which is not unlike what has been
previously reported (21).
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These results provide clues into the requirements for the elicitation of a myosin-reactive
CTL response. It appears that the genetic background of an individual can have an effect on the
development of such a response, as well as, the route of immunization. Interestingly, according
to our results in appears that in order to develop a CTL response to myosin, the necessary
streptococcal antigen, M protein, must access the host systemically.
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Figure 1. C57Bl/6 mice are capable of eliciting a myosin-reactive CTL response following
neonatal i.p. immunization with S. pyogenes. Groups of 4 to 6 mice were immunized by the i.p.
route at least twice as adults (#) or within three days of birth (!) with D471 (a, d), UAB152 (b,
e), or D471* (c, f). Within seven days following the last immunization splenocytes were harvest
and assayed for lytic activity against EL4 cells labeled with M protein (a, b, c) or myosin (d, e, f).
Each animal was assayed individually and each point within the graph represents the combined
geometric mean for each group. y-axis error bars represent the standard error.
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Figure 2. M protein is required but not exclusively responsible for the myosin-reactive CTL
response. C57Bl/6 mice were immunized i.p. at least twice as adults with 200 µg of recombinant
M protein subfragments AB6 (a) or C6 (b) or within three days of birth with 5 µg of recombinant
M protein (c) or M protein fragment C6 (d) and boosted as adults. Within seven days following
the last immunization splenocytes were harvested and assayed for lytic activity against M protein
(!), irrelevant control cytochrome c (") or myosin (!). Each graph represents the combined
geometric mean for each group and the y-axis error bars represent the standard error.
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Figure 3. The myosin-reactive CTL response cannot be elicited by the intranasal route of
immunization. Groups of four C57Bl/6 mice were immunized with D471 as adults (a, b) or
neonates (c, d) by the i.p. route (a, c) or i.n. route (b, d) as described in material and methods.
Splenocytes were harvested for cytolytic activity within seven days following the last i.p.
immunization or ten days of the last i.n. immunization. Lytic activity was monitored against EL4
cells labeled with M protein (!), cytochrome c (") or myosin (!).
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Figure 4. Intranasal immunization with S. pyogenes during the neonatal period primes for a
systemic myosin-reactive CTL response. Groups of four to six C57Bl/6 mice were immunized
by the i.n. route within three days post partum with either 2∗107 D471 (a, c, e) or with D471* (b,
d) and subsequently boosted as adults i.p. with 2∗108 D471 (a, b) or 200 µg M protein (c, d) or
i.n. with M protein (e). Seven to ten days following the last booster, splenocytes were assayed
for lytic activity against EL4 cells labeled with M protein (!), cytochrome c (") or myosin (!).
Each animal was assayed individually and each point within the graph represents the combined
geometric mean for each group. y-axis error bars represent the standard error.
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Figure 5. Role of B lymphocytes in the elicitation of the myosin-reactive CTL response. Groups
of three to four C57Bl/6 Igh-/- mice were immunized as outlined in material and methods with
D471 by either the i.p. (a, b) or i.n. (c, d) route as adults (a, c) or within three days post partum
(b, d). Splenocytes were harvested and assayed for lytic activity against M protein (!), myosin
(!) or cytochrome c (") as described in legend of figure 3.
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Table1. Potential role of genetics in the elicitation of a myosin-specific
CTL response following neonatal immunization with S. pyogenes

Mouse straina

D471 (M+)
b

MP

UAB152 (M-)

MYO

MP

MYO

BALB/c (H-2d)

+c

+

-

-

C57Bl6 (H-2b)

+

+

-

-

DBA/2 (H-2d)

+

+

-

+

CBA/J (H-2k)

+

-

-

-

a

Groups of at least 4 mice were immunized i.p. within three days post partum
with either heat-killed D471 or UAB152 vaccine and boosted once as adults
i.p. with the same vaccine. The representative MHC haplotype is indicated
within the parentheses.
b
Splenocytes were harvested within seven days of the final adult boosting
immunization as assayed lytic activity against MHC matched target cells
labeled with digests of M protein (MP), commercially prepared rabbit
skeletal myosin (MYO) and the irrelevant control protein cytochrome c (not
shown). All lysis against cytochrome c was negligible.
c
Results are represented with plus signs (+) to indicate percent lysis above
20% or minus signs (-) indicating less than 10% lysis. All results represent
the specific lysis at the effector to target cell ratio of 200:1.
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General Discussion
Non-suppurative autoimmune complications such as acute rheumatic fever and
glomerulonephritis are potential outcomes following infection with Streptococcus pyogenes,
especially for children. Research has focused onto two major hypotheses as to the induction of
host cross-reactive immune responses. The first hypothesis suggests that hyper-immune
responsiveness against various streptococcal antigens may trigger or exacerbate an existing
quiescent autoimmune response (Ayoub 1991; Kotb 1998). Proponents have argued a role for
the numerous streptococcal superantigens and drawn attention to the elevated serum antibody
titers witnessed in post-streptococcal autoimmune patients. The second major hypothesis argues
that the autoimmune responses are due to direct antigen cross-reactivity between streptococcal
and host components (Dale and Beachy 1985b; Cunningham et al. 1989; Yoshinaga et al. 1995).
Advocates of the latter theory have focused primarily on the major immunodominant antigen, M
protein, and the group specific carbohydrate, N-acetylglucosamine.
The work presented within this dissertation has addressed the requirements of both the
host and the immunizing organism for the induction of host cross-reactive immune responses in
mice. First, we investigated the qualitative differences between the antibody response generated
in mice as a function of age and M protein. Next, we performed a series of studies designed to
investigate the capacity of S. pyogenes to induce host cross-reactive cytotoxic T cell responses in
mice. Then, we attempted to determine what factors may play a role in the development of the
cytotoxic T cell responses, including age and genetic background of the mice, the route of
infection and the obligate role of M protein.
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Characterization of myosin cross-reactive monoclonal antibodies. Antibodies recognizing
mammalian myosin are a hallmark characteristic of childhood post-streptococcal autoimmune
complications. Antibody deposits have been described in biopsied tissue from ARF patients
(Kaplan 1960; Kaplan et al. 1964b; Kemeny et al. 1989) as well as, serum anti-streptococcal
antibodies that cross-react with myosin (Cunningham and Russell 1983; Cunningham et al.
1989). Immunizing laboratory animals with streptococcal cell wall or membrane preparations
elicit antibody responses against various mammalian proteins, including myosin and keratin
(Dale and Beachy 1985a; Dale and Beachy 1985b; Cunningham and Swerlick 1986; Kraus et al.
1990; Cunningham et al. 1992; Vashishtha and Fischetti 1993). However, despite their presence
in humans and the ability to be induced in animals, assessing a role for such antibodies has
proven difficult. Likewise, the requirements for their elicitation are not well understood.
Our results would suggest that both the age of the animal and the presence of M protein
maintain a pivotal role in the development of a myosin cross-reactive antibody response. We
have observed that in BALB/c mice a single neonatal immunization with heat-killed S. pyogenes
vaccine will induce persistent antibody titers against the group specific determinant Nacetylglucosamine, a portion of which cross-react with myosin. Interestingly, while immunizing
adult BALB/c mice with the vaccine does not elicit a cross-reactive antibody response, giving a
secondary challenge with recombinant M protein or mouse skeletal myosin will induce the
development of myosin cross-reactive antibody responses. Western blot analysis of
representative hybridomas indicate that the cross-reactive antibodies produced in mice
immunized as neonates with S. pyogenes recognize GlcNAc and cross-react predominantly with
the cardiac isoforms of mouse myosin. In contrast, antibodies elicited in mice immunized as
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adults with S. pyogenes and boosted with either myosin or M protein recognize most cardiac and
skeletal isoforms of mouse myosin.
The myosin cross-reactive antibodies elicited following a single neonatal exposure to S.
pyogenes have been shown to persist within the sera up to 60 weeks beyond the immunization.
Maintaining this serum antibody response is unique to the neonatal animal and is characteristic of
the exaggerated antibody response in post-streptococcal autoimmunity patients (Appleton et al.
1985; Ayoub 1991). Considering that the cross-reactive antibodies predominantly recognize
GlcNAc, a classical T independent antigen, the sustainment of the response is probably not likely
due to lymphocytic memory. Therefore, it is conceivable that the cross-reactive antibody
response is maintained as the result of cross-recognition to host antigens. Additionally, it may be
postulated that the antibody response is chronically stimulated due to exposure to enteric
commensal organisms in a manner similar to the immune response maintained against blood
group antigens (Drach et al. 1972, Yang and Boettcher 1992).
We have demonstrated that age and M protein are two requirements for a myosin crossreactive antibody response, however the role for the autoreactive B cells and their antibody
remains in question. Antibody deposition does occur in target tissue and is known to have a role
in mediating tissue damage in certain autoimmune diseases, including post-streptococcal
autoimmune glomerulonephritis (Richards 1991) and systemic lupus erythematosus (Maddison
1999). Also, these autoreactive B cells producing cross-reactive antibodies may potentially serve
as a means to induce autoreactive T cell responses (Lin et al. 1991; Chan et al. 1999). However,
CTL studies conducted by us and others (Asano and Ahmed 1996) using Igh-/- mice indicate that
B cells has no direct significance on the ability to either mount a primary or memory CTL
response.
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Requirements for the induction of a myosin-reactive cytotoxic T cell response in mice. The
pathology associated with ARF is believed to be primarily the result of a cellular mediated
immune response. While it can be demonstrated that biopsied cardiac tissue from ARF patients
contain extensive lymphocytic infiltrates (Raizada et al. 1983; Kemeny et al. 1994), it remains to
be determined if these cells are recruited due to their ability to cross-react with host antigens
(Manjula and Fischetti 1980; Guilherme et al. 1995; el-Demellawy et al. 1997) or as a by-product
of an overzealous immune response (Cairns 1988; Alarcon-Riquelme et al. 1990; Bhatnagar et al.
1999).
It has been our observation that neonatal immunization with heat-killed S. pyogenes
elicits a myosin-reactive cytotoxic T cell response. Producing a T cell response against an
extracellular antigen in neonatal mice can present some obstacles. First, it has been traditionally
viewed that neonatal immunization will not elicit a productive immune response either due to the
induction of tolerance (Billingham et al. 1953) or immune deviation (Singh et al. 1996; Adkins
and Du 1998). Neonates are capable of eliciting protective CTL responses, whether antiallogenic (Pilarski 1977), against viral challenge (Sarzotti et al. 1996; Siegrist et al. 1998) or
following DNA vaccination (Pertmer and Robinson 1999). Furthermore, neonatally
thymectomized mice produce a Th1 response upon challenge with soluble protein later in life
suggesting that T cells have fully mature capacity as early as day one of life (Adkins and Du
1998). Secondly, the ability of an exogenous antigen like GAS to enter the class I processing and
presentation pathway is not completely understood. Observations have been made indicating that
extracellular particulate antigens, whether protein coated beads or extracellular bacteria, can be
processed and presented via class I by activated macrophages in vitro (Pfeifer et al. 1993; Rock et
al. 1993; Kovacsovics-Bankowski and Rock 1995; Harding 1996).
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Based on our observation, the myosin-reactive CTL response induced in neonatal mice is
primarily the result of antigenic cross-reactivity to streptococcal M protein. A large body of
literature exists detailing the importance of M protein in streptococcal infections and subsequent
autoimmune complications. M protein is known to share antigenic determinants with myosin
(Manjula and Fischetti 1980; Manjula et al. 1985; Manjula and Fischetti 1986) and myocarditis
can be induced in MRL/++ mice with an M protein peptide sharing homology with myosin (Huber
and Cunningham 1996). Furthermore, several laboratory studies have shown that M protein has
the potential to induce cytotoxic T cell responses with the capacity to kill myocardial cells
(Friedman et al. 1971; Yang et al. 1977; Dale and Beachey 1987; Kotb et al. 1989; el-Demellawy
et al. 1997). In addition to underscoring the importance of M protein, we have also demonstrated
that the potential cross-reactive epitopes lies within the carboxy terminal region or, more
specifically the C sequence repeat region. M protein is classified into two major classes based
upon C region sequence where class I is more associated with autoimmunity (Bessen et al. 1989).
We also have found that streptococcal strains expressing class I M protein were more capable of
eliciting myosin-reactive CTL responses. These observations are important considering the
efforts underway to develop a streptococcal vaccine designed with M protein conserved region
(Robinson et al. 1993; Pruskakorn et al. 1994a; Pruskakorn et al. 1994b).
Our observations support the hypothesis of autoimmunity as a result of antigenic crossreactivity however, we also wanted to address other conditions, apart from age of immunization,
which may contribute to autoimmune susceptibility. The potential role genetics may play in the
development of post-streptococcal autoimmune complications has been the focus of much
research, not only as a factor that dictates hyperimmunity to streptococcal infections (Greenberg
et al. 1981; Hafez et al. 1990) but also as a correlation factor for the susceptibility to post-
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streptococcal autoimmune diseases (Greenberg et al. 1975; Gibofsky et al. 1991; Ertug 1993). In
a preliminary study we have shown the genetic background, or MHC haplotype, of the animal
can dictate the ability to develop a CTL response against myosin as a result of neonatal
immunization with S. pyogenes. While we were able to elicit a myosin-reactive CTL response in
three strains of mice representing two distinct haplotypes, further experimentation with other
backgrounds is desirable.
The route of immunization appears to be another important factor pertaining to the
capability to elicit a myosin-reactive CTL response. We have observed in BALB/c and C57Bl/6,
two distinct genetic backgrounds, that systemic immunization of neonatal mice with S. pyogenes
vaccine will elicit a myosin specific CTL response. Immunizing these mice intranasally with S.
pyogenes, as a means to mimic the natural infectious route, does not yield a measurable CTL
response to either M protein or myosin, unless a systemic booster of vaccine or M protein is
administered later in life. These results have potential application to the human situation, in that,
where streptococcal skin infections may lead to only AGN, streptococcal throat infections may
lead to one of several autoimmune disorders including ARF, AGN, and psoriasis. Taken
together, this would suggest that an initial intranasal or nasopharyngeal exposure to antigen may
stimulate a potentially cross-reactive systemic immune response that can be restimulated and
detected following systemic challenge with S. pyogenes or an antigenic component thereof,
namely M protein.
Conclusion. Despite the extent to which the cross-reactive antibody and cytolytic response can
be induced, we did not observe any pathological outcome however it does indicate the capability
of S. pyogenes to overcome the immunological privilege of host proteins. Further these results do
not definitively explain the mechanism underlying the elicitation of a myosin-reactive CTL
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response following neonatal exposure to wild-type S. pyogenes, they do provide clues into the
requirements to the development such a response. Accordingly, it appears that the most
important factors are the age of the animal at the initial immunization and the presence of M
protein. Other factors potentially regulating the elicitation of a myosin CTL response include the
genetic background of the animal and route of immunization. Taken together our results would
suggest that in a genetically susceptible individual local exposure to the organism has a lasting,
potentially deleterious, effect upon a subsequent systemic immune response and if the necessary
streptococcal antigens, namely M protein, gain access systemically the primed autoreactive
immune response will be activated and potentially initiate the pathology characteristic of poststreptococcal autoimmune diseases.
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